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Summary
The purpose of the study presented herein was to investigate the RNA-binding 
properties of the nucleocapsid (N) protein of respiratory syncytial virus (RSV). The 
position of the RNA binding-site within the protein was investigated. In addition, the 
ability of N protein to assemble into nucleocapsid-like structures was studied, thus 
determining whether these facets were distinguishable.
The sequence specificity of RNA-binding by the N protein was investigated using 
several RNA probes, one of which represented the RSV leader sequence. Various in 
vitro assays, such as the yeast three-hybrid system, gel mobility shift assay and north­
western blots, were employed to this end. In the absence of other viral proteins, N 
possessed no sequence preference in the manner of its association with RNA.
The locale of the RNA-binding site within the N protein was addressed by employing 
two methodologies. The first approach employed a UV crosslinking assay with 
subsequent analysis by mass spectrometry. A single N-derived peptide was identified 
within the carboxy-domain of N (amino acids 352 to 358) as being potentially modified 
by RNA-binding. Secondly, the use of carboxy-terminal deletion mutants of the N 
protein demonstrated the presence of an RNA-binding domain within the first 92 amino 
acids of the N protein. The two individual binding regions identified demonstrate the 
conformational nature of the RNA-binding domain. However, the role of the carboxy 
terminus was shown to be minimal, as deletion of this region did not prevent RNA- 
binding.
Concurrent with the binding of RNA is the formation of nucleocapsids, helical structures 
formed from N proteins encapsulating the viral genomic RNA. The ability of 
recombinant N to assemble into such structures was investigated by EM. Histidine-tag 
N demonstrated the capacity to form nucleocapsid-like structures and N:RNA rings, the 
latter representing a single turn of the nucleocapsid helix. The rings were shown to 
consist of 10 N protein monomers, a situation different from Sendai virus (13 
monomers) and more similar to that of rabies virus (10 monomers). A mutant 
representing amino acids 1 to 92 of the RSV N protein formed RNase-resistant 
structures that were nucleocapsid-like in appearance. This suggests that 
characteristics of RNA-binding and nucleocapsid assembly are situated within the 
same domain. A potential map of the domain structure of RSV N protein, derived from 
this work and from studies on-going in the laboratory, is presented.
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Chapter 1
1 Introduction
1.1 History
Respiratory syncytial virus (RSV) was first reported in 1956 upon its identification as 
the causative agent of coryza, a respiratory illness in chimpanzees (Morris et al., 1956). 
Shortly after its discovery, the virus was isolated from children in the Baltimore area of 
New York suffering from either pneumonia or from croup. The formation of lung 
epithelial cell syncytia, a characteristic of RSV infection from which it derives its name, 
was first observed in these patients (Chanock et al., 1957). An extensive serological 
investigation of children within the Baltimore area revealed that most individuals had 
been exposed to the virus before the age of four (Chanock & Finberg, 1957). Current 
serological data indicates that by the age of two years, up to 90% of children have 
encountered RSV. Peak rates of RSV infection occur in infants aged between six 
weeks and six months and, in addition to the very young, RSV may also cause serious 
infection in the immunosuppressed and the elderly (Hall, 2000; Simoes, 1999). 
Reinfection is a frequent event in both children and adults due to the highly variable 
nature of circulating strains, similar to the situation with influenza virus.
1.1.1 Epidemiology
In 1992, the World Health Organisation (WHO) estimated that, of the 12.2 million 
annual deaths of children under the age of five, one third were due to infections of the 
lower respiratory tract (Garenne et al., 1992). The predominant respiratory pathogens 
identified in this study were Streptococcus pneumonia, Haemophilus influenza and 
RSV.
RSV has a worldwide distribution. In temperate regions, a clear seasonality may be 
observed with the occurrence of epidemics in the winter months. Epidemics are an 
annual event and have a mean duration of five months with peaks in infection during 
the months of February and March in the Northern hemisphere. In tropical and sub­
tropical regions of the world, epidemics often occur during the cooler, rainy season. 
There is correlation with the spread of infection and large gatherings of people, for 
example, at religious festivals (Simoes, 1999).
1
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1.1.2 Antigenic Subgroups
Investigations of viral isolates using monoclonal antibodies (MAbs) demonstrated the 
existence of two antigenically distinct subgroups, termed A and B (Anderson et al., 
1985; Gimenez et al., 1986; Mufson et al., 1985). Within the laboratory these are 
represented by the strains A2 and 18537, respectively. Within each subgroup, viruses 
appear antigenically relatively stable. Comparison between subgroups indicates an 
antigenic relatedness of only 25%. Such antigenic dimorphism is predominantly the 
result of variation in the virus attachment protein, the G protein, which possesses 1 to 
7% antigenic relatedness between subgroups A and B in comparison with 50% 
antigenic relatedness observed between the different subgroup fusion (F) proteins 
(Hendry et al., 1988); (Johnson et al., 1987a). Examination of the protective antigenic 
regions on the F protein demonstrates that there has been neither extensive nor rapid 
subgroup divergence. In addition, the accumulation of immune-evasive traits with time, 
within a subgroup, is not apparent. This suggests that, unlike influenza A, RSV does 
not undergo antigenic drift (reviewed by Collins et al., 1996b).
Sequences from eight of the genes from RSV strains A2 and 18537 were compared by 
sequencing (Johnson et al., 1987b). Considering only the envelope proteins it was 
shown that the small hydrophobic (SH) and the F protein genes show moderate 
sequence divergence. The G protein gene, however, had extensive divergence 
between the two subgroups. Upon translation of the nucleotide sequence of the open 
reading frames, this represented a 47% difference in amino acid sequence. The 
sequence variation was concentrated in the extracellular domain of the protein which 
suggests selective pressure for the divergence of G protein, perhaps because of 
immune pressure. It is hypothesised that the F protein is less tolerant of sequence 
alteration due to more stringent structural and functional restrictions.
The antigenic divergence between subgroups may contribute to the high incidence of 
reinfection during early childhood. However, it is probable that this has only a modest 
effect, as reinfections may involve viruses from the same subgroup due to rapid RSV 
evolution (Mufson et al., 1987). The G protein has been found not only to be highly 
variable between subgroups but that some subgroup A isolates, from the same locale, 
show up to 20% variability (Cane et al., 1991).
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1.2 Disease in Humans
In temperate climes, RSV is the principal cause of hospitalisation of children, due to 
respiratory illness, in their first year of life (van den Hoogen et al., 2001). However, 
mortality due to RSV is uncommon in the developed world. It’s occurrence is 
predominantly in infants with underlying illness, such as congenital heart disease and 
pulmonary hypertension (Simoes, 1999). RSV is now considered a major cause of 
death in the elderly. Within this age group, at least 10% of hospital admissions during 
the winter months are caused by RSV, a further 10% of which are fatal, presenting a 
similar fatality rate to influenza (Falsey et al., 1995). Acute RSV infections are also a 
common occurrence in adults, though with no requirement for hospitalisation.
RSV is spread in infected respiratory secretions, carried in large droplet form or fomite 
contamination rather than by small-particle aerosols (Hall & Douglas, 1981). Therefore, 
virus spread requires close personal contact or object contamination with fomite, the 
latter of which is more common in hospital-acquired infection (Hall, 2000; Isaacs, 
1991).
RSV has an incubation period of approximately five days (Johnson et al., 1961). 
Initially, virus replicates in the nasopharynx before spreading from the upper to the 
lower respiratory tract. Signs of lower respiratory tract infection appear between one 
and three days after the onset of rhinorrhea, possibly reflecting the timing of viral 
spread to the bronchi and the bronchioles. Infection is limited to the superficial layers of 
the respiratory epithelium. However, virus spread to other tissues and establishment of 
persistent infection may occur in severely immuno-compromised patients (Simoes, 
1999). In severe cases of RSV in infants, the pathology of resulting bronchiolitis or 
pneumonia is similar to that obtained with other respiratory viruses. It is believed that 
the predominant site for RSV infection is the small bronchioles, accompanied by 
inflammation and leukocyte infiltration of surrounding tissue (Hussell eta l., 1998). Such 
inflammation is the predominant cause of RSV pathology, with minor contribution from 
direct virus cytopathology. Therefore, treatment with both anti-inflammatory agents and 
anti-virals may be administered to alleviate the disease state (Simoes, 1999).
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1.2.1 Clinical Features
With RSV, the more common infection is of the upper respiratory tract causing 
symptoms of rhinitis and cough, with low-grade fever in some patients. Upon 
development of lower respiratory infection, bronchiolitis and pneumonia are the most 
common manifestations in children. Croup is a less frequent development of RSV 
infection (Simoes, 1999). In healthy infants that first encounter RSV at six weeks to 
nine months, RSV usually causes upper respiratory symptoms. 25 to 40% of these 
cases progress to lower respiratory infection (Glezen et al., 1986). Most frequently, 
uneventful recovery occurs after illness of between seven and 12 days. However, 
following RSV-induced bronchiolitis or pneumonia during infancy, abnormalities in 
pulmonary function may be observed (Sigurs, 2001). Factors associated with 
development of serious disease include prior underlying anatomic or functional 
abnormality, environmental factors such as family smoking, lower socio-economic 
circumstances and a tendency of the individual to secrete IgE in response to RSV 
(Brandenburg et al., 2001; Simoes, 1999).
RSV has been detected in the lungs of a percentage of children dying from sudden 
infant death syndrome (SIDS) (Ogra et al., 1975). In such instances, the role of RSV is 
unknown. However, it is probable that a subset of sudden deaths is caused by 
respiratory illness and therefore possible that a proportion of these is due to RSV.
1.2.2 Diagnosis
A variety of assays exist for the laboratory diagnosis of RSV infection in older children 
and in adults. An increase in the levels of serum antibody, complement-fixing and 
neutralising antibody may all be used as indicators of infection (Johnson et al., 1961). 
Diagnostic assays for the detection of virus antigens include immunofluorescent 
microscopy and enzyme-linked immunosorbant assays (ELISA) performed on 
nasopharyngeal secretions. Reverse transcription of patient RNA followed by 
polymerase chain reaction with primers specific for virus sequence is an alternative 
method for the diagnosis of RSV in patients with limited virus shed from the 
nasopharynx, a situation frequent in elderly patients (Simoes, 1999).
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1.2.3 Therapeutic Treatment of RSV
Considerable supportive care is required in the treatment of hospitalised patients with 
RSV including the mechanical removal of secretions, positioning of the infant, 
administration of humidified oxygen and possible provision of respiratory assistance 
(Behrendt et al., 1998). In addition to reducing the discomfort of the patient, treatment 
of RSV infection is beneficial by shortening the duration of hospital stay and the 
intensity of nursing required.
A variety of treatments are employed for RSV infection including both drug- and 
immunotherapy. The compound ribavirin, a guanosine analogue, has been used in the 
treatment of RSV since the mid-1980s. Its antiviral properties were first observed in 
cultured mammalian cells and in laboratory cotton rats (Hruska et al., 1982). In RSV 
infection, the drug is administered by aerosol over 18 to 20 hours a day to reduce, or 
eliminate, the acute systemic toxicity of the drug. Studies into the efficacy of the use of 
ribavirin have had conflicting results. The drug has been reported to provide a modest 
but consistent beneficial effect on virus shedding and clinical illness (Hall e ta l., 1983). 
However, there is no evidence that treatment of the virus infection reduces the 
frequency of mortality, the duration of hospitalisation or the need for supportive 
therapies (Law et al., 1997). In most centres, its use is now restricted to 
immunocompromised patients and the severely ill; this limitation arises from the high 
cost of the drug, its application and lack of consensus on its efficacy (Simoes, 2001).
Inhaled salbutamol, a bronchodilator, is used in the therapy of RSV. A meta-analysis 
demonstrated that the drug induced moderate short-term improvement in mild or 
moderate bronchiolitis. However, treatment had no effect on the risk of hospitalisation 
(Kellner et al., 1996). An alternative drug used in the treatment of RSV is racemic 
epinephrine. It is superior to salbutamol in improving airway resistance and clinical 
scores and decreasing the need for hospitalisation of babies with bronchiolitis (Menon 
etal., 1995).
Immunotherapy is used in the treatment of RSV. The use of purified human 
intravenous immune globulin (IVIG) was first tested in laboratory cotton rats. Upon 
inoculation at the height of RSV infection, a reduction in the level of pulmonary virus 
was effected in the rats and there was no evidence of pathology (Prince et al., 1987). 
However, in human trials performed with both intravenous and inhaled antibody
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application, no substantial beneficial effects on lower respiratory tract infection were 
observed (Rodriguez et al., 1997).
Immunoglobulin therapy has been used more successfully in the prevention rather than 
the therapy of RSV infection. Children identified as being at high-risk of serious 
infection can be protected against severe disease by the monthly administration of 
IVIG, or humanised MAb, during the RSV season. In trials, the use of Synagis (or 
palivizumab, as it was previously called), a humanised MAb with specificity for the F 
protein, resulted in fewer hospitalisations within the patient group. Though a 
cumbersome procedure of application, Synagis was found to be well tolerated and 
effective (Johnson et al., 1997). This treatment was licensed in the USA in 1998. 
Synagis is administered to premature babies, bom with an undeveloped immune 
system and limited maternal antibody, to protect them from RSV infection.
1.2.4 Immunology
The effectors of both protection and recovery from RSV infection are secretory 
antibodies, serum antibodies, MHC class l-restricted cytotoxic T lymphocytes (CTL) 
and maternally derived antibodies in the very young. Following RSV infection, CTL- 
mediated protection appears to be short-lived. Both serum and secretory antibodies 
contribute but provide incomplete protection against repeat infection (Brandenburg et 
al., 2001). Cumulative immunity after repeated reinfections provides protection against 
more serious lower respiratory tract infection in older children and adults (Kimman & 
Westenbrink, 1990).
Work performed in mice suggests CD8+ lymphocytes play a role in the pathogenesis of 
RSV infection. Passively transferred RSV-specific CTLs, obtained from mice infected 
with RSV, were observed to clear virus from the lungs of persistently infected, gamma- 
irradiated mice. However, acute pulmonary damage resulted and the mice frequently 
died (Cannon et al., 1988). Experiments involving spleen cells, enriched in CD4+ or 
CD8+ lymphocytes, indicated that both were able to decrease pulmonary virus titre in 
mice, with CD4+ cells being more efficient. Concurrently, CD4+ cells induced pulmonary 
eosinophilia and secreted a TH2 cytokine profile (Alwan et al., 1992). These 
observations, confirmed by related studies, suggest that there is a fine balance 
between the protective and the disease-producing effects of T cells. Despite the
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successful removal of virus by CTLs, it is the mediators of the inflammatory response 
that cause the disease pathology associated with RSV infection. In a variety of 
experimental animals, recombinant M2 and, to a lesser extent, recombinant N protein 
induced a protective effect, mediated by CTLs, and of short duration (Connors et al., 
1991). In adult humans, the CTL response repertoire included the N, SH, F, M, M2 and 
NS2 proteins (Cherrie et al., 1992). The F protein is the major CD4+ cell target antigen 
in both humans and BALB/c mice. Recombinant F protein primarily induced a THi 
response in CD4+ cells compared with the TH2 response elicited by the G protein. This 
corresponded with respectively minimal or enhanced lung histopathology. Therefore, 
the antigen composition of a vaccine can influence the quality of the immune response 
as well as the immunopathology generated upon virus challenge (Openshaw et al., 
2001).
Specific antibodies are generated upon RSV infection. Antiviral IgE may be involved in 
pathogenesis. Upon association with antigen, IgE binds both basophils and mast cells 
stimulating a local allergic response (Campbell, 1993). Association of IgE production 
with pathogenesis again confirms that inflammation is the major cause of RSV 
pathology. Protection against reinfection by respiratory viruses is traditionally attributed 
to secretory antibodies. However, serum antibody appears to have a protective role in 
RSV infection, demonstrated by epidemiological studies and antibody trials. The 
incidence and severity of lower respiratory tract infection in infants with RSV has been 
observed to correlate inversely with serum antibody levels (Brandt et al., 1997; Glezen 
et al., 1981; Kimman & Westenbrink, 1990). The source of protection within the 
respiratory tract of cotton rats appears to be divided. The upper respiratory tract is 
protected primarily by local immunity, including secretary antibody, whereas the lower 
respiratory tract is protected by serum-neutralising antibody (reviewed by Collins et al., 
1996b). The major neutralising antibody response is targeted against the RSV F 
protein whereas the G protein induces only a weak neutralising antibody response 
(Johnson & Collins, 1988).
1.2.5 Interferon
RSV infection frequently fails to induce detectable levels of interferon (IFN) in the nasal 
secretions, which is in contrast to infection by parainfluenza and influenza viruses 
where IFN levels are high at the peak infection and correlate with clearance of the virus
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(Hall et al., 1978). It was suggested that IFN, together with cell-mediated immunity, 
modulates the severity of RSV-induced disease. Severe RSV disease was correlated 
with decreased IFN-y production by peripheral blood monocytes (Bont et al., 1999). 
Atreya & Kulkami (1999) showed that RSV, in tissue culture, was resistant to the 
antiviral effects of type I IFNs and to MxA, unlike some other paramyxoviruses. The 
mechanism of the resistance is unknown but Schlender et al. (2000) demonstrated that 
the bovine RSV (bRSV) non-structural proteins NS1 and NS2 are both required for 
anti-IFN effect. Young et al. (2000) showed that simian virus 5 (SV5), Sendai virus 
(SeV) and parainfluenza types 2 and 3 exert anti-IFN effects by interfering with the 
STAT1/STAT2 transcription pathway, effectively blocking the signalling pathway. RSV 
did not block the IFN signalling response therefore it must use some other mechanism 
to combat IFN effects. Thus, it appears that while RSV replication is unaffected by IFN, 
the effect of decreasing IFN is to enhance the inflammatory response that results in 
disease. There is evidence that use of IFN therapy, given with an appropriate antiviral 
may help abate the severity of the disease (van Schaik et al., 2000).
1.2.6 Vaccine
A clinically approved vaccine is not yet available for RSV. Problems such as the 
insufficient attenuation of vaccine virus, its thermolability and the need to include both 
A and B strains have hindered vaccine development (Simoes, 1999). In addition, to be 
effective against infant bronchiolitis and pneumonia, the vaccine must be capable of 
stimulating effective resistance before the second month of life. However, the 
immunosuppressive effects of maternally derived serum RSV-neutralising antibody, 
and immunological immaturity of the infant, present additional problems in vaccine 
design and delivery (Brandenburg et al., 2001).
In the mid-1960s, a formalin-inactivated, parenterally administered RSV vaccine (Fl- 
RSV) was developed. Vaccine recipients developed a high titre of serum complement- 
fixing antibody and a moderate titre of serum-neutralising antibody. Despite this, an 
unusually large proportion developed severe lower respiratory tract illness upon 
subsequent RSV challenge, similar to the severe bronchiolitis observed during infancy 
(Chin et al., 1969; Fulginiti et al., 1969; Kim et al., 1969). Therefore, the vaccine 
appeared to induce sensitisation leading to severe disease in subsequent infection. 
The vaccine may have stimulated an imbalance in the systemic immunoglobulin 
response. It is possible that vaccine failed to induce appreciable local respiratory tract
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RSV secretory IgA antibody because of its parenteral administration. In addition, a high 
titre of serum antibody directed towards the F protein was generated but exhibited only 
a low level of neutralising activity. Formalin treatment of the virus may affect the 
antigenicity of viral glycoproteins F and G and expose less favourable epitopes. In vitro 
analysis of lymphocytes obtained from vaccinees, demonstrated that RSV antigens 
stimulated an exaggerated proliferative CTL response. It was proposed that formalin- 
inactivated vaccine induces a high level of RSV-specific CD4+ but not CD8+ memory 
cells (Kim et al., 1976). In mice immunised with FI-RSV and subsequently challenged 
with RSV, CD4+ lymphocytes were observed to predominate in the pulmonary infiltrate. 
In addition, contrary to the usual observation in mice during unmodified RSV infection, 
the CD4+ lymphocyte cytokine profile TH2 predominated (Graham et al., 1993). These 
observations suggested that vaccinees might also experience an imbalance in their 
cell-mediated immune response.
To over-come the failure of FI-RSV, the development of attenuated viruses for use as a 
live vaccine was attempted. Live vaccines have been developed for other members of 
the Paramyxoviridae, the viral super-family to which RSV belongs, such as measles 
and mumps viruses. To this effect, attenuated, immunogenic cold-passaged (cp) or 
temperature sensitive (ts) viruses were generated (Crowe et al., 1994a; Crowe et al., 
1994b; Friedewald et al., 1968; Gharpure etal., 1969; McKay et al., 1988). Early trials 
in susceptible infants and young children yielded discouraging results as immunisation 
by parenteral inoculation of live virus proved ineffective (Belshe et al., 1982). 
Attenuated strains possessed only a low level of residual virulence and were 
genetically unstable. To produce mutants free of these deficiencies, cp-RSV was 
further mutated. Two distinct lineages of mutagenised virus each yielded promising 
candidate vaccine strains (Crowe et al., 1994b). Despite reduced replication in 
chimpanzees, these mutants induced almost complete protection to subsequent RSV 
infection (Crowe et al., 1994a). Their usefulness will not be known until they have been 
evaluated in susceptible sero-negative infants.
The application of viral proteins to induce protection has been investigated. F protein, 
purified from RSV culture (Walsh et al., 1987), and a chimeric F-G protein, expressed 
from recombinant baculovirus, have been studied (Kakuk et al., 1993; Wathen et al., 
1991). In cotton rats, RSV protection was provided when challenged several months 
post-immunisation. However, though a high level of F-specific antibody was stimulated,
9
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only a low level of neutralising activity was exhibited (Connors et al., 1992). Vaccinia 
virus recombinants expressing the F and the G proteins generated encouraging results 
in both rodents and monkeys (Olmsted et al., 1986). Unfortunately, they were only 
weakly immunogenic in chimpanzees and failed to induce resistance to RSV challenge.
Bovine RSV has been considered as a live vaccine for use in humans. Initial studies in 
rodents yielded encouraging results (Piazza et al., 1993). However, the virus does not 
replicate efficiently in chimpanzees and therefore fails to induce resistance to hRSV 
challenge. Bovine RSV is unable to infect human cells, however, it may yet prove a 
viable vaccine candidate upon generation of recombinant bRSV expressing hRSV F 
and G proteins.
1.3 Animal RSV
Bovine RSV is an economically important disease in cattle. The naturally occurring 
virus may be divided into at least two antigenic subgroups. The genome organisation of 
human and bovine RSV is identical. Differences in nucleotide and amino acid 
sequence occur in similar regions to those between subgroups of human RSV, though 
differences are approximately two-fold greater. In addition, antibody cross-reactivity 
exists between several human and bovine RSV proteins (N, P, M and F). Despite such 
similarities, bovine RSV is unable to replicate efficiently in chimpanzees and to infect 
human cells.
Other ruminant forms of the virus exist. Caprine RSV is very similar to the bovine virus. 
It is possible that ovine and bovine RSV are two antigenic subgroups rather than 
distinct viruses. Therefore, it is possible that ruminant RSVs represent antigenic 
subgroups rather than the distinct viruses of different hosts (Collins et al., 1996b).
1.4 Virology
1.4.1 Classification
The genome of RSV is composed of nonsegmented, single-strand, negative-sense 
RNA, placing the virus within the taxonomic Order, Mononegavirales (Pringle, 1991). 
Figure 1.1 shows the taxonomic organisation of the Mononegavirales, with particular 
regard to the Paramyxoviridae. The Order Mononegavirales contains four virus
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families, the Filoviridae, Bomaviridae, Rhabdoviridae and the Paramyxoviridae, 
example members of which are listed in Table 1.1. The viruses of this order most 
extensively studied include SeV (Murine Parainfluenza Subtype 1, family 
Paramyxoviridae) and VSV (Vesicular Stomatitis Virus, family Rhabdoviridae). From 
investigations into these prototype viruses, much information on the biology of the 
Mononegavirales has been elucidated. Parallels are drawn and investigated in related 
viruses. There are a number of similarities, which result in the grouping of viruses into 
the Mononegavirales, some of which are listed in Table 1.2. However, there are 
marked differences between the virus families (Table 1.2) such as the method of cell 
entry (pH dependent or independent), presence or absence of heamagglutinin activity 
or site of replication. Nevertheless, it is the common replication strategy, and the use of 
a virally encoded RNA-dependent RNA polymerase, that unites the group.
The RS viruses are members of the genus Pneumovirus, of the family 
Paramyxoviridae. In 1993, the Paramyxoviridae family was further partitioned forming 
two subfamilies, the Paramyxovirinae and the Pneumovinnae. Division of the family 
was based on morphology, genome organisation and the biological activity and 
sequence relatedness of the proteins. Subfamily Paramyxovirinae contains three 
genera, Respirovirus, Morbillivirus and Rubulavirus (Table 1.1). The genera 
Pneumovirus and Metapneumovirus are present in the subfamily Pneumovirinae (Lamb 
& Kolakofsky, 1996; Pringle, 1997). RSV is a member of the genus Pneumovirus. The 
genus Metapneumovirus was generated to accommodate the avian pneumoviruses. 
Subsequently, a novel virus has been isolated from children with respiratory infection in 
the Netherlands; virus sequence homology and genome organisation suggest it too 
may be classified as a Metapneumovirus. The provisionally named “human 
metapneumovirus” causes symptoms similar to those of RSV (van den Hoogen et a!., 
2001).
1.4.2 Virus Growth
RSV grows relatively poorly in tissue culture and in many experimental animals. 
However, virus growth is permissible in a wide variety of human and animal cells. Upon 
growth, RSV does not shut down host macromolecular synthesis. Approximately 90% 
progeny virus remains cell associated, in the form of viral filaments (Bachi, 1988). RSV 
rapidly looses infectivity upon storage, handling and purification and is consequently
11
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Family Subfamily Genus Example Species
Filoviridae Filovirus Ebola Virus 
Marburg Virus
Bomaviridae Bomavirus Boma Virus Disease
Rhabdoviridae
Vesiculovirus
Lyssavirus
Ephemerovirus
Cytorhabdovirus
Nucleorhabdovirus
Vesicular Stomatitis 
Virus 
Rabies Virus 
Bovine Ephemeral Fever 
Virus
Lettuce Necrotic Yellows 
Virus 
Potato Yellow Dwarf 
Virus
Paramyxoviridae
Paramyxovirinae Respirovirus
Morbillivirus
Rubulavirus
Sendai Virus 
Human Parainfluenza 
Virus Types 1&3 
Measles Virus 
Mumps 
Simian Virus 5 
Newcastle Disease 
Virus
Pneumovirinae Pneumovirus
Metapneumovirus
Human RSV 
Bovine RSV 
Pneumonia Virus of 
Mice
Avian Pneumovirus 
(Turkey Rhinotracheitis 
Virus)
Table 1.1: Members of the Order Mononegavirales.
Chapter 1
Similarities Differences
1 Possess a similar gene order.
2 Genome is always tightly associated 
with viral protein along its entire 
length, forming the nucleocapsid.
3 Transcription of viral genes is by 
sequential, interrupted synthesis of 
mostly non-overlapping mRNAs.
4 Replication is achieved by production 
of a complete positive-sense 
transcript.
5 Virus maturation occurs by budding 
through the host cell plasma 
membrane that the virion then retains.
6 Virus encodes a virion-associated 
RNA-dependent RNA polymerase.
1 There is variation in genome size.
e. g. 11 161 kilobases (kb) of vesicular 
stomatitis virus (Rhabdovirus) 
compared with 19 108 kb of Marburg 
virus (Filovirus).
2 Differences in virion morphology.
3 Viruses differ in the cellular site of 
replication.
4 Variation in pathogenic potential.
5 Differences in virus host range, 
e.g. the Rhabdoviridae host range 
includes plants, invertebrates and 
vertebrates; the filoviruses are 
restricted to primates.
6 Method of cell entry varies, 
e.g. rhabdoviruses use a ph- 
dependent lysosomal pathway; 
paramyxoviruses use a ph- 
independent pathway.
Table 1.2: The similarities and differences between members of the Order 
Mononegavirales.
(Reviewed by Lamb & Kolakofsky, 1996).
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difficult to concentrate (Femie & Gerin, 1980). Within tissue culture, RSV has been 
shown to bud from the apical membrane of the host cell (Roberts et al., 1995). This 
might have implications in vivo and could explain the restriction of RSV to the lungs of 
infected individuals.
Several small experimental animals, for example the cotton rat, have been used as 
models for RSV infection. However, in most cases replication is only semi-permissive 
and disease does not occur. Of non-human primates, only the chimpanzee appears to 
be highly permissive to RSV replication (Collins et al., 1996b). However, chimpanzee 
use in vaccine studies is naturally restricted by availability, expense and ethical 
considerations. As a model for human disease, the study of bRSV in cattle may be 
useful.
1.4.3 Virus Morphology
The virions of RSV are of a similar size and shape to those of the Paramyxovirinae. 
They are generally spherical with a diameter of between 150 nm and 300 nm but are 
pleomorphic in appearance. Figure 1.2 shows a stylised image of an RSV virion. In 
addition, filamentous forms of virus have been observed in tissue culture but their 
significance is unknown (Pringle et al., 1981; Roberts etal., 1995). The RSV envelope 
is derived from the host cell as it buds from it (Lamb and Kolakofsky, 1996). Inserted 
into the membrane are viral glycoproteins which can be visualised by negative-stain 
electron microscopy as spikes extending 8 to 12 nm from the virion surface (Bachi & 
Howe, 1973; Lehmkuhl et al., 1980). In the case of RSV, there are three glycoprotein 
species, the SH (small hydrophobic), F (fusion) and G (viral attachment) proteins 
(Collins et al., 1996b)
Within the virion is the nucleocapsid; its core structure is composed of viral genomic 
RNA and the N (nucleocapsid) protein. The viral P (phospho-) protein and L (large) 
protein are also attached to this helical structure, which is the template for RNA 
synthesis. The nucleocapsid is very stable, able to withstand the high salt and gravity 
forces of caesium chloride density gradient centrifugation. Nucleocapsids band at a 
density of between 1.29 and 1.31 g / cm3 within caesium chloride gradients, typical of a 
ribonucleoprotein (RNP) complex. The nucleocapsids of the Paramyxoviridae may be 
viewed by negative-stain EM; those of the Paramyxovirinae are approximately 18 nm in
12
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Figure 1.2: Stylised image of a Pneumovirus virion.
The Pneumovirus virion consists of a ribonucleoprotein (RNP) core containing genomic 
RNA and viral proteins N, P, L and M2. The RNP complex is surrounded by a protein 
matrix (M), itself surrounded by cell-derived lipid membrane containing the F and the G 
proteins, responsible for fusion and attachment respectively. The viral membrane 
protein SH is absent from this image.
Figure courtesy of A. Easton, University of Warwick, UK.
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diameter, 1 in length and 5.5 nm in pitch length, although variation does occur 
(Egelman et al., 1989). The nucleocapsids of the Pneumovirinae are of similar 
dimensions but are narrower, with a diameter of between 12 nm and 15 nm (Bachi & 
Howe, 1973; Lehmkuhl etal., 1980).
1.5 The Genome
The genomes of the Paramyxoviridae are of similar size, ranging between 15.2 and
15.9 kilo bases (kb). A cartoon of the genome organisation of family members is 
present in Figure 1.3. The genome sequence of human RSV strain A2 has been 
determined; the RNA is 15 222 nucleotides in length and encodes ten genes (see 
Genbank, accession number M75468) (Collins et al., 1987; Mink et al., 1991; Stec et 
al., 1991). This gene number is shared by all members of the Pneumovirinae 
subfamily, with the exception of the avian pneumoviruses, which lack the genes 
encoding non-structural proteins, NS1 and NS2 (Randhawa etal., 1997). In contrast, 
the genomes of the Paramyxovirinae subfamily contain only six (Respirovirus and 
Morbillivirus) or seven (some members of genus Rubulavirus) genes (Figure 1.3). The 
genes for NS1 and NS2 are the first on the RSV genome map, which is a significant 
difference to the Paramyxovirinae subfamily where N is the first gene encountered on 
the genome (Lamb & Kolakofsky, 1996). As well as lacking NS1 and NS2, APV and the 
human metapneumovirus differ from other Pneumovirinae in their gene order, F-M2- 
SH-G compared with SH-G-F-M2.
A feature that appears to be unique to RSV is that the start of the L gene overlaps with 
the end of the M2 gene. As discussed later, this overlap may down-regulate expression 
of the L gene.
1.5.1 Extending the coding potential of the genome
Other members of the Paramyxoviridae have extended their genome coding potential 
by using alternative expression methods. Using the P gene of SeV as an example, the 
coding potential of this gene has been expanded by the use of alternative translational 
open reading frames (ORFs) by a mechanism of “leaky” scanning by the ribosome, the 
presence of AUG codons in poor translational contexts and the use of non-AUG 
codons to initiate translation (Curran & Kolakofsky, 1988a; Curran & Kolakofsky, 
1988b; Curran et al., 1986). SeV also extends the coding potential of the P gene by
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Chapter 1
RNA editing, which involves the insertion of non-templated nucleotide residues into the 
mRNA (Vidal et al., 1990). Unmodified mRNAs from the SeV P gene encode the P 
protein. Upon insertion of extra nucleotides within the mRNA, a frameshift occurs 
downstream of the insertion point allowing the ribosome to translate the V carboxy 
region, characterised by a zinc-finger motif. There is evidence that RSV utilises an 
RNA editing mechanism in the G protein to generate antibody escape mutants (Garcia- 
Barreno et al., 1990). RSV extends the coding potential of the M2 gene. The gene 
contains two ORFs, producing the M2-1 and M2-2 proteins which use a unique 
translational event. Within the mRNA, the start codon of M2-2 is 5’ proximal to the M2-1 
protein stop codon. Ahmadian et al. (2000) demonstrated the ability of ribosomes to 
terminate on the M2-1 ORF, and effectively backtrack to re-initialise translation on the 
M2-2 ORF.
1.5.2 Defective Interfering genomes
Defective interfering (Dl) particles possess deleted genomes resulting from errors in 
replication. Such errors are caused by the polymerase complex creating either internal 
deletions or inverted terminal repeats, also referred to as copy-back DIs. Only copy 
backs duplicating the 3’ end of the antigenome have been identified naturally. The 
necessary proteins, supplied by co-infecting helper genomes, replicate Dl genomes. 
The Dl particles interfere with helper virus growth as, being smaller, they replicate 
faster and remove proteins that would normally be used in the formation of infectious 
genomes (Re, 1991). Dl particles were found in RSV preparations after four passages 
in Hep2 cells (Treuhaft & Beem, 1982).
1.5.3 Rescue of Non-Segmented Negative Strand RNA Virus
The rescue of negative strand RNA virus, referred to as reverse genetics, is a useful 
tool for the investigation of both genome and protein function. Collins et al. (1991) 
developed the RSV rescue system. Genome leader and trailer sequences were 
retained but viral genes were replaced by marker gene chloramphenicol transferase 
(CAT), effectively constructing an element that could be described as a Dl genome. 
Investigation with the mini-genome confirmed that the genome-end sequences were 
sufficient to allow replication and transcription of the model genome (Collins et al., 
1991; Collins et al., 1993). The ability to rescue virus entirely from cDNA was later 
achieved (Collins et al., 1995). The technique produces infectious virus from cDNA-
14
Chapter 1
encoded RNA and from cDNA-encoded viral genes the expression of which is driven 
by T7 polymerase supplied, normally, by a vaccinia virus recombinant. By this method, 
mutations can be introduced into cDNA encoding either RNA or proteins making it 
possible to create defined mutants for study and vaccine development.
1.6 Virus Replication and assembly
Following G protein-mediated adsorption to the target host cell and fusion of viral and 
cell membranes, the nucleocapsid is released into the cytoplasm. Primary transcription, 
which does not require concurrent protein synthesis, is performed by virion-associated 
polymerase complexes, carried into the infected cell by the nucleocapsid (Portner & 
Murti, 1986; Portner et al., 1988).
1.6.1 Transcription
The ten genes of RSV are transcribed in their 3* to 5' genomic order. This suggests 
entry of the polymerase complex into the genome at a single upstream position. Using 
the reverse genetic system, Collins and co-workers have demonstrated that the 3' 
leader sequence is the promotor for RSV (Collins et al., 1991; Collins et al., 1995). 
Thus, the model of sequential transcription proposed in VSV and SeV may be 
applicable to RSV (Lamb & Kolakofsky, 1996). This model proposes that the viral 
polymerase associates with the 3' leader sequence of the genome. Transcription 
initiates within the leader region and the polymerase proceeds until it reaches the 
junction between the leader and first gene (NS1 in the case of RSV). Presumably, the 
leader is released and the polymerase transcribes the first gene until it reaches the 
gene-end sequence. The complex then initiates transcription of the next gene, thus the 
polymerase progresses along the length of the genome transcribing each of the genes 
in turn. Signals directing the capping and polyadenylation of the nascent mRNA, again 
achieved by the polymerase, are present within the gene-start and stop sequences 
(see below).
The RSV polymerase complex recognises gene-stop signals with a frequency of 
between 90 and 95%. In the remaining incidents, readthrough, or polycistronic, 
mRNAs, are generated (Fearns & Collins, 1999b). Only the first ORF present in a 
polycistronic transcript is translated (Wong & Flirano, 1987). This may be a means by 
which virus down-regulates (attenuates) expression of 5' proximal genes. Messenger
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RNA abundance decreases with gene distance from the 3' leader sequence. This 
phenomenon is unrelated to mRNA half-lives and is due mainly to polymerase fall-off 
during sequential transcription, affected by increasing distance from the 3' promoter as 
has been shown for the rhabdovirus VSV. The overlap of 68 nucleotides existing 
between RSV genes M2 and L reduces transcription of this last gene. Feams and 
Collins (1999a) propose that a proportion of polymerases that terminate at the M2 
gene-end sequence, scan back along the genome to initiate transcription at the L gene- 
start signal.
1.6.2 Replication
RSV genome replication requires the concurrent synthesis of viral proteins to enable 
concomitant encapsidation of the nascent RNA. The same viral polymerase complex is 
responsible for both transcription and RNA replication. A model describing the change 
from transcription to RNA replication has been proposed following the study of VSV 
and SeV. Investigations suggest that there is a switch from the stop-start mechanism of 
transcription to an anti-termination read-through mode, producing full-length positive- 
sense antigenome. This is complementary to the genome, encapsidated with N, and 
behaves as a template for genome synthesis. The model proposed that N protein 
availability is a limiting factor, determining whether or not genome replication may 
occur (Lamb & Kolakofsky, 1996). It suggests that N is able to bind an encapsidation 
signal, present in the leader sequence of the negative-strand genome template. When 
N concentration is not limiting, the protein binds and therefore suppresses the 
termination signal, allowing the transcription of full-length antigenome and initiating 
nucleocapsid assembly. A similar termination signal is present within the promoter of 
the antigenome to ensure genome production does not occur in the absence of N 
protein. Upon its utilisation, N concentration decreases. When N is limiting, the protein 
does not bind the encapsidation sequence, therefore replicative RNA synthesis 
terminates at the leader junction and the polymerase reinitiates at the first gene and 
synthesises mRNAs (Blumberg et al., 1981). The model of an N-controlled switch is 
very much debated. Upon its investigation in RSV, no evidence was obtained of a 
dynamic switch between transcription and RNA replication. Results indicated that the 
ratio between these processes remained relatively constant even when an excess of N 
was supplied which should, according to the model, favour replication (Fearns et al.,
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1997). However, at present, this model remains a popular explanation of the 
mechanism of control between transcription and RNA replication.
1.6.3 Rule of Six
The study of the replication of some members of the Paramyxoviridae, using various 
rescue systems, indicated the importance of genome length. Work performed with 
defective interfering virus particles established that efficient replication was achieved 
only when genome length was a multiple of six. Calain & Roux (1993) found that the 
addition or deletion of a single nucleotide destroyed viral replication in the SeV system; 
replication was restored by the addition of nucleotides returning the genome to a 
multiple of six. The phenomenon was referred to as the "Rule of Six", and can be 
applied to the Morbillivirus genus e.g. MV (Radecke et al., 1995) and to a lesser extent 
the Rubulavirus genus e.g. SV5 (Murphy & Parks, 1997). The situation for RSV 
appears to be different, as it shows no requirement for its genome to be a multiple of 
six or any other integer (Samal & Collins, 1996). Vulliemoz & Roux (2001) postulate 
that where the Rule of Six applies, the interaction of six nucleotides, in context with the 
N protein, is critical for the presentation of the viral promoter to the polymerase. This 
may be a reflection of differences in the organisation between the 3' viral promotor of 
the Pneumovirinae and the Paramyxovirinae. The Paramyxovirinae promotor is 
effectively bi-partite, with one element in the leader region and the other within the N 
gene (i.e. downstream of the leader/N gene junction). It is suggested that the inter­
relationship between the correct number, and therefore correct spacing of nucleotides, 
and the N protein bring the two elements into some form of functional alignment. 
Incorrect spacing, by the addition or deletion of nucleotides, disrupts the alignment and 
has a deleterious effect on functionality. However, the Pneumovirinae promoter is 
mono-partite, as shown by the rescue system (Collins et al., 1991). It is found solely 
within the leader region and can accommodate changes in length, as it does not have 
to align with downstream sequences.
1.7 Regulatory RNA Sequences
The genome contains all the necessary signals to regulate the synthesis of RNA, either 
as mRNA or as genome/antigenome. Production of mRNA requires transcriptional 
modification (for example capping and polyadenylation) such that the viral messages 
are functionally identical to those of the cell. Since RSV replicates in the cytoplasm and
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utilises it's own polymerase, the virus requires specific control signals to regulate RNA 
production and the switch from mRNA production to replication of the genome.
1.7.1 Extragenic RNA -  Sequences at Genome Termini
Short, non-coding sequences are present at both the 3'- (leader) and 5'- (trailer) termini 
of the paramyxovirus family genome; these contain the viral promotors and the genome 
encapsidation signal. In RSV, the leader sequence is 44 nucleotides long and the 
trailer sequence, 155 nucleotides in length. The extreme 3'-terminal and 5'-terminal 
sequences of the leader and trailer share 81% complementarity (21/26 bases may be 
aligned) (Mink et al., 1991) suggesting that they base pair or share a common function. 
The first 12 nucleotides of the leader region are well conserved between the 
paramyxoviruses and the pneumoviruses. This sequence conservation suggests the 
region may be of functional importance. The ability of the trailer region to act as a 
promoter to produce genome RNA was demonstrated by the deleterious effects of 
mutating this region (Fearns et al., 2000; Peeples & Collins, 2000).
1.7.2 Intragenic RNA -  Gene-Start and Gene-Stop Sequences
A characteristic common to all members of the Paramyxoviridae family is the presence 
of non-coding sequence surrounding the open reading frame (ORF) within each gene. 
That occurring at the 3’-end of the gene is described as the gene-start sequence and 
the region present at the 5 ’-end, as the gene-end sequence. Both regions are 
transcribed into the mRNA.
The RSV gene-start sequences are nearly identical. The nine nucleotide sequence 3'- 
CCCCGUUUA-5' is present at the beginning of each gene, with the exception of L, 
where it differs by two nucleotides (Collins et al., 1986). Transcription by the 
polymerase complex begins at the first nucleotide of this sequence and continues to 
the gene-end sequence, a semi-conserved signal that contains a short stretch of U 
residues. The gene-end sequence directs polyadenylation and transcription 
termination. It is suggested, by analogy to SeV and VSV, that the polymerase complex 
stutters upon transcription of the U region producing the polyadenylated tail of the 
mRNA. This proposed reiterative copying produces a tail of approximately 200 
adenosine (A) residues (Lamb et al., 1996). Analysis of the gene-start and gene-end
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signals has shown that mutations can adversely affect the replication of recombinant 
mini-genomes (Kuo et al., 1996b).
1.7.3 Interqenic RNA -  Non-Coding Sequence between Genes 
There are intergenic regions of non-coding RNA present in the Paramyxoviridae family 
genome (Amesse et al., 1982). Among members of the Morbillivirus and the 
Respirovirus genera, these regions consist of a conserved three nucleotide sequence 
(3'-GAA-5'). Such conservation suggests they may be regulatory signals. The 
rubulaviruses do not possess intergenic sequence conservation. Within the 
Pneumovirus genus, the intergenic sequences are highly variable, ranging from one 
base (between the N and P genes) to 52 nucleotides (between the G and F genes) in 
length (Collins et al., 1986). The intergenic regions are not transcribed into mRNA, 
though they are passed over by the polymerase complex without its becoming 
detached from the genome. Excepting the requirement for at least one base, the 
variation in length of RSV intergenic regions does not appear to affect the transcription 
of the proceeding gene (Kuo etal., 1996a).
1.8 Virion Assembly
The assembly of the nucleocapsid occurs in the cell cytoplasm. The nucleocapsids are 
transported to the plasma membrane where they associate with the envelope proteins.
I
j  The mechanism of virus particle assembly at the cell surface is thought to be mediated
by the M protein though this remains to be determined. Virion maturation appears to 
occur in circumscribed regions of the cell surface. This may reflect dependence of virus 
budding from the cell membrane on localised sub-cellular structures (for example, lipid 
rafts) or the clustering of virus components (P. Yeo, personal communication). Teng & 
Collins (1998) demonstrated that N, P, L, M and F constituted the minimal 
requirements for packaging of the genome into an infectious particle.
1.9 The Protein components of RSV
! There are ten major mRNA products of the RSV genome. Of the 11 resulting proteins
I
(the M2 gene gives rise to two proteins), eight are known to be virion-associated, 
structural proteins. These include the transmembrane surface proteins G, F and SH, 
responsible for host cell adsorption and virus entry. The non-glycosylated M protein
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forms the virion matrix beneath the viral membrane. The N, P, L and M2-1 proteins are 
associated with the genomic RNA to form the viral nucleocapsid and are the functional 
components of the polymerase. Protein distribution within the virus particle of RSV is 
demonstrated in Figure 1.2. The two remaining mRNA products are the non-structural 
proteins, NS1 and NS2, present only in trace amounts in the virion (if at all).
1.10 The Viral Envelope Proteins
1.10.1 The Fusion (F) Protein
The fusion protein of RSV is related in both structure and function to its counterparts in 
the Paramyxovirinae subfamily and provides perhaps the best reason for grouping 
pneumoviruses into the same taxonomic family (Collins et al., 1984; Spriggs et al., 
1986). RSV F is similar in size (540-580 amino acids, aa) to those of the 
paramyxoviruses though it possesses low sequence relatedness with these proteins. 
The F proteins of this family resemble one another in the location of hydrophobic 
domains and the possession of an internal cleavage peptide. As suggested by the 
name, the F protein mediates the fusion between the viral and host cell membranes, 
enabling cell entry. It is also responsible for syncytium formation during host infection.
The F protein is a Type I glycoprotein with a cleaved amino-terminal signal sequence 
and a membrane anchor near the carboxy-terminus. The protein spans the membrane 
and possesses a short cytoplasmic tail. It is synthesised in the rough endoplasmic 
reticulum (RER) as the precursor polypeptide F0. Within the RER, F0 is co- 
synthetically modified by the addition of N-linked sugars and is assembled into a trimer. 
This precursor is cleaved, possibly in the fra/?s-Golgi network, by the cellular protease 
furin, a subtilisin-like endoproteinase, creating the biologically active protein form 
(Sugrue et al., 2001). Cleavage generates a short amino-terminal F2 peptide and the 
longer carboxy-terminal F1 peptide, linked by disulphide bridges. The newly exposed 
amino-terminus of F1 is termed the fusion peptide and is well conserved among the 
Pneumovirinae but not between sub-families, although all are highly hydrophobic. The 
hydrophobic residues are involved in the membrane insertion function of the protein 
and mediates the fusion event (Gonzalez-Reyes et al., 2001; Zimmer et al., 2001).
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1.10.2 The Attachment Protein (G)
The viral attachment protein G binds the receptor on the target cell membrane, 
facilitating adsorption of the virus. This was confirmed by the prevention of virus 
adsorption by a G protein-specific Mab (Levine et al., 1987). The cellular receptor for 
RSV in vivo is, as yet, unknown but within tissue culture, heparin has been implicated 
as a ligand for G protein dependent cell-surface attachment (Krusat & Streckert, 1997).
The G protein (298 aa) possesses no significant sequence relatedness or structural 
similarity with those of the paramyxovirus subfamily (Wertz et al., 1985) and has 
neither neuraminidase nor haemagglutinating activity. The G protein is a Class II 
glycoprotein with an extracellular carboxy-terminal domain and an uncleaved signal- 
anchor sequence at its amino-terminus. The RSV G protein is palmitylated and is 
heavily glycosylated with both N- and O- linked sugars, possessing a higher 
carbohydrate content than its counterparts in the paramyxoviruses. Both N-linked 
glycosylation and the assembly of polypeptide into homotrimers occur within the RER. 
Addition of O-linked sugars takes place in the frans-Golgi network. The carbohydrate 
may serve to shield the polypeptide chain and prevent its recognition by the host 
(reviewed by Melero et al., 1997).
Approximately 15% of the RSV G protein is expressed in a soluble form. It is created 
when translation initiates from an internal AUG start codon and subsequent post- 
translational removal of amino-terminus amino acids (Hendricks etal., 1988). Secretion 
of G protein may influence the host immune response in a manner favourable for the 
virus although there is no evidence as to what.
1.10.3 The Small. Hydrophobic (SH) Protein
SH is a small glycosylated envelope protein, with a carboxy-terminal extracellular 
domain and an amino-terminal membrane anchor. This Type II envelope protein 
contains a single internal hydrophobic domain and possesses potential sites at both the 
amino- and carboxy-termini for the addition of carbohydrate. A variety of SH protein 
species accumulate within infected cells, differing in their extent of glycosylation and 
their use of internal start codons (Collins & Mottet, 1993). The significance of these 
different forms is unknown though it appears that only certain glycosylated derivatives 
are packaged within the virion. The function of the RSV SH protein is unknown though
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it has been shown to greatly enhance fusion in vitro when co-expressed with G and F 
proteins (Pastey & Samal, 1997). However, within the context of the virus, when 
recombinant RSV with the SH gene deleted was propagated in tissue culture, no effect 
on the fusion potential of the virus was observed. However, in an animal model, such 
viruses are attenuated (Whitehead et al., 1999).
1.10.4 The Matrix (M) Protein
M is the most abundant virion protein. RSV M is a basic, non-glycosylated protein of 
256 aa in length. It lacks sequence relatedness with the matrix proteins of the 
paramyxoviruses. However, they share the common feature of a hydrophobic domain 
in the carboxy-terminal half and presumed similarity of function. The hydrophobic 
domain is insufficient in length to span the lipid membrane. Fractionation studies 
suggest that M protein is peripherally associated with the viral envelope, possibly 
located in an electron dense layer beneath this membrane (Lamb & Kolakofsky, 1996). 
M protein is believed to mediate interaction between the nucleocapsid, envelope 
proteins and the lipid bilayer, behaving as the central organiser of virion assembly and 
morphology. In Sendai Virus, M protein interacts specifically with membrane 
expressing F and HN, indicating an interaction with the glycoprotein cytoplasmic tails 
(Sanderson et al., 1993). In VSV, interaction between M and the nucleocapsid appears 
to arrest RNA synthesis, forcing the nucleocapsid into the dormant state observed in 
the virion (Carroll & Wagner, 1979); similar behaviour may occur with the 
Paramyxoviridae M proteins.
1.11 The Nucleocapsid-Associated Proteins
1.11.1 The L Protein
The RSV large protein L is the least abundant of the structural proteins. It is similar in 
size to the L proteins of paramyxoviruses and rhabdoviruses (approximately 2200 aa) 
but shares little overall sequence homology. However, there are five regions of high 
homology near the protein centre. These conserved domains are also present within 
the RNA-dependent RNA polymerases of other virus families. It is not within the scope 
of this thesis to give a full discussion on the complexity of L, suffice to say that it 
contains the necessary enzymatic functions for the production of RNA, both genome 
and message. The protein has been assigned functions such as methylation, capping 
and polyadenylation (Collins et al., 1996b). As with the L proteins of all
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Mononegavirales, there is a requirement for an accessory factor, the Phospoprotein 
(see Section 1.11.4). The template for activity is the nucleocapsid, naked RNA will not 
serve.
1.11.2 The Non-Structural Proteins
The non-structural proteins NS1 and NS2 are present in certain members of the 
Pneumovirinae, including RSV, but are absent from the Paramyxovirinae subfamily. 
NS1 and NS2 genes are located adjacent to the leader sequence and encode 
polypeptides of predicted length 139 aa and 124 aa, respectively (Johnson & Collins, 
1989). The proteins accumulate within the cytoplasm of infected cells and have not 
been detected within the virion (Evans et al., 1996). At present, the functions of NS1 
and NS2 are not known. NS1 has been shown to be a negative regulator of genome 
replication and transcription (Atreya et al., 1998). However, neither NS1 or NS2 are 
essential for virus replication (Teng et al., 2000). Recent work on the NS1 and NS2 of 
bRSV has implicated them in playing a role in combating the IFN response (see 
Section 1.2.5).
1.11.3 The M2-1 and M2-2 Proteins
As mentioned previously, the M2 gene gives rise to two protein species M2-1 and M2- 
2, both of which are translated from the same mRNA (Ahmadian et al., 2000). The M2- 
1 protein was originally identified as a fourth membrane protein, with supposedly, a 
matrix-type function (Huang et al., 1985). However, this is no longer the case. M2-1 
has been ascribed a function as an elongation factor necessary for the efficient 
production of long RNAs during replication and transcription (Fearns & Collins, 1999b). 
M2-2 was shown to be a down-regulator of RNA synthesis (Collins et al., 1996a). 
Subsequently, Bermingham & Collins (1999) implicated M2-2 in the switch between 
transcription and replication. This has obvious implications for the model, discussed in 
Section 1.6.2 in which N protein concentration regulates the switch. However, RSV N 
is significantly smaller than those in the Paramyxovirinae, thus M2-2 may supply a 
function normally associated with the N protein.
1.11.4 The P Protein
The P protein of RSV is highly phosphorylated and is smaller than its counterparts 
within the Paramyxovirinae subfamily (241 aa compared with 392 aa for SV5 and 568
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aa for SeV) (Morgan, 1991). By analogy to the SeV P, the RSV P protein may perform 
two functions, one as a transcription and replication factor, in complex with L, and the 
other as a chaperone to unassembled nucleocapsid protein N (P-N°), maintaining the 
latter in a soluble, active form preventing illegitimate nucleocapsid assembly of non- 
viral RNA (Curran et al., 1993; Curran etal., 1995).
The RSV P protein is modular in organisation with the separation of amino- and 
carboxy-terminal domains by a hypervariable region. Domains responsible for P protein 
oligomerisation, association with the L protein and for binding N protein in the 
assembled (i.e. the nucleocapsid), and possibly unassembled, form appear to be within 
the proteins carboxy-terminus (Garcia-Barreno etal., 1996; Khattaretal., 2001; Slack 
& Easton, 1998). All studies agree that the carboxy-terminus is essential to enable P 
protein to function in the interaction with N, notably when P behaves as a transcription 
co-factor. The role of the amino-terminus is less clear but it may participate in the 
chaperone function, as proposed for SeV (Curran et al., 1995).
1.11.5 The N Protein
N is the most abundant protein in the nucleocapsid core and is associated with the P, L 
and M2-1 proteins (Garcia-Barreno et al., 1996; Khattar et al., 2001; Samal et al., 
1993). The N protein performs a number of functions. Its major role is the 
encapsidation of the viral genome generating the RNase-resistant nucleocapsid. N 
tightly binds the RNA along its entire length, providing support, and protection from 
RNAses, of the phosphodiester backbone of the genome, yet enabling the continuation 
of transcription and RNA replication (Lamb & Kolakofsky, 1996).
The human RSV N protein was sequenced by Collins et al. (1985). It is smaller than 
the Paramyxovirinae counterparts, being only 391 aa in length and has a mass of 
approximately 43 kDa. Upon sequence comparison of human and bovine strains of 
RSV, N is observed to be a highly conserved protein with 93 to 94% sequence identity 
at the amino acid level (Samal et al., 1991). There is relatively low N sequence 
homology with other non-segmented negative strand viruses. However, alignment of 
the RSV N protein with the N-terminal 400 aa of Paramyxovirinae N proteins shows the 
presence of three segments of limited sequence similarity. These sequences are semi­
conserved and appear to share a predicted secondary structure. This sequence 
similarity suggests the region is of fundamental importance to protein function (Morgan, 
1991).
24
Chapter 1
1.12 N proteins and nucleocapsid assembly
Many nucleocapsid protein sequences of the negative-strand RNA viruses have now 
been determined. Within the Paramyxoviridae, little more than 50% identity exists 
between N proteins, though conservation is greater within genera. In the 
Paramyxovirinae, N proteins range in length from 489 to 553 aa and are between 53 
and 58 kDa in size (Morgan, 1991). With the exception of Mumps Virus N protein, their 
net charges fall within the range of -7 to -12. This is an unexpected observation of 
proteins known to associate with negatively-charged RNA. Several RNA-binding 
protein families have been identified, each possessing a common sequence motif 
believed to interact with RNA. A family may have representatives in a diverse range of 
organisms ranging across viruses, prokaryotes and eukaryotes (Mattaj, 1993). The N 
proteins of the Mononegavirales are not classical RNA-binding proteins and lack 
recognised RNA-binding motifs. Leader regions of the Mononegavirales, which 
presumably contain the putative encapsidation signal, have no secondary structure. It 
is the primary RNA sequence that is responsible for binding N (Grinnell & Wagner, 
1984; Hoffman & Banerjee, 2000). When expressed alone, N proteins do not appear to 
have sequence specificity and may bind cellular RNAs forming structures that are 
morphologically identical to nucleocapsids produced during normal viral infection (Meric 
et al.t 1994; Myers et al., 1997; Spehner et al., 1997. Wames et al., 1995) The 
specificity of RNA binding would appear, at least for SeV and MV, to be a function of 
the N-P complex (Curran et al., 1995).
1.13 The nucleocapsids of the Paramyxoviridae
Despite their importance, very little ultra-structural information is available for 
Paramyxoviridae nucleocapsids, visualised by electron microscopy as single left- 
handed helices (Compans et al., 1972). Studies on SeV show that its nucleocapsid 
varies extensively in the coiling and flexibility of the helical structure (Egelman et al., 
1989), which may be affected by salt concentration (Heggeness et al., 1980). Upon 
salt-induced conformational change, accessibility of the N protein to trypsin cleavage 
alters. At low salt concentrations, the nucleocapsid has an extended conformation, 
leaving the N protein accessible to protease digestion. Upon the partial degradation of 
N, the SeV nucleocapsid structure remains intact. This is mediated by regions within 
the amino-terminal domain of the protein. Through-out investigations, the viral genome 
remained protected from RNase digestion. This demonstrated that neither the tightness
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of the helix nor the proteolytic cleavage in N protein affected the binding of RNA by N 
or its protection from ribonuclease digestion (Heggeness et al., 1980; Heggeness etal., 
1981). The ability to vary the nucleocapsid structure may be important in the 
mechanism of RNA transcription and replication. It was determined that proteolytic 
removal of the carboxy-terminus prevented RNA synthesis from the nucleocapsid.
1.14 Aims of this study
Within the Institute of Virology, RSV research was a new initiative thus there was no 
historical background upon which to build. Although C. Pringle worked on RSV in the 
early eighties, most of his reagents were not available. Paul Yeo instigated several 
areas of research developing his interests in the RSV proteins N and M and in virus 
assembly. The long-term objectives of the group were to achieve structural 
determination of the proteins above and to map biological interactions. Therefore, a 
feature of the work presented herein was to develop reagents and protocols that may 
be of use in future structural and biological investigations of the RSV N protein. Several 
areas were targeted as being of interest and have been addressed within this thesis.
• The purification of recombinant N protein, suitable for in vitro analysis
• Determination of the N protein’s sequence specificity for binding RNA
• Identification of the RNA binding domain on the N protein
• Effect of mutations on assembly of nucleocapsid-like structures in bacteria
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2 Materials and Methods
2.1 Statement of Safety
Tissue culture and work with both Respiratory Syncytial Virus and with Baculovirus 
were restricted to a sterile Class II flow cabinet. The cabinet was wiped with 70% (v/v) 
ethanol before and after use and was sterilised by UV light. Bacterial work was 
performed in a Class II laboratory.
Used growth medium and buffers were neutralised with 1 % (w/v) virkon and incubated 
overnight prior to being discarded. Used glassware was steeped in 1% (v/v) chloros 
overnight prior to being washed and autoclaved.
All cell and chemical reagent work was performed wearing protective gloves and 
laboratory coat to minimise personal contact. When working with radioactivity, a double 
layer of gloves and a laboratory coat were worn. Radioactive work was performed 
behind Perspex shielding.
2.2 Source of Chemical Reagents
Tissue culture reagents were obtained from GibcoBRL (Scotland).
BDH (Poole, England) provided the majority of laboratory chemicals. Remaining 
chemicals were obtained from Sigma, R.P. Normapur A.R. Prolabo (France) and from 
Boehringer Mannheim, GmbH (Germany).
2.3 Sources of Enzymes
Restriction endonucleases were obtained from New England Biolabs. Additional 
enzymes were provided by Promega and by Sigma.
2.4 Sources of Antibodies
Antibodies directed against various RSV proteins were generated in the laboratory. 
Those frequently used in the project are listed in Table 2.1. Purified antibodies directed 
against Histidine-tag were obtained from Sigma.
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Antibody Designation Antibody Type Species RSV Protein Specificity
N003 Monoclonal Mouse N
N009 Monoclonal Mouse N
N015 Monoclonal Mouse N
P001 Monoclonal Mouse P
M024 Monoclonal Mouse M
22k/302 Monoclonal Mouse M2-1
P658 Polyclonal Rabbit P
N14 Polyclonal Rabbit N
N15 Polyclonal Rabbit N
Table 2.1: RSV-specific antibodies generated in the laboratory and used during 
the project.
|
i
2.5 Tissue Culture
i
! 2.5.1 Maintenance of Cultured Cells
\
f
The laboratory cell line CV-1, derived from African green monkey kidney, was used to 
culture respiratory syncytial virus. Cells were cultivated as a monolayer in T180 flasks 
and maintained in Dulbecco's Modified Eagle Medium (DMEM) with 2 mM L-glutamine, 
1% (w/v) non-essential amino acids, 1% (w/v) penicillin and streptomycin antibiotics 
and 10% (v/v) heat-inactivated foetal calf serum (FCS). The cells were incubated at
37°C, 5% (v/v) carbon dioxide (CO2 ). Cells were passaged at 80-100% monolayer 
confluency. The cell layer was washed with 0.25% (w/v) trypsin (Sigma) in versene. 
The supernatant was discarded and the flask incubated for three to five minutes. The 
loosened cells were resuspended in 10 ml fresh 10% FCS growth medium. The desired 
volume of cell suspension was placed in a new T180 flask and combined with fresh
growth medium. Cells were returned to incubation at 37°C, 5% CO2 .
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2.6 Virus Growth and Maintenance
2.6.1 Preparation of Respiratory Svncvtial Virus
RSV strain A2 was provided by C. Pringle, Warwick University, and was used 
throughout the project. A CV-1 cell monolayer was grown to 70% confluency in a T180 
flask. The monolayer was washed twice with phosphate-buffered saline (PBS). RSV 
was added to the monolayer in growth medium with 2% FCS at a multiplicity of
infection (m.o.i.) of 0.1. The flask was incubated for one to two hours at 33°C to enable 
virus adsorption to the cells. The inoculum was removed and the cells washed twice 
with PBS. 20 ml fresh 2% FCS medium was added to the flask and the infected cells
incubated for three to five days at 33°C, 5% CO2 until cytopathology, in the form of 
fused cells, was evident. To harvest virus from the infected culture, the medium was 
first removed. 10 ml fresh medium, followed by half a bijoux of sterile glass beads (2.5 
mm diameter) were poured into the flask. The flask was shaken vigorously for 
approximately one minute to cause cell lysis and disrupt cell-associated virus. The 
resulting supernatant was decanted and cell debris and glass beads removed by 
centrifugation for 10 minutes at 3000 xg. The clarified supernatant was divided into 1 
ml aliquots and stored at -70°C.
2.6.2 Measurement of Virus Titre by Plaque Assay
CV-1 cells cultured in growth medium in a six-well plate (35 mm diameter) were grown 
to 80-90% confluency. The medium was removed and the cells washed twice with 
sterile PBS. Ten-fold serial dilutions of the virus sample were added to each well in 1
ml 2% FCS growth medium. The cells were incubated for one to two hours at 33°C, 5% 
CO2 . The inoculum was removed and the cells washed with PBS. An overlay mixture of 
2% FCS, 0.8% Noble agar and DEAE-dextran (100 p.g ml'1) in DMEM was prepared
and maintained at 42°C. Three millilitres of overlay mixture was added to each well and 
allowed to set at room temperature. The plate was then inverted and incubated for five 
to seven days. Three millilitres glutaldehyde fixative (50% Cidex in PBS) was added to 
each well in a fume hood. The plate was incubated for three to four hours at room 
temperature. The fixative and agar were removed by washing with water. The cells 
were stained with giemsa stain (BDH) for one hour at room temperature. The stain was 
removed by washing with water. The wells were examined under the light microscope 
and the number of virus plaques, visible by the absence of stain, was recorded.
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2.6.3 Immunofluorescence (IF) of Virus-Infected Celts
Sterile glass cover-slips (13 mm diameter) were placed in individual wells of a 24-well 
plate. 4x104 CV-1 cells were seeded in each well in a volume of 1 ml 10% FCS growth
medium. The plate was incubated overnight at 37°C, 5% CO2 . Upon 80% confluency of 
the cell layer, the medium was removed and the cells washed twice with PBS. RSV 
was added to each well at m.o.i. 1.0 in 200 pi 2% FCS growth medium. The cells were
incubated for one to two hours at 33°C, 5% CO2 . The virus medium was removed and 
the cells washed with PBS. One millilitre 2% FCS growth medium was added to each 
well and the cells, incubated for 16 to 20 hours at 33°C, 5% CO2 . The medium was
removed and the cells washed with PBS. The cells were fixed with cold methanol (-
20°C) and incubated at -20°C for up to 20 minutes or overnight. The methanol was 
removed and the cells washed three times with PBS. Antibodies generated in the 
laboratory and directed against various RSV proteins are listed in Table 2.1. Purified 
RSV monoclonal antibodies were diluted 1/1000 in PBS with 1% FCS. RSV polyclonal 
antibodies were diluted 1/500 in PBS with 1% FCS. Antibodies were added individually 
or in combination to the wells. The plate was incubated for one hour at room
! temperature. Primary antibody was removed and the cells washed with PBS with 1%
i
; FCS. The appropriate anti-species antibody conjugated to FITC or TRITC, diluted
i
[ 1/200 in PBS with 1% FCS, was added to each well. The plate was incubated for one
| hour at room temperature in the dark. Antibody was removed and the cells washed
three times with PBS. The cover-slips were removed from each well, allowed to air-dry 
and mounted on glass slides with Citifluor. Immuno-staining was visualised under a 
fluorescence microscope (Nikon) or by confocal microscopy (courtesy of J. Murray).
2.6.4 Labelling of RSV-infected CV-1 Cells with r35S1-Methionine
CV-1 cells, grown as a monolayer in a T180 flask, were infected with RSV at m.o.i. 0.1 
as described in Section 2.6.1. At 48 hours post-infection, the cell monolayer was
starved of methionine for one hour by incubating in methionine-free growth medium 
(Gibco), followed by the addition of [35S]-methionine at 100 pCi ml'1. Cells were 
incubated for three hours then harvested into RIPA buffer and clarified by centrifugation 
at 10 000 xg. The supernatant was pre-cleared using Pansorbin cells (Calbiochem) and 
a non-specific antibody.
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2.6.5 Radiolabelled Immunoprecipitation Assay
[35S]-methionine-labelled RSV-infected CV-1 cells were used in a radiolabelled 
immunoprecipitation assay (RIPA) with antibodies directed against RSV proteins. One 
microlitre purified mono- or polyclonal antibody was added to a 50 pi aliquot of 
radiolabelled, infected cell lysate (Section 2.6.4) and incubated for one hour at 4°C with 
shaking. Sepharose-bound protein A was used to precipitate antibody-antigen 
complexes from solution. Protein A associates more strongly with rabbit- rather than 
with mouse-derived antibodies. An extra labelling step was therefore included with the 
addition of rabbit anti-mouse (Sigma) to each sample and further incubation for one 
hour, 4°C with shaking. 20 pi protein A (50% (w/v) in lysis buffer) was added and the 
samples incubated for one hour, 4°C with shaking. The protein A complexes were 
pelleted by centrifugation for one minute at 6000 xg. The supernatant was discarded 
and the pellet resuspended in 200 pi lysis buffer. This process was repeated five times. 
The pellet was combined with sample loading buffer, heated for five minutes at 95°C 
and separated by SDS-PAGE (Section 2.10.7).
2.6.6 Extraction of Cellular and Viral RNA
The Total RNA Isolation Kit (Ambion) was used to extract cellular and viral RNA from 
RSV-infected CV-1 cells. The growth medium from a T180 flask of infected CV-1 cells 
was discarded and the cells washed three times with PBS. Ten millilitres denaturing 
solution was added and the flask, agitated for approximately three minutes. The 
resulting supernatant was combined with 0.1 volume of 3 M sodium acetate and one 
volume of phenohchloroform (1:1) solution, shaken vigorously for one minute and 
placed on ice for 15 minutes. The mixture was subjected to a centrifugal force of 12 
000 xg for 15 minutes. The aqueous layer (top) was retained and combined with one 
volume of acid phenol:chloroform (1:1) solution. The sample was again shaken and 
centrifuged as above. The resulting aqueous layer was combined with one volume iso-
propanol and incubated overnight at -20°C. The sample was subjected to a centrifugal 
force of 7500 xg for 10 minutes to pellet the RNA. The supernatant was discarded and 
the pellet washed with 70% (v/v) ethanol and allowed to air-dry. The RNA pellet was 
resuspended in 1 ml de-ionised water (dh^O) and its optical density (O.D.260) 
determined (Section 2.9.7).
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2.6.7 Recombinant Baculovirus Infection in Sf21 Insect Cells
Sf21 insect cells were grown in a monolayer in T180 flasks and maintained in TC100 
growth medium with 10% FCS at 27°C, 5% C 0 2. Upon confluency, cells were 
passaged by knocking the adherent cells into 10 ml growth medium and reseeding 1 ml 
into a fresh T180 flask. Baculovirus Bac-Nwt was obtained from P. Yeo. The 
recombinant virus expresses the N protein gene of RSV strain A2 under the control of 
the baculovirus polyhedrin promoter. Sf21 cells were infected with Bac-Nwt at an m.o.i. 
of 5-10 and maintained at 27°C, 5% C 0 2 for 72 hours before harvesting the protein 
(Section 2.12.1.2).
2.7 Bacterial Work
2.7.1 Strains of Bacteria
Various laboratory strains of Escherichia coli (E.coli) were employed during the course 
of the project (Table 2.2). Strains DH5 and JM109 were used for the purpose of 
plasmid DNA amplification and maintenance. BL21(DE3)pLysS and NovaBlue (DE3) 
strains were used for the expression of recombinant protein. Strain BMH 71-18 mutS is 
tolerant of initial plasmid strand-mismatch. It was used in site-directed mutagenesis to 
obtain mutant DNA.
Bacterial Strain (source) GenotvDe
DH5 (Stratagene) supE44 hsdR17 recA1 endA1 gyrA96 thi-1 relA1
BL21(DE3)pLysS (Novagen) F  ompT hsdSB(rBmB) gal dcm (DE3) pLysS (CmR)
NovaBlue (DE3) (Novagen) endA1 hsdR17(rK12mK12 ) supE44 thi-1 recA1 gyrA96 relA1 
lac [F  proA*B* lacfZAM15 *Tn10(TcR)] (DE3)
BMH 71-18 mutS (Promega) thi supE A(lac-proAB) [m utS: :Tn10] [F ’proAB laqfZA M 15
JM109 (Promega) recA1 supE44 endA1 hsdR17 gyrA96 relA1 thi A(lac- 
proAB) F[traD36 proAB+ lacF lacZAM15\
Table 2.2 : Laboratory strains of E.coli employed during the course of the 
project.
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2.7.2 Growth and Maintenance of Bacteria
Routinely, bacteria were grown on L-broth agar or in 2YT liquid medium. Bacterial 
samples were either streaked using a sterile loop or evenly spread over the surface of 
an L-broth agar plate. Antibiotics were frequently included to select for the growth of 
bacteria possessing plasmid containing a particular resistance gene. Bacterial plates 
were inverted and incubated for 16 to 20 hours at 37°C. To isolate a single bacterial 
clone, an individual colony was picked from the plate using a sterile tooth-pick and was 
placed in 10 ml selective 2YT medium. The culture was incubated for 16 to 20 hours at 
37°C with shaking at 200 rpm.
2.7.3 Storage of Bacterial Stocks
Bacterial stocks were prepared by combining an aliquot of the 10 ml culture grown from 
a single colony with an equal volume of sterile glycerol. Samples were transferred to a 
glass bijoux and placed at -70°C for long term storage.
2.7.4 Antibiotic Stocks
Stock ampicillin was prepared at 100 mg ml'1 in dH20 at -20°C; its working 
concentration was 100 pg ml'1. Stock chloramphenicol was prepared at 34 mg ml'1 in 
ethanol at -20°C; its working concentration was 34 pg ml'1.
2.7.5 Production of Competent Bacteria
2.7.5.1 Electro-competent Bacteria
A single bacterial colony was picked from an L-broth agar plate and used to inoculate 
10 ml 2YT medium. The culture was incubated overnight at 37°C with shaking at 200 
rpm. To generate bacteria competent for transformation by electroporation, 500 ml 2YT 
medium was inoculated with a dilution of 1/500 overnight culture and incubated at 
37°C, 200 rpm until an O.D.600 0.6-0.8 was obtained. The culture was placed on ice for 
up to one hour and then subjected to a centrifugal force of 1700 xg for 10 minutes, 4°C. 
The supernatant was removed and the cell pellet resuspended in 300 ml ice-cold dH20 . 
This procedure was repeated with 150 ml, 75 ml, 30 ml and 15 ml volumes of ice-cold 
10% (v/v) glycerol. The volume of the final pellet was estimated and resuspended in an
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equal volume of 10% glycerol. The resulting competent bacteria were stored at -70°C in 
200 |x( aliquots.
2.7.5.2 Calcium Chloride-Competent Bacteria
To generate bacteria competent for transformation by calcium chloride, 100 ml 2YT 
medium was inoculated with 1 ml overnight culture and incubated at 37°C, 200 rpm 
until O.D.eoo 0.5. The culture was placed on ice for 15 minutes and then subjected to a 
centrifugal force of 1700 xg for 15 minutes, 4°C. The supernatant was discarded and 
the cell pellet, resuspended in 50 ml ice-cold 100 mM calcium chloride. The bacteria 
were incubated on ice for 30 minutes to one hour followed by centrifugation. Steps 
were repeated with 10 ml and 1 ml 100 mM calcium chloride. The resulting 1 ml of 
competent cells was incubated on ice for 30 minutes prior to their immediate use.
2.7.6 Transformation of Competent Bacteria
2.7.6.1 Electroporation
40 pi electro-competent bacteria were combined with either -0.1 pg plasmid DNA or 3 
pi ligation reaction (Section 2.9.9) in an ice-cold cuvette with gap size 0.1 cm. The 
cuvette was tapped to dislodge air bubbles and placed in the ice-cold cuvette holder. 
The electroporater (BioRad) was set to the following parameters: Capacitance 25 pFD; 
Resistance 400 Ohms and Volts 1.6 kV. After application of the electric current, 1 ml 
2YT broth was added to the cuvette and the bacteria transferred to a universal tube. 
The bacteria were incubated for one hour at 37°C, with shaking. One microlitre, 10 pi 
and 100 pi aliquots were spread on L-broth agar plates, with appropriate selective 
antibiotics. The plates were inverted and incubated overnight at 37°C.
2.7.6.2 Calcium Chloride-Heat Shock
0.5 pg plasmid DNA and 300 pi competent cells were combined and incubated for 30 
minutes on ice. The mixture was transferred to 42°C for two minutes and then returned 
to ice for a further two minutes. 700 pi 2YT broth was added and the bacteria, 
incubated for one hour at 37°C, 200 rpm. Aliquots were spread on selective L-broth 
agar and the plates incubated, as previously described (Section 2.7.6.1).
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2.7.7 Plasmid DNA Extraction
QIAprep Spin Miniprep Kit (Qiagen) was used to extract plasmid DNA from small 
volume cultures of transformed bacteria. The kit employs an alkaline method of 
bacterial lysis and captures plasmid DNA on a resin from where it is washed and 
subsequently eluted. A single bacterial colony was used to inoculate 10 ml selective 
2YT medium. The culture was incubated for 16 to 20 hours at 37°C, 200 rpm. Between
1.5 and 6 ml culture was then subjected to a centrifugal force of 14 000 xg for five 
minutes. The supernatant was discarded and the pellet, resuspended in 250 pi Buffer 
P1 (with 100 pg ml'1 RNase A). 250 pi lysis buffer (P2) was added and the reagents 
mixed by inverting the tube. Following a five minute incubation at room temperature, 
350 pi neutralising buffer (N3) was added and the reagents again mixed by inverting. 
The mixture was subjected to a centrifugal force of 14 000 xg for 10 minutes to pellet 
cell debris. The resulting supernatant was retained and applied to a QIAprep spin 
column. The column was centrifuged for one minute and the flow-through discarded. 
750 pi wash buffer (PE) was applied and the column centrifuged for one minute. The 
flow-through was discarded and the column was centrifuged for a further one minute to 
remove residual buffer. DNA was eluted by the addition of 50 pi dH20 to the column 
and centrifugation for one minute. The DNA was either used immediately or stored at - 
20°C.
2.7.8 Expression of His-Tagged Nucleocapsid Protein
E.coli strain BL21(DE3)pLysS (Novagen) was transformed with pET16b-Nucleocapsid 
gene plasmid DNA by calcium chloride-heat shock. An individual colony from the 
resulting transformation was picked and placed in 10 ml 2YT medium, with 10 pg ml'1 
ampicillin and 34 pg ml'1 chloramphenicol. The culture was incubated for 16 to 20 hours 
at 37°C, 200 rpm. 100 ml selective 2YT medium was inoculated with overnight culture 
creating a 1/100 dilution. The culture was incubated at 37°C, 200 rpm until O.D.eoo 0.8 
was obtained. Recombinant protein expression was induced upon addition of 1 mM 
isopropyl-(3-D-thiogalactopyranoside (IPTG) and the culture incubated for a further 
three hours at 37°C, 200 rpm. The culture was subjected to a centrifugal force of 1700 
xg for 15 minutes. The supernatant was discarded and the pellet processed for protein 
purification (Sections 2.10.1 and 2.12.1).
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2.8 Yeast Three Hybrid System
2.8.1 Yeast Growth and Transformation
Recombinant yeast strain L40-coat was used in the yeast-three-hybrid assay. The 
strain possesses a gene encoding the MS2 bacteriophage coat protein fused to the Lex 
A DNA binding domain integrated into the chromosome. Daughter strains L3-2 RSV 
and L40-HCV were generated upon transformation of L40-coat with plasmids 
expressing RSV-MS2-2 and HCV 3’NCR-MS2-2 transcripts, respectively. The latter 
plasmid was kindly provided by J. Wood (MRC Virology Unit). Plasmids encoding RNA 
transcripts possess a gene enabling the yeast to survive in uracil-depleted medium 
(Ura). Yeast strains were later transformed with plasmid expressing N-fusion protein. 
These plasmids encode a gene enabling yeast survival in the absence of leucine. 
Individual colonies of the transformed yeast strains L40-coat, L3-2 RSV and L40-HCV 
were picked, resuspended in 1 ml dH20  and added to 50 ml aliquots YPD medium 
(L40-coat) or Ura' medium (L3-2 RSV and L40-HCV). The cultures were incubated 
overnight at 30°C, 200 rpm. 30-40 ml overnight cultures were added to 300 ml YPD 
medium (O.D.6oo 0.2). The cultures were incubated at 30°C, 200 rpm until O.D.6oo 0.4- 
0.6 was obtained. The cultures were subjected to a centrifugal force of 1200 xg for five 
minutes at room temperature. The supernatant was discarded and the pellets, each 
resuspended in 200 ml dH20 . The spin was repeated, the supernatants discarded and 
the pellets, each resuspended in 1.5 ml Lithium Acetate/TE buffer. 100 jllI aliquots yeast 
suspension were combined with 1 jog plasmid DNA and 100 fig herring sperm DNA and 
vortexed. 600 jul 40% (w/v) PEG3000 Lithium Acetate/TE buffer was added and the 
mixture again vortexed. The yeast aliquots were incubated for 30 minutes at 30°C, 200 
rpm. 70 |il dimethyl sulphoxide (DMSO) was added and the yeast transformed by heat- 
shock -  transferral from 42°C for 15 minutes to ice for two to five minutes. The yeast 
was pelleted by centrifugation at 14 000 xg for five minutes. The supernatants were 
discarded and the pellets, each resuspended in 500 fil dH20 . 100 fil aliquots of 
transformed yeast were spread on agar plates, with relevant supplements excluded 
from the medium. The yeast was incubated for two to four days at 30°C.
2.8.2 Colony Lift Filter Assay
The colony lift filter assay was performed to investigate the expression of the reporter 
gene p-galactosidase by transformed yeast. It’s expression is indicative of an
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association between the recombinant RNA and protein resulting in stimulation of the 
GAL4 activation domain. Colonies were transferred to Whatman #5 filter papers by 
placing papers on the yeast agar plates and smoothing over the surface. The filters 
were removed and submerged in liquid nitrogen for 10 to 30 seconds. The filters were 
thawed and then transferred colony-side up to blotting paper soaked in Z Buffer/X-Gal 
solution. The filters were incubated at room temperature for eight hours. The degree of 
colour development, resulting from reporter gene expression, was estimated by eye on 
a scale from zero to three.
2.9 DNA Manipulation
All nucleic acid samples were dissolved in either dH20  or TE buffer. Samples were 
maintained at -20°C.
2.9.1 Reverse-Transcription (RT)
The First Strand cDNA Synthesis Kit for RT-PCR (Boehringer Mannheim) was used to 
generate cDNA from the total RNA extracted from RSV-infected CV-1 cells (Section
2.6.6). Random hexamers were used to prime cDNA synthesis.
10 x RT-PCR Reaction Buffer 2 pi
25 mM Magnesium Chloride 4 pi
Deoxyribonucleotide (dNTPs) Mix 2 pi
Random Primer p(dN)6 2 pi
RNase Inhibitor 1 pi
(AMV) Reverse Transcriptase 0.8 pi
Gelatine 0.4 pi
dH20 6.8 pi
RNA Sample 1 pi / 20 pi
The reaction was incubated for 10 minutes at 25°C, followed by 60 minutes at 42°C. 
The sample was heated to 99°C for five minutes to denature the enzyme then placed 
on ice for a further five minutes.
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2.9.2 Polymerase Chain Reaction (PCR)
The Expand High Fidelity PCR System (Roche) was used to amplify the viral 
nucleocapsid gene using specific primers (Appendix). The system employs the thermo­
stable DNA polymerases Taq and Pwo. The latter enzyme has proof-reading abilities.
Mix 1 Mix 2
200 pM 
300 nM 
300 nM 
0.01-0.1 pg 
or
1 pi RT products 
Up to 25 pi dH20
Each dNTP 
Upstream Primer 
Downstream Primer 
Template DNA
10 x
2.6 units
Expand HF Buffer with 15 mM 
Magnesium Chloride 
Enzyme Mix 
Up to 25 pi dH2Q
Mixes 1 and 2 were assembled individually and combined immediately before use. The 
sample was incubated for three minutes at 94°C in a Hybaid Touchdown thermo-cycler. 
The sample was then incubated for 15 seconds at 94°C, 30 seconds at 50°C and 90 
seconds at 72°C for 30 cycles. After five cycles, the annealing temperature was 
reduced by 0.5° per cycle. The reaction was finally incubated for 10 minutes at 72°C. 
PCR products were analysed by agarose gel electrophoresis.
2.9.3 Agarose Gel Electrophoresis
Agarose and TAE buffer were combined creating a gel of the required percentage 
(frequently 1 to 2%). The mixture was heated until the agarose dissolved. Ethidium 
bromide (10 pg ml'1) was then added. The mixture was poured into a gated mini-gel 
tank (BioRad), the comb put in place and the gel allowed to set. The comb and gates 
were removed and the gel, immersed in TAE buffer. DNA sample was combined with 
the appropriate volume of loading buffer and loaded into a well. The gel was subjected 
to a potential difference of 150 V  for 10 to 15 minutes. The gel was removed from the 
apparatus and viewed under ultra violet (UV) light (280 or 302nm).
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2.9.4 DNA Isolation and Extraction from Agarose
The Gene Clean Kit (BIO 101) was used to extract DNA bands from agarose gel. This 
was performed to isolate DNA of a specific size and to remove nucleotides and primers 
residual from synthesis steps. The DNA sample was separated by agarose gel 
electrophoresis and visualized under long wave UV light (302 nm). Keeping UV 
exposure time to a minimum, the desired DNA band was excised from the gel with a 
clean scalpel. The gel slice was combined with 400 pi GC Spin Glassmilk® in a Spin™ 
filter and heated to 55°C for five minutes, inverting the tube every minute to prevent 
settling of the matrix. The tube was subjected to a centrifugal force of 14 000 xg for one 
minute and the resulting liquid in the catch tube was discarded. 500 pi GC Spin Wash 
was added and the tube centrifuged for 30 seconds. The liquid was discarded and the 
wash, repeated. The tube was centrifuged for one minute to remove remaining liquid 
from the filter. The Spin™ filter was transferred to a fresh catch tube. 25 pi GC Spin 
Elution Solution was added and the Glassmilk® resuspended by flicking the tube. The 
tube was centrifuged for 30 seconds and eluted DNA collected.
2.9.5 Phenol.Chloroform Extraction of Nucleic Acid
Phenol:chloroform extraction was performed to remove contaminating protein from 
nucleic acid. Addition of iso-amyl-alcohol (IAA) further removes lipids.
The DNA sample was increased to a volume of 100 pi with dH20 . An equal volume of 
phenol (pH >6) (Sigma) was added and the sample vortexed for 30 seconds then 
placed on ice for one minute. The sample was subjected to a centrifugal force of 14 
000 xg for one minute. The aqueous layer (top) was carefully removed and transferred 
to a fresh tube. 100 pi dH20  was added to the phenol. The mixture was vortexed, 
placed on ice and centrifuged to back extract remaining DNA. The second aqueous 
layer was combined with the first extraction. This procedure was repeated. A single 
extraction with chloroform:IAA (24:1) was then performed. The extraction of RNA 
follows the same procedure excepting the use of acidic, in place of alkaline, phenol (i.e. 
pH <6).
2.9.6 Ethanol Precipitation of Nucleic Acid
Ethanol precipitation removes salt from a nucleic acid sample and enables it’s 
resuspension in the desired buffer and volume.
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The sample was combined with 0.1 volume 3 M sodium acetate (pH 4.8) and 2.5 
volume ethanol and incubated at -20°C for one hour. The sample was exposed to a 
centrifugal force of 14 000 xg for 15 minutes, the supernatant discarded and the pellet, 
washed with 70% (v/v) ethanol. The sample was again centrifuged, the supernatant 
discarded and the pellet allowed to air-dry. The pellet was resuspended in dH20 .
2.9.7 Determination of Nucleic Acid Concentration by Spectrophotometry
One microlitre nucleic acid sample was combined with 1 ml dH20  in a quartz cuvette. 
Using dH20  alone as reference, the absorbence at 260 nm (O.D.26o) was measured. 
Nucleic acid mass was calculated by approximating as follows:
1 O.D.260 = 50 ^g DNA
= 40 jig RNA
= 30-35 fig Oligonucleotide (depending on sequence and length)
2.9.8 Restriction Endonuclease Digestion of DNA
DNA digestion by restriction enzymes was performed to create the correct ends in 
plasmid and PCR-generated DNA enabling later ligation. It was also used to confirm 
the presence and orientation of a gene insert in plasmids. The restriction enzymes Bam 
HI, Xba I and Hind III were frequently used throughout the course of the project. 
Digestions were performed with phenol:chloroform-extracted, ethanol precipitated 
DNA. Approximately 1 fig DNA was combined with 10 units of restriction enzyme and 
the appropriate restriction buffer. To reduce the possibility of vector DNA self-ligation, 
calf intestinal phosphotase (CIP) was occasionally added to the reaction mix. The 
reaction was incubated for three hours or overnight at 37°C. The reaction mixture was 
ethanol precipitated (Section 2.9.6) and the resulting pellet resuspended in 10 fil dH20.
2.9.9 DNA Ligation
The RSV nucleocapsid gene was introduced into plasmid vectors pGEM3Z (Promega) 
and pET16b (Novagen). Digested PCR product and plasmid were combined in a molar 
ratio of 3:1, with a total DNA mass of approximately 100 ng. The DNA, ligation buffer 
and 4 units T4 DNA ligase were combined in a reaction volume of 15 fil and incubated
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overnight at 16°C. Again, the ligation mixture was ethanol precipitated and the resulting 
pellet resuspended in 10 pJ dH20 .
2.9.10 Sequencing Analysis
The majority of DNA sequencing was performed by the Institute’s Sequencing Unit 
using an automated system. Upon occasion, the Thermo Sequenase Cycle 
Sequencing Kit (Amersham) was used to manually determine cloned DNA sequence. 
T7 promoter and terminator primers and internal primers specific to the RSV 
nucleocapsid gene were used. Primer details are listed in the Appendix.
Primer-Labelling Reaction 
0.5 pmole Primer 
~0.1 jug Template DNA 
5pCi [ot-32P]-dNTP 1 
dNTP 2 
dNTP 3
Reaction Buffer 
Thermo sequenase
The primer was first extended in the presence of a 32phosphorous (32P)-labelled 
deoxynucleotide (dNTP). Primer and template DNA were combined with two unlabelled 
and one radiolabelled nucleotides. Upon addition of enzyme, the reaction was cycled 
between 95°C for 15 seconds and 60°C for 30 seconds 50 times to achieve primer- 
extension to a length limited by absence of the fourth nucleotide (approximately a 
further 10 nucleotides). The exact reagent conditions varied between vectors.
Four reaction mixtures were provided with the kit, each containing one di- 
deoxynucleotide species and three deoxyribonucleotides. Four microlitres of each was 
placed in individual 0.5 ml tubes. 3.5 jul radiolabelled reaction sample was added to 
each tube and the tube contents were mixed by pipetting. The reactions were cycled 
between 95°C for 30 seconds and 72°C for 90 seconds 50 times. Four microlitres stop 
solution was added to each reaction. The samples were heated to 70°C for five 
minutes, loaded and separated on a large 5% acrylamide TBE sequencing gel for 
approximately 1.5 hours at 80 Watts. The gel was fixed in 10% (v/v) methanol, 10%
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(v/v) acetic acid for 30 minutes at room temperature, dried for one hour at 80°C and 
exposed to a phosphorimager screen. The image was analysed on a BioRad 
phosphorimager using Quantity One software.
2.9.11 Site-Directed Mutagenesis
The GeneEditor Mutagenesis Kit (Promega) was used to generate deletion mutations 
within N gene in pET16b. Mutation primers were designed to create terminal deletions 
of 100 and 200 amino acids in the resulting protein. In addition, primers designed to 
generate internal deletions of 40 amino acids through-out the length of the protein were 
synthesised. Mutation primer details are listed in the Appendix.
2.9.11.1 Preparation of Mutagenic Primers
The primers employed in this mutagenesis system become incorporated into the 
mutant plasmid strand. Therefore, they require phosphorylation to enable subsequent 
ligation of the newly-synthesised mutant strand to their 5’ terminus. 12.5 nmol each 
mutagenic primer was combined with polynucleotide kinase (PNK), PNK buffer and 25 
nmol ATP in a volume of 25 pi. The phosphorylation reactions were incubated for 30 
minutes to one hour at 37°C. The enzyme was denatured by incubation for 50 minutes 
at 65°C. Primers were combined with ethanol and 7.5 M ammonium acetate and 
precipitated. The resulting DNA pellets were dissolved in dH20  to create primer 
solutions of 1.25 pM.
2.9.11.2 Preparation of Template DNA
0.5-5 pmol DNA was denatured in 0.2 M sodium hydroxide, 1 mM EDTA in a volume of 
20 pi for five minutes at room temperature. DNA was then ethanol precipitated from 
solution. The resulting DNA pellet was dissolved in 100 pi TE buffer pH 8. Denatured 
DNA recovery was confirmed by agarose gel electrophoresis.
2.9.11.3 Site-Directed Mutagenesis
Two GeneEditor primers, specific to the top and the bottom DNA strands of the same 
sequence, are provided with this system. Both primers introduce a mutation into the 
ampicillin-resistance gene carried in the plasmid. This alters the translation product 
enabling host resistance to both ampicillin and an additional, related antibiotic. Within 
this system, the GeneEditor primer is incorporated into the mutant strand. Therefore,
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the choice between GeneEditor primers is determined by the orientation of the 
mutagenic primer. It is required that both primers adhere to the same strand to 
generate DNA with mutations in both N and the ampicillin gene. Approximately 0.1 
pmol denatured template DNA was combined with 1.25 pmol mutation primer, 0.25 
pmol GeneEditor primer and annealing buffer in a volume of 25 pi. Primer and template 
DNA were annealed by incubation for five minutes at 75°C followed by slowly cooling to 
37°C. 5-10 units T4 DNA polymerase, 1-3 units T4 DNA ligase and synthesis buffer 
were added to the hybridisation reaction, increasing the volume to 35 pi. The reaction 
was incubated for 1.5 hours at 37°C. DNA was ethanol precipitated and the resulting 
pellet, resuspended in 10 pi dH20.
2.9.11.4 Bacterial Transformation and Selection
40 pi electro-competent BMH 71-18 were transformed with 5 pi mutated DNA sample 
by electroporation. Transformed bacteria were incubated in 800 pi 2YT broth for one 
hour at 37°C, 200 rpm. Four millilitres 2YT broth and 100 pi GeneEditor selection 
antibiotic were added and the cultures were incubated overnight at 37°C, 200 rpm. 
Plasmid DNA was extracted from the cultures using QIAprep Spin Miniprep Kit. DNA 
recovery was confirmed by agarose gel electrophoresis. 40 pi competent JM109 were 
transformed with 5 pi Miniprep DNA by electroporation. Transformed bacteria were 
combined with 800 pi SOC and incubated for one hour at 37°C, 200 rpm. 100 pi culture 
was spread on an antibiotic selection mix L-broth agar plate and incubated for 16 to 20 
hours at 37°C. Individual colonies were picked, placed in 10 ml 2YT broth with antibiotic 
selection mix and incubated overnight at 37°C, 200 rpm. Plasmid DNA was again 
extracted using QIAprep Spin Miniprep Kit. Restriction endonuclease digestions were 
performed to determine resulting N gene fragment size. DNA sequence was 
determined manually using Thermo Sequenase Cycle Sequencing Kit (Amersham). 
E.coli strains BL21(DE3)pLysS and NovaBlue were transformed with mutant pET16b-N 
constructs by electroporation and mutant His-tag protein expression induced (Section 
2.7.8).
2.9.12 PCR Mutagenesis
A series of primers were designed for use in PCR to create carboxy-terminal deletions 
within the N gene in pET16b. Primers introduced a premature stop codon and a Bam 
HI restriction site. Expand High Fidelity PCR System (Roche) was used to amplify N
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gene mutants. Reagents previously listed were used with 50 pmol each primer and
12.5 ng template DNA in each reaction. Samples were thermo-cycled using the 
programme previously described (Section 2.9.2). DNA amplification was confirmed by 
agarose gel electrophoresis. The resulting PCR products were purified by Gene Clean. 
The products and fresh pET16b vector were then digested with the restriction enzyme 
Bam HI, the latter DNA in the presence of CIP to prevent re-ligation. Digested DNA 
was precipitated in ethanol and salt. Digested PCR product and pET16b were 
combined and ligated. Resulting plasmid DNA was used to transform E.coli strain DH5 
by electroporation. Transformed bacteria were cultured on selective L-broth agar for 16 
to 20 hours at 37°C. 10 ml aliquots of selective 2YT medium were inoculated with 
individual colonies and incubated overnight at 37°C, 200 rpm. Plasmid DNA was 
extracted by QIAprep Spin Miniprep. Resulting DNA was individually digested with 
restriction endonucleases Bam HI, Xba I and Hind III and the products visualised on an 
agarose gel to confirm insert size and orientation within the plasmid. BL21 (DE3) pLysS 
and NovaBlue E.coli strains were transformed with plasmids containing insert of the 
desired size and orientation by calcium chloride-heat shock. His-tag protein expression 
was induced as previously described.
2.10 The Purification of Histidine-tag Nucleocapsid Protein
2.10.1 Metal Chelate Chromatography
Histidine (His)-tag N protein was purified by HiTrap affinity chromatography (Pharmacia 
Biotech). Nickel ions, immobilised on an agarose matrix, are able to bind histidine 
residues under initial buffer conditions. Captured His-tag protein may be washed and 
subsequently eluted using phosphate buffer with increasing imidazole concentration. 
Protein purification was initially achieved manually using a syringe to apply sample and 
pass buffer through the column in steps of increasing imidazole molarity. This was later 
replaced by use of the automated Akta Purifier Chromatography System and 
generation of an elution buffer gradient. His-N protein was expressed in BL21 (DE3) 
pLysS (Section 2.7.8). The resulting bacterial pellet, resuspended in 5 ml 10 mM 
imidazole start buffer, was lysed by repeated freeze/thaw in a dry ice-methanol bath 
and 37°C water bath. Two units per millilitre DNase (Sigma) and 160 pg ml'1 RNase 
(Sigma) were added and the lysate, incubated at 37°C for a further 30 minutes, until 
viscosity had reduced. The lysate was ultra-centrifuged for 20 minutes at 70 000 xg at 
4°C. The resulting supernatant was passed through a 0.45 pm filter to remove any
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remaining solid debris. A 1 ml HiTrap chelating column, charged with nickel ions, was 
connected to an Akta Purifier Chromatography System, controlled by Unicorn software. 
The column was equilibrated with 10 ml 10 mM imidazole phosphate buffer at a flow 
rate of 2 ml min'1. The clarified lysate was then applied to the column. The column was 
washed with 10 ml 10 mM imidazole phosphate buffer. A gradient of 10 mM to 500 mM 
imidazole phosphate buffer was applied to the column over a 25 ml volume. Elutant 
was collected in 1 ml fractions. Throughout elution, protein and nucleic acid distribution 
was determined by optical density (wavelengths of 280 nm and 260 nm, respectively). 
The presence and purity of His-tag protein in the different fractions was assessed by 
SDS-PAGE and western blot analysis (Sections 2.10.7 and 2.10.11). Purified His-N 
protein was stored at 4°C.
2.10.2 Iso-electric Focusing (IEF) Gels
The iso-electric point (pi) of His-N protein was determined using the Phast System and 
PhastGel IEF media (Pharmacia Biotech). Approximately 100 ng His-N protein was 
placed in a gel applicator at each end of a PhastGel IEF3-9 (broad pH range). Four 
microlitres pi calibration marker (Pharmacia Biotech) was placed in an applicator at 
only one gel end. The pre-formed gel was placed in the Phast system and the 
electrodes put in position. Electrophoresis was performed at 3.5 W, 15°C and the 
voltage was varied. Initially, the voltage was maintained at 2000 V for 75 Vh. It was 
then reduced to 200 V  for 15 Vh during sample application before returning to 2000 V 
for 410 Vh. The gel was removed from the apparatus and proteins visualised by silver 
or coomassie blue stain (Sections 2.10.9 and 2.10.10). The pi of His-N protein was 
estimated by comparison with marker proteins of known pi.
2.10.3 Ion-Exchange Liquid Chromatography
Ion-exchange liquid chromatography was employed to improve His-N protein purity. 
Initial experiments were performed with sepharose-bound ions SP and DEAE to 
establish which was better able to bind His-N. These suggested the weak cation DEAE 
as the preferred choice for His-tag N protein purification by ion-exchange liquid 
chromatography (Chapter 7). A 1 ml DEAE-sepharose column was fitted to the Akta 
Purifier Chromatography System. The column was equilibrated with 5 ml 0.2M Tris (pH
6.5) at a flow rate of 1 ml min'1. His-N protein in 0.2 M Tris (pH 6.5), purified by HiTrap 
affinity chromatography, was applied to the column. The column was washed with 10
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ml 0.2 M Tris (pH 6.5). A gradient from 0 M to 1 M sodium chloride in 0.2 M Tris (pH
6.5) was applied to the column over a volume of 15 ml. Fraction volumes of 1 ml were 
collected and investigated for presence and purity of His-N protein by SDS-PAGE and 
western blot (Sections 2.10.7 and 2.10.11).
2.10.4 Size-Exclusion Liquid Chromatography
To further purify His-tag N protein, size-exclusion liquid chromatography was 
employed. A Superdex 6 column (Pharmacia Biotech) was used for this purpose. 
Superdex is a matrix of beads with an internal pore of pre-determined size. Upon 
sample application, large proteins pass around the beads and are swiftly washed 
through the column, appearing in early elution fractions. Smaller proteins pass through 
the bead pores. This hinders their progress through the column resulting in their 
appearance in later fractions. A 30 ml Superdex 6 column was attached to the Akta 
Purifier Chromatography System. The column was equilibrated with 30 ml binding 
buffer (Appendix). 0.5 ml DEAE-purified His-N protein was applied to the column. 30 ml 
binding buffer was passed through the column and the elutant retained in 1 ml 
fractions. Fractions were investigated by SDS-PAGE and western blot (Sections 2.10.7 
and 2.10.11).
2.10.5 Protein Dialysis
2.10.5.1 Slide-A-Lyzer Dialysis
Protein samples were dialysed using Slide-A-Lyzer dialysis cassettes (Pierce) with a 10 
000 molecular weight cut-off (mwco). The cassette was pre-wetted with the buffer into 
which protein was to be transferred. Using a needle and syringe, 0.5-1.5 ml protein 
sample was introduced into the cassette at one corner. The cassette was floated in 500 
ml buffer for one hour at room temperature, with stirring. The buffer was then refreshed 
and the sample incubated overnight at 4°C. The membrane was gently rubbed with 
gloved fingers to dislodge any adhered protein. The sample was then removed from 
the cassette using needle and syringe.
2.10.5.2 Centricon 10 Buffer Exchange
Centricon 10 (Millipore), containing a 10 000 mwco membrane, offered an alternative 
method of buffer transfer. 1 ml protein sample was placed in a Centricon 10 tube and 
centrifuged for one hour at 3000 xg, 4°C. Under centrifugal force, the buffer passes
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through the membrane and structures with a molecular weight greater than 10 000 are 
retained on the membrane. 0.5 ml buffer was used to wash the membrane by pipetting. 
The tube was centrifuged for a further 30 minutes. The retained protein sample was 
suspended in the desired volume of buffer and removed from the tube. In addition to 
buffer transfer, this technique enabled protein samples to be concentrated.
2.10.6 Protein Quantification
Protein concentration was determined by the Lowery method using the DC Protein 
Assay Kit (BioRad). Known concentrations of bovine serum albumin (BSA) were used 
as reference. In individual wells of a 96-well plate, 25 pi Reagent A was combined with 
5 pi protein sample. 200 pi Reagent B was added to the well and the plate incubated 
for up to 30 minutes. Sample absorbency at O.D. 705 was measured and protein 
concentration calculated using a plate reader.
2.10.7 Tris-Glvcine SDS-Polvacrvlamide Gel Electrophoresis (SDS-PAGE)
BioRad Proteon II minigel apparatus was employed to separate protein samples 
through polyacrylamide gel (Laemmli, 1970). The glass plates were wiped with dH2Ot 
followed by ethanol and placed in gel pouring apparatus. The resolving gel mix of 
desired acrylamide percentage was assembled and immediately poured between the 
glass plates (Appendix). 200 pi iso-propanol was placed on top and the gel left to 
polymerise for 30 minutes. The iso-propanol was discarded and the gel surface 
washed with dH20 . Excess dH20  was removed by draining and blotting. The stacking 
gel mix was then combined and poured on to the resolving gel. A comb was inserted 
and the gel left to polymerise for 20 minutes. The gel was transferred to the 
electrophoresis apparatus and submerged in tank buffer. The comb was removed and 
unpolymerised acrylamide washed from the wells by flushing with tank buffer using a 
needle and syringe. The protein sample was combined with sample loading buffer, 
boiled for five minutes and loaded onto the gel. Rainbow marker (Amersham) was also 
loaded onto the gel and used as a guide to protein size. Electrophoresis was performed 
at 150 V until the bromophenol blue dye-front reached the gel bottom (approximately 
one hour). The gel was removed from the electrophoresis apparatus and the protein 
visualised by staining with coomassie blue or silver-stain. Alternatively, the protein was 
transferred from gel to nitrocellulose for western blot analysis.
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2.10.8 Tris-Tricine SDS-Polvacrvlamide Gel Electrophoresis
Tris-tricine SDS-PAGE was performed when resolution of small proteins (< 10 kDa) 
was required. The separating and stacking gel solutions (Appendix) were assembled 
and a minigel poured following the above procedure. The gel was placed in the 
electrophoresis apparatus and each running buffer, added to the correct electrode. 
Protein was combined with tricine sample buffer and heated for five minutes at 95°C. 
Samples were loaded and the gel run for approximately four hours at 30 mA. The gel 
was then removed from the apparatus and either silver-stained or dried and exposed to 
a phosphorimager screen.
2.10.9 Coomassie Blue Staining
A minigel was incubated in 50-100 ml coomassie blue stain for approximately one 
hour. It was then transferred to de-stain solution and incubated until background stain 
had reduced. The resulting gel was viewed over a light box and photographed.
2.10.10 Silver Staining
The Protein Silver Staining Kit and protocol from Pharmacia Biotech was used. The 
protein gel was first incubated for 30 minutes in fixative buffer. It was incubated for a 
further 30 minutes in sensitising buffer. The gel was then washed three times with 
distilled water, five minutes per wash. The gel was transferred to silver solution and 
incubated for 20 minutes. It was twice washed with dH20  for one minute, placed in 
developing buffer and incubated for five to 30 minutes. Upon adequate staining of the 
protein, stop buffer was added to the gel. The gel was visualised over a light box and 
photographed.
2.10.11 Western Blot Analysis
Protein samples were separated by SDS-PAGE. Using western blot apparatus 
(BioRad), protein was transferred to nitrocellulose membrane. The gel was placed in 
contact with enhanced chemiluminescence (ECL) nitrocellulose membrane 
(Amersham) in a cassette, sandwiched between pieces of blotting paper and sponge, 
pre-wetted in transfer buffer. The cassette was placed in the blotting apparatus with the 
gel adjacent to the cathode. An ice block was placed in the tank and the cassette, 
submerged in transfer buffer. A current of 250 mA was applied for one hour. The
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apparatus was dismantled and the membrane placed in blocking buffer (TPBS with 5% 
(w/v) Marvel Powdered Milk) and incubated for one hour at room temperature. The 
membrane was washed three times with TPBS, 10 minutes per wash. The desired 
dilution of primary antibody was made in blocking buffer and added to the membrane. 
The membrane was incubated for one hour at room temperature. The membrane was 
washed as previously described. Secondary antibody conjugated to horseradish 
peroxidase (HRP) was diluted in block buffer and applied to the membrane, which was 
incubated for a further one hour at room temperature. The membrane was again 
washed and ECL performed. 5 ml each of ECL solutions 1 and 2 were combined and 
immediately added to the membrane. The membrane was incubated for one minute 
with shaking. Excess solution was removed by blotting and the membrane, placed in a 
developing cassette and exposed to film for two to 60 seconds. The film was then 
developed in a Kodak Xomat machine and antibody-bound protein visualised.
2.11 Protein-RNA Interaction Assays
2.11.1 Radiolabelled RNA Probe Synthesis
The T7-MEGAShortscript™ Kit (Ambion) was used to generate radiolabelled RNA 
oligonucleotides. Each template DNA contained a T7 promoter sequence and resulting 
transcripts were between 30 and 50 nucleotides. The template of the specific probe 
was an oligonucleotide and that of the non-specific probe was a linearised plasmid. 
Template sequences are listed in the Appendix.
10 x Reaction Buffer
7.5 mM CTP, GTP and UTP solutions
3.75 mM ATP solution
50 pCi [<x-32P]ATP
~1 p g Template DNA
4  ul T7 MEGAShortscript™ Enzyme Mix
4 0  jllI
Reagents were combined and the transcription reaction incubated for five hours at 
37°C. Template DNA was removed by digestion with 4 units RNase-free DNase for 30 
minutes at 37°C. The reaction was terminated upon addition of formamide gel loading
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buffer. The sample was heated for one minute at 95°C, placed on ice for two minutes 
and loaded onto a 10% acrylamide TBE minigel. Electrophoresis was performed for 45 
minutes at 150 V. The gel was removed from the apparatus, placed in a cassette and 
exposed to film for five minutes. The film was developed and aligned with the gel to 
identify the position of the radiolabelled RNA. The band was sliced from the gel using a 
scalpel blade and placed in 1 ml TE buffer (pH 7.4) with 0.5% (w/v) SDS. The RNA was 
eluted for 16 to 20 hours at 37°C. The eluted RNA was extracted by phenol (pH <6) 
and by chloroform:IAA extraction. The RNA was precipitated upon addition of 3 M 
sodium acetate and ethanol. The RNA pellet was dissolved in 60 pi dH20 . One 
microlitre was combined with scintillation fluid and the radioactivity measured in a 
scintillation counter.
2.11.2 Detection of Radiolabelled Products
A phosphorimager (BioRad) was frequently used to detect radiolabelled products. 
Radiolabelled experimental samples were separated by polyacrylamide gel 
electrophoresis, the gel was dried under vacuum for one hour at 80°C and exposed to 
a phosphorimager screen overnight. The resulting image was visualised on the multi­
imager. Densitometric analysis was also performed on the multi-imager using BioRad 
Quantity One software. Densitometry was performed on radiolabelled bands detected 
by phosphorimagery and on protein bands visualised by western blot and ECL.
2.11.3 Gel Mobility Shift Assay
10 000 counts per minute (cpm) radiolabelled RNA probe was incubated for one minute 
at 95°C, then transferred to ice for two minutes. It was combined with 0.01-10 pg His-N 
protein and binding buffer in a final volume of 7.5 pi. The reaction was incubated for 15
minutes at 33°C. One microlitre sterile glycerol was added and the sample loaded onto 
a 5% acrylamide TBE gel (Hoeffer). Gel loading buffer was placed in a free well and 
used as a migration marker. Electrophoresis was performed for approximately 2.5 
hours at 200 V. The gel was removed from the apparatus, dried at 80°C under vacuum 
and exposed to a phosphorimager screen overnight. The resulting image was detected 
by phosphorimaging.
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2.11.4 North-Western Blot Analysis
Protein samples were separated by 10% acrylamide SDS-PAGE and blotted onto ECL 
nitrocellulose membrane. The membrane was washed twice with PBS, placed in PBS 
containing 5% Marvel and 1 mM DTT and incubated for 16 to 20 hours at room 
temperature with shaking. The membrane was washed three times with HBB buffer 
and once with HYB100, 15 minutes per wash. The membrane was then transferred to 
HYB100 buffer with radiolabelled RNA probe (50 000 cpm ml'1). The membrane was 
incubated for two hours at room temperature with shaking and was then transferred to 
4°C overnight. The membrane was washed three times with HYB100 buffer, 15 
minutes per wash, to remove unbound probe. It was then exposed to a 
phosphorimager screen overnight.
2.11.5 North-Western Blot Analysis: Competition Assay
This assay was devised to compare the affinity of His-N protein for viral and non-viral 
RNA sequences. It was performed to investigate the possibility of sequence preference 
by N protein.
Eight wells on a minigel comb were taped together to create a single large well in a 
10% acrylamide SDS-PAGE minigel. 16 pg His-N protein was combined with sample 
loading buffer, incubated for five minutes at 95°C and loaded into the large well. Five 
microlitres Rainbow Marker was loaded into an adjacent single well. Electrophoresis 
was performed for one hour at 150 V. Protein was transferred from gel to ECL 
nitrocellulose membrane as above. The membrane was incubated in PBS with 5% 
Marvel and 1 mM DTT for 16 to 20 hours at room temperature with shaking.
The region of membrane containing His-N protein was vertically sliced into eight pieces 
of equal size. By alignment with Rainbow Marker, the approximate position of protein 
was isolated in each slice. The membrane slices were washed three times with HBB 
and once with HYB100, 15 minutes per wash. Pieces were then placed in individual 1.5 
ml microtubes.
To investigate N protein sequence preference, radiolabelled target RNA was competed 
out with increasing amounts of unlabelled RNA. Using spectrophotometry (O.D.26o), the 
mass and hence, molarity of radiolabelled specific and unlabelled non-specific (i) RNA 
probes were calculated. RNA probes were combined in increasing molar ratios in
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aliquots of HYB100 buffer in a final volume of 500 pi. Radiolabelled probe was 
maintained at the same concentration (~15 pmol per strip). The ratio of unlabelled 
probe was extended from 0 to 729 molar excess in a three fold molar ratio dilution 
series. The membrane was incubated at room temperature for two hours and 
transferred to 4°C overnight. The membrane pieces were washed three times with 
HYB100, 15 minutes per wash. They were then exposed to a phosphorimager screen 
overnight. Densitometric analysis was performed on the resulting bands using Quantity 
One software on the multi-imager.
The assay was repeated with radiolabelled non-specific (ii) probe, using the same RNA 
molarity as that used with specific probe. Due to differences in specific activity between 
the probes, the actual amount of radioactivity (cpm) applied differed slightly. Results 
from the different RNA probes were normalised to enable their comparison.
2.11.6 Filter Assays
2.11.6.1 Dot Blot Assay
100 to 500 ng His-N protein was combined with 5000 cpm radiolabelled probe and 
binding buffer in 10 pi. The reaction was incubated for 20 minutes at 33°C. ECL 
nitrocellulose membrane was placed in dot blot apparatus and a vacuum applied. Each 
dot was pre-wetted with 200 pi binding buffer. The samples were applied to the 
membrane then washed with 200 pi 5% (w/v) trichloro-acetic acid (TCA). The vacuum 
was maintained for a further one minute to dry the membrane. The membrane was 
investigated by phosphorimaging. Western blot analysis was performed to confirm 
protein was retained on the membrane.
2.11.6.2 Individual Filter Binding Assay
The dot blot assay procedure was repeated with the exception of the use of glass fibre 
(Sigma and Millipore) filters in place of ECL nitrocellulose membrane and the dot blot 
apparatus. The filters were wetted with binding buffer, sample passed through and 
washed with 5% (w/v) TCA under vacuum. The filters were placed in scintillation fluid 
and their radioactivity measured in a scintillation counter.
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2.11.7 UV Cross-linking Assay
The UV cross-linking assay was performed with purified His-N protein and with 
radiolabelled specific RNA probe. 0.5-2  jug recombinant protein was combined with 10 
000 -  15 000 cpm (~5 ng) RNA and binding buffer in individual wells of a covered 96- 
well plate. Samples were incubated for 20 minutes at 33°C. The plate was placed on 
ice, transferred to a Stratalinker UV Cross-Linker 1800 and positioned at a distance of 
5 cm from the light source. The lid was removed and the plate exposed to UV light 
(2500 pjoulescm'2 x100). 0.1-1 pg RNase A was added to each sample and the plate 
incubated for 15 minutes at 33°C. The samples were then transferred to individual 1.5 
ml microtubes. 0.1 jig sequencing grade trypsin (Promega) was added to each sample 
and the digestion incubated for three hours to overnight at 37°C. Additional proteases 
had been investigated for their ability to digest N protein. Trypsin was the enzyme of 
choice due to the number and size of digest fragments created and enzyme efficiency 
(see Chapter 7). The sample was combined with tricine sample buffer, heated to 95°C 
for five minutes and separated in a 16% acrylamide Tris-tricine gel. The gel was dried 
for one hour at 80°C, exposed to a phosphorimager screen overnight and the image 
analysed in a phosphorimager. Upon optimisation of the protocol and visualisation of 
the digested radiolabelled-protein fragments, fresh samples were prepared for analysis 
by mass spectrometry. This involved the substitution of labelled- with unlabelled- 
specific RNA probe. The above protocol was repeated. The samples were then 
transferred to Slide-A-Lyzer mini-dialysis units (3000 mwco). The units were placed in 
one litre 0.1% trifluoro-acetic acid (TFA) and incubated for two hours at 4°C with 
stirring. The buffer was refreshed and dialysis repeated for a further two hours. The 
samples were transferred to 1.5 ml microtubes, snap-frozen in a dry ice-methanol bath 
and freeze-dried overnight at -60°C under vacuum. The samples were analysed by 
mass spectrometry. Analysis was kindly performed by P. Ashton at the Department of 
Microbiology, University of York.
2.12 Structural Studies
2.12.1 Preparation of Ribonucleocapsid-like Structures
2.12.1.1 Preparation from Transformed Bacteria
The following procedure was used to generate and isolate ribonucleoprotein (RNP)-like 
structures from bacteria transformed with pET16b-N and mutant derivatives.
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50 ml cultures of BL21 (DE3) pLysS E.coli, transformed with pET16b-N gene or mutant 
derivatives, were incubated at 37°C until an O.D.60o 0.8 was obtained. Recombinant 
protein expression was induced by addition of 1 mM IPTG. The cultures were 
incubated for a further three hours at 37°C. The cultures were exposed to a centrifugal
force of 1700 xg for 15 minutes at 4°C. The supernatant was discarded and each 
pellet, resuspended in 5 ml TNE buffer with 0.6% (v/v) Nonidet-P40 (N-P40). Bacteria 
were lysed by three rounds of freeze/ thaw in a dry ice-methanol bath and 37°C water 
bath. DNase (units ml’1) and RNase A (200 pg ml'1) were added and the lysate 
incubated at 37°C for 30 minutes until viscosity had reduced. The lysate was subjected 
to a centrifugal force of 3000 xg for 10 minutes at 4°C. The supernatant was removed 
and placed at 4°C.
2.12.1.2 Preparation from Sf21 cells infected with Bac-Nwt
RNP-like structures were extracted from Sf21 cells infected with Bac-Nwt (Section
2.6.7). The cells were harvested and centrifuged at 3000 xg. The cell pellet was 
washed twice in NTE buffer and resuspended in NTE buffer with 0.6% N-P40 to lyse 
the cells. The lysate was treated in the same manner as the bacterial samples.
2.12.2 Caesium Chloride Buoyant Density Gradients
2.12.2.1 Buoyant Density Step and Equilibrium Gradients
A step gradient was created in a 14 ml ultra-centrifuge tube with 2 ml each of 25%, 
30% and 40% Caesium Chloride (CsCI) in TNE buffer (Appendix). One millilitre 5% 
sucrose in TNE buffer was placed at the gradient top by pipette. 1.5-5 ml clarified 
lysate was laid at the gradient top. The gradient was subjected to a centrifugal force of 
250 000 xg for two hours, 15°C in a TST41 swing bucket rotor.
The resulting gradient was viewed under a direct light source. Using a needle and 
syringe, the tube was pierced and the visible band in the 30% CsCI (~1.3 g / cm3) 
region was removed from the gradient. The volume of the extract was increased to 5 ml 
with 30% CsCI and the final concentration confirmed by refractometry. The gradient 
was subjected to a centrifugal force of 155 000 xg for 36 hours, 15°C in an AH650 
Sorvall swing bucket rotor to achieve buoyant equilibrium. The gradient was manually 
divided into 200 pi fractions from the gradient top to bottom. Individual fractions were 
analysed by western blot and by electron microscopy (EM).
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2 .12.2.2 Preformed Buoyant Density Gradient
This gradient type provided a quicker method to isolate RNP-like structures. However, 
resulting RNP density data may be taken only as an indication as equilibration is not 
fully achieved in the preformed gradient.
A 20-40% CsCI preformed gradient was created. Steps of 6 ml each of 20% and of 
40% CsCI in TNE buffer were placed in an ultra-centrifuge tube suitable for TST41. The 
tube was placed in a Biocomp Gradient Master and a continuous gradient created (65°; 
30 rpm; 2.5 minutes). 0.5 ml 5% sucrose was added at the gradient top. 1.5-4 ml 
bacterial lysate was laid at the top of the gradient. The gradient was subjected to a 
centrifugal force of 250 000 xg for 16 hours at 15°C in a TST41 swing bucket rotor.
When viewed under a direct light source, a band was visible at the gradient middle. 
The gradient was manually divided into 200 pi fractions from the gradient top to the 
bottom. Fractions were investigated by western blot and EM analysis.
2.12.3 EM Grids
Five microlitres protein sample was placed on a carbon-coated copper grid and 
incubated for one minute at room temperature. The grid was washed three times with 
water, one minute per wash. The sample was then stained with 1% (w/v) 
phosphotungstic acid (PTA) for one minute. Excess stain was gently removed by 
blotting the grid edge against Whatman #5 filter paper. The grid was allowed to air-dry. 
The mounted sample was observed under the electron microscope (100 V Phillips) at a 
magnification of 32000 x. Photographs were kindly developed and images digitally 
scanned by Dr. D. Bhella.
2.12.4 RNA Extraction from Mutant RNP-like Structures
The RNP-like structures isolated by buoyant density gradient were investigated to 
establish whether or not they were associated with RNA.
2.12.4.1 Immuno-Precipitation of RNP-Like Structures
Gradient fractions with a density of ~1.3 g / cm3 and containing N or mutant N protein 
were analysed by immuno-precipitation. 150 pi of each fraction was combined with 3 pi
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anti-His tag antibody (Sigma) and incubated for one hour at 4°C with shaking. 100 pi 
protein A-sepharose (50% (w/v) in Machamer buffer), 100 pi Machamer buffer and 150 
pi dH20  were added and the sample incubated for two hour at 4°C with shaking. The 
sample was centrifuged for one minute at 6000 xg. The supernatant was removed and 
the sepharose-protein A pellet was washed with 500 pi lithium chloride buffer. The 
sample was again centrifuged and the wash twice repeated. The pellet was 
resuspended in 120 pi dH20 . Twenty microlitres were removed for western blot 
analysis to confirm presence of His-tag protein.
2 .12.4.2 RNA Extraction
RNA was extracted from 100 pi protein A sample with phenol (pH <6) and with 
chloroform:IAA. The RNA was precipitated by the addition of ethanol and 3 M sodium 
acetate pH 4.8 and incubation for one hour at -20°C. The resulting RNA pellet was 
resuspended in 5 pi dH20  and 1 pi RNasin.
2 .12.4.3 End-Labelling of RNA
RNA isolated from the RNP-like structures was radiolabelled with 32P. The RNA sample 
was combined with polynucleotide kinase (PNK), PNK exchange buffer and 2.5 pCi 
[y32P]-ATP in a volume of 10 pi. The phosphorylation reaction was incubated for 30 
minutes at 37°C. Formamide loading buffer (T7-MEGAShortscript kit, Ambion) was 
added and the sample was heated at 95°C for one minute then placed on ice for two 
minutes. The sample was separated in a large 15% acrylamide TBE gel (Hoeffer) for 
approximately 2.5 hours at 200 V. The gel was dried for 1.5 hours, exposed to a 
phosphorimager screen overnight and analysed on the multi-imager.
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3 Growth of RSV
3.1 Introduction
Before addressing the aims of the project, a few preliminary experiments were 
performed to study the interactions of the N protein within RSV-infected cells. The RSV 
strain A2 was used in each experiment. It was routinely cultured in CV-1 cell 
monolayers as this cell-type produced the highest yield of infectious virus compared 
with other cell lines (J. Murray, personal communication). Results include the 
determination of virus titre by plaque assay. The expression of viral proteins was 
analysed by western blot and by immuno-precipitation, the latter demonstrating the 
occurrence of certain protein-protein interactions. The intracellular distribution of RSV 
proteins was observed by immunofluorescent microscopy. This allowed visualisation of 
structures in the cell relating to viral replication. Also included in this chapter is data, 
where relevant, accrued by other members of the laboratory. Some of the data 
presented herein was used in the publication of Murray et al. (2001).
3.2 Preparation of RSV Stock
RSV stock was routinely generated by infecting CV-1 cell monolayers, at 70 to 80% 
confluency, for three to four days. The majority of RSV is cell-associated, therefore, to 
release infectious virus, the cells were disrupted with glass beads in a volume of 10 ml 
growth medium. Cell debris was removed by centrifugation and viral stocks stored at - 
70°C.
Similarly, sub-confluent monolayers were infected at low multiplicity for three to four 
days prior to preparation of cell lysates for western blot and for RIPA. These conditions 
were identified as ideal for the preparation of virus (J. Murray, personal 
communication).
3.3 Titration of RSV by Plaque Assay
CV-1 cells, cultured as monolayers in six-well plates, were infected with RSV in a 10 
fold dilution series. Cells were overlaid with agar-DMEM and incubated for five days 
prior to fixing and giemsa staining. The plate was viewed under the light microscope 
and the number of plaques visible in each well counted. RSV plaques were observed 
as small gaps (< 2 mm diameter) in the cell monolayer.
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Virus Dilution Plaque Number
Neat TNTC
10"1 TNTC
10"2 TNTC
10"3 TNTC
10"4 250
10"5 47
0 0
Table 3.1: Titration of RSV in CV-1 cells using the plaque assay.
(TNTC -  Too numerous to count)
Table 3.1 lists results from a typical plaque assay. In this instance, the virus titre was 
calculated to be 4.7x106 plaque forming units per ml (pfu ml'1). The yield of RSV is low 
when compared with other members of the Mononegavirales. For example, a yield in 
excess of 1x108 pfu ml"1 was routinely obtained with measles virus, prepared in a 
similar manner (P. Yeo, personal communication).
3.4 Western Blot
Whole cell lysates from RSV-infected CV-1 cells or from mock-infected cells were 
separated by SDS-PAGE and transferred to nitrocellulose. The membrane was divided 
into strips of 0.5 cm width and each strip probed with one of a number of antibodies to 
different RSV proteins (Figure 3.1). Antibodies employed had been raised against 
recombinant RSV proteins expressed and purified from E.coli (see Chapter 2). Each 
antibody detected a single band in the strips containing RSV antigen. The estimated 
molecular weights of the detected protein bands corresponded to their predicted size, 
as determined from amino acid sequence information (reviewed by Collins et al, 1996) 
with the exception of P. The N protein, present in lanes 1, 2, 4, 5 and 6, migrated as a 
band of 42 to 43 kDa which corresponded to the calculated mass of 43.4 kDa. The M 
protein (lane 8) was observed at 28 kDa, corresponding to it’s calculated mass of 28.7 
kDa. M2-1 (lane 9) was present at 22 kDa, again close to it’s calculated mass of 22.2 
kDa. The P protein (lanes 3 and 7) appeared as a band of approximately 38 kDa, 
considerably larger than it’s calculated mass of 27.2 kDa. This phenomenon has
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Figure 3.1: Western blot analysis of RSV-infected CV-1 cell lysates.
RSV-infected (a) and mock-infected (b) CV-1 cell lysates were separated by 10% 
polyacrylamide SDS-PAGE and transferred to nitrocellulose membrane. The 
membrane was blocked with 5% Marvel in TPBS, divided into strips and probed with a 
variety of RSV-specific antibodies. Protein bands were visualised by ECL and 
autoradiography. Membrane strips were probed with RSV antibodies as follows: 1 
aN014, 2 aN015, 3 aP658, 4 aN3, 5 aN9, 6 aN15, 7 aP001, 8 aM, 9 a22k.
The viral proteins are expected to migrate as the following masses: N (43.4 kDa), P (38 
kDa), M (28.7 kDa) and M2-1 (22.2 kDa).
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previously been reported and is caused by the acidity of the protein affecting it’s 
interaction with SDS. The mass/charge ratio is disturbed resulting in the retarded 
migration of P through the gel (Caravokyri & Pringle, 1992).
Bands were absent from the majority of strips containing mock-infected CV-1 cell 
lysates with the exception of those probed with polyclonal antisera aN014 and aN015 
and with monoclonal antibody aN3. A faint band of 50 to 55 kDa was present in each of 
these strips possibly generated by cross-reactivity of the primary or secondary antibody 
to cellular protein. These bands were absent from strips containing infected lysate 
possibly due to saturation of antibody binding to the target viral protein.
3.5 Radiolabelled Immuno-Precipitation Assay (RIPA)
Cell extracts in RIPA buffer, radiolabelled with [35S]-methionine, were prepared and 
incubated with RSV antibodies for one hour at 4°C. The antibody-protein complexes 
were precipitated using Protein A-sepharose beads. Each reaction was washed three 
times with cold RIPA buffer before the addition of sample loading buffer and separation 
by 12% polyacrylamide SDS-PAGE. The gel was dried and exposed to a 
phosphorimaging screen for 10 to 12 hours at room temperature before being scanned 
by a phosphorimager (Figure 3.2).
Antibodies against proteins N, P, M and M2-1 were used to precipitate RSV antigen. 
The majority of antibodies caused the precipitation of more than one viral protein. 
Polyclonal antisera aN014 and aN015, and MAbs aN3 and aN9 each precipitated a 
protein of the expected size of N (43.4 kDa). In each lane, an additional band migrated 
to a position expected of the P protein (38 kDa). The N-P interaction has previously 
been documented for RSV and other members of Mononegavirales, for example, 
Sendai virus (Curran et al., 1995; Garcia-Barreno et a i, 1996). In each sample, the N 
band was of greater intensity than that of P. This may have arisen due to a difference 
in protein radiolabelling -  the N protein contains 14 methionines compared with 7 
methionines in the P protein. Alternatively, it may represent the stoichiometry of N-P 
protein association. The N antibodies also precipitated a protein similar in size to that of 
M (28.7 kDa). A faint band with a size corresponding to that of M2-1 (22.2 kDa) was 
detected when N was precipitated by aN014, aN015 and aN9.
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Figure 3.2: Immuno-precipitation from RSV-infected [^Sl-methionine-labelled CV- 
1 cell lysates.
The [35S]-methionine-labelled lysates of RSV-infected (i) and mock-infected (m) CV-1 
cells were incubated with various RSV antibodies for 1 hour at 4°C. Antibody-protein 
complexes were precipitated with Protein A-sepharose beads. The beads were 
washed, combined with sample loading buffer, boiled and separated by 12% 
polyacrylamide SDS-PAGE. Radiolabelled bands were visualised by phosphorimagery. 
The viral proteins N (43.4 kDa), P (38 kDa), M (28.7 kDa) and M2-1 (22.2 kDa) are 
indicated in the figure.
There are four protein bands of unknown origin precipitated from RSV-infected cell 
lysates. Bands are identified as follows: 1 * (> 66 kDa), 2 * (30 kDa), 3 * (25 kDa) and
4 * (< 14.3 kDa). (Marker, M).
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Monoclonal antibody aN15 precipitated only a small amount of N, forming a faint 
protein band. The P protein was notably absent from this sample. The epitope 
recognised by this antibody has been mapped, using a blocking peptide assay, to a site 
on the N protein inaccessible when complexed with P (Murray et al., 2001). Therefore, 
the faint band of N, precipitated by aN15, may represent either free-protein (N protein 
not complexed with P, prior to assembly into the nucleocapsid) or N protein, assembled 
with RNA into the nucleocapsid. When compared with the other aN MAbs, the band 
intensities suggested that the majority of N is in soluble form and is complexed with P 
protein. In experiments where recombinant N was expressed in the absence of P, MAb 
aN15 precipitated protein as efficiently as do aN3 and aN9 (P. Yeo, personal 
communication). Thus, the failure to precipitate N efficiently from RSV-infected cell 
lysates was not due solely to the affinity of the antibody.
Polyclonal antiserum aP658 and MAb aP001, directed against P, co-precipitated N 
with the P protein. The band intensities were the inverse of those obtained with the N 
antibodies, that is, P was more intense than N. The stoichiometry of the N-P interaction 
has been estimated from 1N: 2P to 1N: 4P in related viruses (the reverse has been 
estimated in VSV -  2N: 1P (Green et al., 2000)). However, the data here does not 
allow estimation of the numbers of P monomers interacting with N. Protein bands 
corresponding in size to M and very small amounts of M2-1 were also present within 
these lanes.
Anti-Matrix precipitated M and small amounts of N. Anti-22k antibody recovered the 
proteins M2-1, M and N. The M2-1 protein band is very faint, as observed upon its co­
precipitation with other viral proteins. This may reflect either low M2-1 concentration 
within the infected cell lysate or poor radiolabelling of the protein. The co-precipitation 
of N, M and M2-1 by a22k and by N-specific antibodies and of N and M by aMatrix 
suggests a possible relationship exists between these proteins. The N-M interaction 
has been postulated for related viruses and would be important in the assembly of the 
mature virion prior to and during budding (Coronel et al., 1999).
A number of bands occurred in precipitates from infected cell lysates that were not 
readily identified as viral proteins. A 30 kDa band (2 *) was present in several lanes 
derived from infected cell lysate. A band of 25 kDa (3 *) was detected in lanes of 
infected lysate precipitated by N and P antibodies. A band greater than 66 kDa (1 *)
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and another less than 14.3 kDa (4 *) occurred in infected samples precipitated with 
monoclonal antibodies. Each band, absent from mock samples, may represent protein 
of either viral or cellular origin. If viral, the species with a mass of less than 14.3 kDa 
corresponds approximately with the size of either NS1 (15.6 kDa), NS2 (14.7 kDa) or 
partially processed SH (13 to 15 kDa). However, the identity and origin of this protein is 
unknown. The RIPA illustrates interactions that occur between viral and, potentially, 
cellular proteins. The unambiguous association of N with P has been demonstrated 
and possible associations between N, M and M2-1 proteins suggested.
3.6 Immunofluorescence
CV-1 cells, seeded on 13 mm-diameter glass cover-slips, were infected with RSV at an 
m.o.i. of 0.5 and incubated for 16 hours. Cells were fixed with ice-cold methanol and 
probed with primary antibodies directed against viral proteins. Antibodies were used 
either individually or in combination. Viral proteins were detected with the appropriate 
anti-species secondary antibody, containing a fluorescent conjugate, and viewed using 
a Nikon fluorescent microscope (Figure 3.3 a to e). For co-localisation experiments, 
images were obtained on a Zeiss LSM510 laser confocal microscope (Figure 3.3 f to i; 
courtesy of J. Murray). Several distinct features were apparent, most notably that N, P 
and M2-1 (Figure 3.3 a, b, and c respectively) share a common staining pattern. All 
showed diffuse cytoplasmic staining with concentration in what appeared to be large 
aggregates of protein (arrowed). These structures, referred to as cytoplasmic inclusion 
bodies (CIs), appear to contain many of the components necessary for transcription 
and replication of the genome. Confocal images showed the co-localisation of N and P 
(panel f), N and M2-1 (panel g) and P and M2-1 (panel h) within the Cl bodies. The 
presence of L within CIs has yet to be confirmed.
A second region of viral protein accumulation was in spike-like structures around the 
periphery of the cell, presumably representing regions of virion assembly. The spike 
structures are most clearly seen in Figure 3.3 e (polyclonal aN015), the sizes of which 
range from 5 to 10 nm. The structures are analogous to the filamentous form of human 
Parainfluenza virus type 2 (hPIV-2) described by Yao & Compans (2000). The spikes 
are actin-dependent structures and are composed of detergent insoluble membranes 
or lipid rafts (J. Murray and G. Henderson, personal communication).
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Figure 3.3: IF images of primary RSV infection in CV-1 cells.
CV-1 cells, grown as a monolayer on cover-slips, were infected with RSV and 
incubated overnight at 33°C. Cells were fixed and probed with antibody specific to viral 
antigens. Cells were then probed with secondary antibody containing a fluorescent 
label and viewed by fluorescent microscopy (a to i). Panels (f) to (i) were viewed under 
a confocal microscope to visualise protein co-localisation.
Individual antibodies employed in panels (a) to (e) are as follows: polyclonal a-N015 (a) 
& (e), polyclonal a-P658 (b), monoclonal a-22k (c) and monoclonal a-Matrix (d).
The antibody combinations used in panels (f) to (i) are as follows: polyclonal a-N015 & 
monoclonal a-P001 (f), polyclonal a-N015 & monoclonal a-22k (g), polyclonal a-P658 
& monoclonal a-22k (h) and polyclonal a-N015 & monoclonal a-Matrix (i).
Arrows indicate inclusion bodies (CIs) visible within the cytoplasm upon staining for N, 
P and M2-1. At least at this stage in infection, the M protein is absent from CIs. Each 
protein has a diffuse pattern of staining in the cytoplasm. N, P and M also occur in 
spikes protruding from the cell membrane.
In (f), N and P co-localisation is observed. N and M2-1 (g) and P and M2-1 (h) co- 
localise in the CIs but not in the membrane spikes. Little obvious co-localisation of N 
and M (i) is observed in this instance.
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The distribution of M within infected cells was also analysed. Notably, the protein 
showed a diffuse cytoplasmic staining pattern and was detected in the spikes (Figure
3.3 d). However, at least in this stage of infection, M did not accumulate within the CIs 
(Figure 3.3 panel i). Thus, it is probable that the main site of N and M interaction is at 
the plasma membrane. An interaction between the RSV N and M proteins may be 
demonstrated in vitro (G. Henderson and C. Loney, personal communication). Coronel 
et ai. (2001) demonstrated that the M protein of hPIV-1 interacts with the carboxy- 
terminus of the nucleocapsid protein to aid packaging of the nucleocapsid into virus-like 
particles.
The distribution of N in infected cells was investigated by IFA using MAbs that map to 
three antigenic sites (Figure 3.4). The MAbs were mapped by a peptide scanning 
methodology; the peptide positions within N are indicated in Figure 3.4. MAbs aN3 and 
aN9 showed very similar patterns of staining, similar to the pattern obtained by 
polyclonal antisera (Figure 3.3 a). In contrast, MAb aN15 had a different staining 
pattern. As did aN3 and aN9, staining with aN15 detected protein within CIs and 
membrane spikes, but the diffuse cytoplasmic stain was no longer evident. This 
suggested that aN15 detected a form of N different from that identified by aN3 and 
aN9. Subsequently, it was shown that aN15 competes with P for binding to N protein 
(Murray et al., 2001), thus by inference, it is probable that the cytoplasmic pool of N is 
mostly complexed with P.
3.7 Discussion
Experiments presented within this chapter confirm several established observations of 
RSV growth. The plaque assay demonstrated in vitro growth of the virus to relatively 
low titre. The figure obtained of 4.7x106 pfu ml'1 is representative of RSV infection in 
tissue culture and is lower than viruses of the same taxonomic order. Despite the low 
yields, the expression of viral proteins may be detected by western blot, RIPA and IFA. 
The size of the RSV proteins observed by both western blot and RIPA agree with both 
the published observations and calculated molecular weights. In accordance with 
previous observations, the P protein migrated as a larger-sized protein than expected 
from its calculated molecular weight.
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Figure 3.4: IF images of primary RSV infection in CV-1 cells probed with 
monoclonal antibodies directed against the N protein.
CV-1 cells, grown as a monolayer on cover-slips, were infected with RSV and 
incubated overnight at 33°C. Cells were fixed and probed with N protein-specific 
monoclonal antibodies, a-N9, a-N15 and a-N3. Cells were then probed with secondary 
antibody containing a fluorescent label and viewed by fluorescent microscopy. The 
monoclonal antibodies are specific to the following antigenic sites within N protein (391 
aa): 16-35 aa (a-N9), 331-345 aa (a-N15) and ~346-365 aa (a-N3). 
a-N9 (a) and a-N3 (c) demonstrate a similar staining pattern detecting CIs, membrane 
spikes and diffuse cytoplasmic-distribution. In contrast, a-N15 (b) does not detect this 
cytoplasmic staining, recognising only protein present in the Cl bodies and the spikes.
M
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The RIPA revealed protein interactions that occur within RSV-infected cells. With the 
exception of MAb aN15, each N and P antibody strongly precipitated their reciprocal 
partner and to a lesser extent, M and M2-1 proteins. Antibodies directed against the M 
protein appeared to co-precipitate M and N. Anti-22k appeared to precipitate M2-1, N 
and M. The interaction between N and P has been characterised for a number of 
viruses though the exact relationship between the proteins needs to be further refined. 
Possible relationships are suggested between proteins N and M and M2-1, though their 
precise interaction may not be elucidated from this assay. Antibodies aMatrix and a22k 
do not co-precipitate the P protein indicating that P interacts either weakly, or not at all, 
with M and with M2-1. However, this may be a reflection of the antibodies used in this 
assay as a strong P-M2-1 interaction may be detected in vitro using purified 
recombinant proteins and the yeast two-hybrid system (C. Loney, personal 
communications). Hengst & Kiefer (2000) demonstrated that N and M2 interact directly 
but were unable to detect a P-M2 interaction in a similar yeast two-hybrid assay. Four 
proteins of sizes greater than 66 kDa, 30 kDa, 25 kDa and less than 14.3 kDa were 
routinely co-precipitated with the viral proteins. Both the identity and origin of each 
protein are unknown.
The MAb aN15 detects only N protein dissociated from P. This specificity results from 
P protein and the antibody sharing a common binding domain upon N, preventing their 
simultaneous association (although the epitopes are distinct, Murray et a i, 2001). 
Therefore, only free-N or that assembled into nucleocapsid may be recognised by this 
antibody. No additional proteins were precipitated and the presence of RNA was not 
investigated.
The co-localisation of viral proteins within infected cells was visualised by IFA. N and P 
proteins were distributed within the cytoplasm and at the cell membrane. Garcia- 
Barreno et a i (1996) showed that the co-expression of RSV N and P was required for 
Cl body formation and that the carboxy-region of the P protein was important for this 
interaction. In contrast, the expression of Measles virus N resulted in the formation of 
CIs in the absence of P (Spehner et al., 1997). Thus, the CIs may be regions of active 
transcription/replication and nucleocapsid assembly, or regions where genomes 
undergo quiescence with a possible lead into persistence. RSV is able to persist in vitro 
in macrophages (Guerrero-Plata et a i, 2001) whether it does so in the host is not 
known.
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4 Production and Purification of the RSV Nucleocapsid 
Protein
4.1 Introduction
The principal direction of research was to investigate the interaction between RNA and 
the N protein of RSV. To address this aim, a variety of in vitro assays were selected, 
creating a requirement for relatively large amounts of purified N protein. This was 
achieved by cloning of the N protein open reading frame (ORF) and subsequent 
expression of recombinant protein. A bacterial expression system was selected as the 
N protein has no requirement for directed post-translational modification, thereby 
negating the need for a taxonomically higher expression system. Also, the bacterial 
system was selected due to expertise present in the lab at the time of research. 
Recombinant N protein was expressed with 10 histidine residues fused at its amino 
terminus, providing a tag for ease of identification and of purification.
4.2 Cloning of the RSV nucleocapsid protein gene ORF
The ORF of the N gene was cloned by RT-PCR using RNA isolated from RSV infected 
CV-1 cells. Total RNA was isolated from the infected cell layer by phenol extraction 
(Section 2.6.6). Recovery of RNA was confirmed by separation and visualisation in an 
ethidium bromide-stained formaldehyde agarose gel under ultra violet (UV) light 
(results not included). cDNA was prepared by reverse transcription from the RNA using 
AMV reverse transcriptase with random hexamer primers (Section 2.9.1). The newly 
synthesised cDNA was used as a template for PCR amplification of the RSV N protein 
ORF (Section 2.9.2). Primers complementary to sequences at the gene termini were 
used to amplify full-length N, including transcription initiation and stop codons. Each 
primer introduced a Bam HI restriction sequence to facilitate the cloning of N 
(Appendix). The amplification products were separated and visualised in an ethidium 
bromide-stained agarose gel under long wave UV light. In each reaction, a single PCR 
product of the desired size was obtained (1244 base pairs, bp). The resulting DNA 
band was excised from the gel and extracted from the agarose by Gene Clean (BIO 
101).
Gene Clean DNA was digested with Bam HI and subsequently extracted from solution 
by ethanol precipitation. The resulting DNA was viewed by ethidium bromide-stained
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agarose gel electrophoresis (Figure 4.1). Figure 4.1 shows the N ORF fragment and 
plasmid pGEM 3Z (Promega), digested with Bam HI and ethanol precipitated.
4.2.1 Cloning of N ORF into pGEM 3Z
The digested N gene and plasmid pGEM 3Z were combined in a ligation reaction. The 
N gene was introduced into pGEM 3Z as the plasmid was readily available in the 
laboratory making it a good candidate for use to increase familiarity with cloning 
techniques. The reaction products were used to transform competent DH5 cells by 
electroporation which were selected on L-broth agar with ampicillin (Section 2.7.6.1). A 
number of colonies were picked with sterile tooth-picks, placed individually in 10 ml 
selective 2YT broth and incubated overnight at 37°C. Plasmid DNA was extracted from 
1 to 5 ml of the overnight culture by Qiagen Miniprep.
Each plasmid mini-preparation was digested with Bam HI to confirm the presence of 
the fragment in the plasmid (Figure 4.2). In Figure 4.2, two bands were present in lanes 
b, e, f and i. The upper band was linearised plasmid (2743 bp) and the lower was N 
gene insert of the expected size (ca. 1220 bp). Lanes g and h possessed a band of 
linearised plasmid DNA and a very faint DNA band of less than 500 bp in length of 
which the identity is unknown. The single DNA bands in lanes a, d and j were larger 
than the linearised plasmid. Their size was approximately that of ligated plasmid and 
insert, which suggested the plasmid had been linearised by digestion at only one 
restriction site.
4.2.2 Cloning of N ORF into pET16b
N insert was isolated from the clone in lane i, Figure 4.2. The DNA band was excised 
from agarose gel, Gene Cleaned and subsequently cloned into pET16b. Due to the 
design of primers used in the PCR of the original fragment, the N ORF was introduced 
in-frame with an amino-terminal histidine-tag sequence present in the vector. DH5 cells 
were transformed by electroporation and selected on L-broth agar. Individual bacterial 
colonies were picked, grown in selective liquid culture and plasmid DNA extracted by 
Miniprep. Plasmid DNA was digested with the restriction enzymes Bam HI, to confirm 
presence of insert, orXba I, to determine N ORF orientation relative to the T7 promotor 
(Figure 4.3). The N ORF possesses an Xba I site approximately 400 bp from the AUG 
codon.
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M pGEM N
Figure 4.1: N and pGEM 3Z DNA digested with Bam HI and ethanol precipitated.
DNA was separated in a 1% agarose TAE gel, stained with ethidium bromide and 
visualised by UV light. Digested N is i220 bp and pGEM 3Z is 2743 bp in length. 
(Marker, M).
Restriction Digest of pGEM 3Z N
3054
Figure 4.2: Digestion of pGEM 3Z N with Bam HI.
Digested plasmid samples a to j were separated by 1% agarose TAE gel, stained with 
ethidium bromide and visualised by UV light. Linearised plasmid and N insert of the 
correct size are present in lanes b, e, f and i. (Marker, M).
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N ORFT7 /ac( XaHis-Tag
517 bp
Figure 4.3: A schematic of the RSV N ORF in plasmid vector pET16b.
Transcription is controlled by the T7 promoter, adjacent to a lac operator, and 
commences upstream of the Histidine-tag. The His-tag is separated from the N ORF by 
the protease Factor Xa cleavage site. Bam  HI endonuclease sites are indicated in blue 
and Xba  I sites, in red. The size and position of restriction enzyme cleavage products 
are marked.
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The Xba I orientation digests of five pET16b N clones are shown in Figure 4.4. 
Samples 1 and 3 possessed a band of approximately 510 bp that corresponds with 
excision of N in the correct orientation with the T7 promoter and His-tag. The digest 
patterns of the remaining clones represented N in an incorrect orientation (lanes 2 and 
4) or a mixed plasmid population (lane 5).
To confirm N insert orientation in pET16b N samples 1 and 3 (Figure 4.4), DNA 
sequencing was performed both manually and by an automated system (Section 
2.9.10). Primers to T7 promoter and terminator regions in the plasmid and to internal 
sequences within N were employed (Appendix). In addition to the correct orientation of 
insert in the plasmid, results confirmed the sequence of N was in agreement with that 
published in Genbank (accession code M74568) and that N insert was present in-frame 
with the histidine-tag.
4.3 Recombinant N Protein (His-N) Expression
pET16b N (Figure 4.5) was introduced by heat shock into competent BL21 (DE3) 
pLysS and selected on L-broth agar with appropriate antibiotics. Individual colonies 
were picked from the plate, placed in 10 ml selective 2YT medium and incubated 
overnight at 37°C. 100 ml selective 2YT medium was inoculated with overnight culture 
to create a 1 / 200 dilution. The transformed bacteria were incubated until an O.D.6oo of 
0.8 was obtained. Protein expression was then induced by addition of 1 mM IPTG and 
incubation for a further three hours at 37°C.
The expression of recombinant His-tag N protein was investigated by western blot of 
bacterial cell lysates (Figure 4.6). Antibodies directed against RSV and the histidine-tag 
were employed to confirm expression. At the time of investigation, antibodies specific 
to N protein had not been generated therefore a commercial anti-RSV antibody mix 
was used (Figure 4.6 a). Three bands were visible in the positive control. The upper 
faint band was that of N (43.4 kDa), smaller than bacterially-expressed protein due to 
the absence of a histidine-tag. Lower bands were the viral proteins P (38 kDa) and M 
(28.7 kDa). A single band of approximately 46 kDa was detected in lanes with lysates 
prepared from induced bacteria. The size corresponded to that of N (43.4 kDa) plus 
approximately 2 kDa derived from the His-tag fusion.
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Figure 4.4: Orientation digestion of pET16b N with restriction enzyme Xba I.
Digested clones were separated in a 1% agarose TAE gel, stained with ethidium 
bromide and visualised by UV light. The upper DNA band in each sample is linearised 
pET16b with a fragment of the N gene. Lower bands in lanes 1 and 3 (~510 bp) 
represent Xba  I excision of N, present in the correct orientation in the plasmid. (Marker, 
M)
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Figure 4.5: pET16b N plasmid DNA.
Plasmid DNA (6934 bp) was separated in a 1% agarose TAE gel, stained with ethidium 
bromide and visualised by UV light. DNA bands represent the plasmid in super-coiled 
and open-circle conformations. (Marker, M).
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Figure 4.6: Western blot analysis of transformed bacterial cell lysates.
Whole lysate was separated by 10% polyacrylamide SDS-PAGE. Proteins were 
transferred to nitrocellulose membrane, blocked with 5% Marvel in TPBS and probed 
with anti-RSV (a) and with anti-His-tag (b) antibodies. Membranes were probed with an 
appropriate secondary antibody conjugated to HRP and the protein bands visualised by 
ECL and autoradiography. Lysates of transformed bacteria expressing recombinant 
histidine-tagged p-galactosidase (His-pGal) and of CV-1 cells infected with RSV strain 
A2 were used as controls. In (b), His-N protein is detected in the un-induced bacterial 
lysate.
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A band of 46 kDa was also detected in bacterially-derived N samples when probed with 
anti-His-tag antibody (Figure 4.6 b). An additional band of approximately 30 kDa was 
also observed. This smaller band is unlikely to be of bacterial origin as it was absent 
from the un-induced sample. More probably, it is an N protein breakdown product. 
Detection by the anti-His MAb suggested it represents the amino-terminus of His-N, 
possibly after some proteolytic event that has removed the C-terminal region. A band of 
full-length His-N was present in the un-induced sample suggesting the lac operon 
control of protein expression is not as stringent as was expected.
4.4 N Protein Purification by Metal Chelate Liquid Chromatography
The experimental techniques selected to address the aims of this project required the 
production of purified protein. The histidine-tagged N protein was purified by means of 
metal ion chelate affinity chromatography.
The recombinant protein was expressed in bacteria as previously described. The 
bacteria were harvested by pelleting, lysed by freeze/thaw and the resulting solid 
debris removed by centrifugation. The clarified lysate was applied to a HiTrap column 
(Pharmacia Biotech) and washed with buffers of increasing imidazole concentration. 
The flow-through was retained and investigated by SDS-PAGE and coomassie blue 
staining. An example of the manual purification of His-N is shown in Figure 4.7. His-N 
protein (46 kDa) was eluted at an imidazole concentration of 300 mM and greater. 
Protein was noticeably retained in the wells of the protein gel and at the interface 
between the stacking and separating gels, possibly as a result of N protein 
aggregation. After fractions 1 and 2 at 300 mM, the protein appeared to be relatively 
devoid of bacterial protein contamination. Considerable amounts of His-N appeared in 
the column flow-through. A faint band of approximately 30 kDa was visible in the initial 
300 mM fractions, potentially the same band detected by the His-tag antibody in Figure 
4.6.
In the latter stages of the project the AKTA FPLC apparatus was used in the 
purification of His-N. Figure 4.8 shows the output of the FPLC in the form of a 
chromatogram. Subsequent SDS-PAGE analysis confirmed the presence of purified 
His-N in the second peak particularly fractions 10 to 16 (results not included). The 
nucleic acid trace mapped closely to that created by protein. This may indicate protein-
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Figure 4.7: Manual purification of Histidine-tag N protein.
The clarified and filtered lysate of bacteria expressing recombinant His-N protein was 
manually applied to a HiTrap metal ion affinity column (Pharmacia Biotech). The 
column was washed with 5 ml aliquots of buffer of increasing imidazole concentration. 
The flow-through of buffers with 300 mM and 500 mM imidazole was collected in 1 ml 
fractions. 20 pi each fraction was separated by 10% polyacrylamide SDS-PAGE. 
Proteins were visualised by staining the gels with coomassie blue. The position of His-
N within the gels is marked by the symbol (Marker, M; Flow-through, FT).
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Figure 4.8: Metal ion chelate liquid chromatography of Histidine-tag N protein by 
FPLC.
9 ml clarified and filtered transformed bacterial cell lysate was loaded on to a HiTrap 
metal ion affinity column and washed with 10 ml 10 mM imidazole buffer. An elution 
buffer gradient of 10 mM to 500 mM imidazole was applied to the column and the flow­
through collected in 1 ml fractions. Buffer volume applied to the column is followed on 
the x-axis. Absorbency (absorbence units x10~3, mAU) and buffer gradient 
concentration are monitored on the y-axes.
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nucleic acid association, especially in terms of the N protein peak. The purity of N 
protein obtained in this manner was similar to that obtained manually.
Following purification, His-N fractions were concentrated and buffer exchange into PBS 
achieved using Centricon 10 spin concentrators (Millipore). A yield of approximately 2.5 
mg L'1 purified His-tag N protein was routinely obtained.
The purity of recombinant His-N was further investigated by the separation of protein 
by SDS-PAGE and it’s visualisation by silver-stain (Figure 4.9). Silver-staining is more 
sensitive than staining with coomassie blue (1 to 5 ng compared with 40 to 50 ng, 
respectively). Therefore, silver-stain was used to investigate the possible presence of 
low concentrations of contaminating proteins. In Figure 4.9, His-N may be seen as an 
over-stained protein band at 46 kDa in each lane. Also present were bands of smaller 
proteins. These may be residual bacterial proteins, surviving purification or they may be 
N protein breakdown products. In particular, there was a band present at 30 kDa, the 
same size as the potential amino-terminus breakdown product of N. Neither the 
number nor intensity of these smaller bands altered with the age of the protein sample, 
suggesting they were not accumulating post-purification.
The level of purity achieved by metal ion chelate affinity chromatography was 
considered acceptable to enable subsequent investigation of the RNA-binding 
properties of the N protein.
4.5 Discussion
The nucleocapsid protein ORF of RSV strain A2 was successfully cloned into the 
vectors pGEM 3Z and pET16b. Digestion with Xba I demonstrated the correct 
orientation of N insert with respect to the T7 promoter within pET16b. This was 
validated by sequence analysis. In addition, this data confirmed the N amino acid 
sequence as identical to that published in Genbank (M75468) and that insertion 
occurred in-frame with the histidine-tag. The His-tag is present at the amino terminus of 
the recombinant fusion protein.
Expression of histidine-tag N protein was performed in E. coli strain BL21 (DE3) pLysS. 
This bacterial system was selected as it should allow relatively stringent control of
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Figure 4.9: Histidine-tag N protein purified by metal ion chelate FPLC.
Purified His-N protein samples were separated by 10% polyacrylamide SDS-PAGE and 
visualised by silver-staining.
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recombinant protein expression. A system with such control was selected due to the 
possible toxicity of the N protein to the host cell.
The RNA polymerase gene of bacteriophage T7 is present within the bacterial 
chromosome under lacUVS promoter control. Upon transcription by host RNA 
polymerase and subsequent expression, the T7 RNA polymerase effects the 
transcription of N, itself controlled by T7 promoter. The expression system selected 
affords three opportunities of transcriptional control. Lac /, encoding the lac repressor 
protein, is present in the host chromosome. In the absence of an inducer, the lac 
repressor binds the operator sequence present in the lac promoter controlling the T7 
RNA polymerase gene, thereby preventing transcription. Should low levels of 
transcription and hence protein expression occur, an additional control is available. The 
plasmid pLysS present in the bacteria expresses low levels of T7 lysosyme, a natural 
inhibitor of T7 RNA polymerase. Lysosyme binds and inactivates any escaping T7 
polymerase protein. As a final level of control, transcription of recombinant protein gene 
is controlled by the T7 promoter immediately adjacent to a lac operator sequence. 
Again in the absence of inducer, the repressor, expressed from Lac I present in 
pET16b, binds the operator sequence disrupting N transcription. Repressor control at 
the lac promoter is overcome upon addition of the inducer IPTG enabling expression of 
T7 RNA polymerase and hence recombinant protein. The increase in T7 polymerase 
level following IPTG addition overcomes the level of restriction offered by T7 lysosyme. 
Despite such controls being in place, the expression of His-N protein was detected by 
western blot in un-induced samples indicating that the system was not effectively 
regulating control. Despite this expression, the bacteria grew well in culture suggesting 
that the protein was not especially toxic to host survival.
A relatively large amount of recombinant protein was detected in the pellets of solid 
bacterial lysate (data not shown). Accumulation of His-N within this insoluble fraction is 
probably due to protein aggregation in inclusion bodies. However, this was not further 
investigated as sufficient recombinant protein was present in the soluble fraction to 
enable successful purification. 2.5 mg L‘1 purified protein was routinely obtained from 
the bacterial expression system.
Examination of His-N protein by SDS-PAGE and silver-stain showed the presence of 
faint bands of unidentified protein. These proteins may be of bacterial origin or
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truncated His-N protein. A band of approximately 30 kDa, visible by silver stain, may be 
the same as that detected by western blot. The proteins detection with antibody 
directed to the histidine-tag suggests that it is the truncated amino terminus of His-N, 
cleaved approximately two-thirds along its length. The number of additional proteins 
and their intensity was sufficiently low that the level of His-N protein sample purity was 
considered acceptable for use in subsequent experiments.
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5 The Specificity of RNA-Binding by RSV N Protein
5.1 Introduction
The interaction between RNA and the N protein of RSV was investigated using a 
variety of in vitro assays. Other N proteins from the Mononegavirales have shown a 
lack of specificity when expressed as individual proteins (Masters & Banerjee, 1988; 
Spehner et ai.% 1991; see Introduction Section 1.12), thus it was of interest to determine 
whether RSV N acted similarly. For this purpose, histidine-tag N protein, expressed in a 
bacterial system and purified by NTA-nickel affinity chromatography (Chapter 4), and 
radiolabelled RNA probes (Section 2.11.1) were employed. Two probe sequences were 
selected to represent viral and non-viral RNA. One was described as ‘specific RNA’ 
and represented the first 47 nucleotides of the positive sense, RSV leader sequence. A 
second probe was described as ‘non-specific RNA’ and was transcribed from the Sal I 
digest of Bluescript plasmid, creating a 32 nucleotide sequence. Radiolabelled probes 
were used to investigate the specificity in RNA-binding of the N protein and to 
determine the existence of RNA sequence preference. A second objective of this work 
was to determine conditions that would prove favourable for the in vitro binding of RNA 
for future studies on locating the RNA-binding domain of N. Thus, assays had to meet 
the criteria of reliability and reproducibility.
5.2 Filter-Binding Assays
The association between RNA and the N protein was investigated using filter-binding 
assays. Purified histidine-tag N protein and radiolabelled specific probe were combined 
and allowed to associate, as described in Section 2.11.6. Samples were passed 
through nitrocellulose membrane present in dot blot apparatus (Figure 5.1). The figure 
demonstrates that N protein is able to capture RNA and that binding is observed only 
after incubation at 33°C for 20 minutes. Passing RNA over N protein, previously 
captured by nitrocellulose, showed only a marginal increase of signal above 
background. The specificity of this RNA-protein interaction with His-N was apparent 
when it was observed that the negative control, His-tag p-galactosidase, failed to bind 
RNA under identical conditions. There was little difference in dot intensity upon 
increase in N protein concentration from 0.1 to 0.5 i^g perhaps suggesting that the RNA 
was saturated with protein.
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Figure 5.1: A dot blot filter-binding assay with His-tag N protein and specific 
RNA.
0.1 pg and 0.5 pg His-N protein samples were incubated with 5000 cpm radiolabelled 
specific RNA for 20 minutes at 33°C. Samples were applied under vacuum to pre­
wetted nitrocellulose membrane in dot-blot apparatus. Certain samples were not 
incubated prior to application to the membrane. In such instances, His-N protein was 
applied to the membrane followed by radiolabelled RNA. The membrane was washed 
with 5% TCA and examined by phosphorimagery.
RNA only and RNA with histidine-tag p-galactosidase (His-pGal) were employed as 
negative controls. Controls confirm that RNA alone is not captured by the membrane 
and that RNA is not retained due to the presence of histidine-tag non-specific protein.
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An alternative capture protocol, employing glass fibre filters, was not successful (Figure 
5.2). Samples were prepared in the same manner as for the dot blot assay, captured 
onto individual filters and the radioactivity measured in a scintillation counter. The 
radioactivity of N protein-RNA samples increased only slightly with an increase in 
protein concentration. Levels of radioactivity in N protein samples were very low, 
ranging between 1.2 and 1.6% of the total radioactivity added. This may result from 
only weak protein-RNA association, poor retention of complexes by the filters or may 
indicate protein saturation by only small quantities of RNA. Radioactivity levels 
obtained with N protein were only slightly above background.
Results obtained by dot blot and by glass filter-binding assays proved un-reproducible 
over a number of attempts. Frequently in the dot blot assay, no difference was 
observed between negative controls and reaction samples. On occasion, a negative 
control would be visible as an intense dot possibly as a result of dust on the 
membrane. The individual filter-binding assays were similarly erratic. High levels of 
radioactivity were frequently retained in the negative controls. Conversely, low 
radioactivity levels occurred in the N protein samples, with no observable correlation 
with N protein concentration. In each assay, retention of protein by the membrane was 
demonstrated by western blot (data not included). This suggested that the absence of 
radioactivity from the membrane was due to N protein-RNA complexes not being 
formed.
The filter-binding assays produced reasonable results upon occasion. However, the 
ability of RNA and His-N to associate in vitro was confirmed and investigated more 
satisfactorily using subsequent techniques. Therefore, the filter-binding assays were 
abandoned.
5.3 Yeast Three Hybrid System
The RNA sequence specificity of N was investigated using the yeast three-hybrid 
system (SenGupta et ai, 1996); the components of the system were kindly provided by 
M. Wickens (State University of New York, USA). The system has strong analogies to 
the yeast two-hybrid system, which is used to investigate protein-protein interactions. 
Within the yeast three-hybrid system, two recombinant proteins, when in close 
proximity to one another, form an active transcriptional activator that induces
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Figure 5.2: A graph of data obtained from a filter-binding assay with His-tag N 
protein and specific radiolabelled RNA.
0.1 pg to 5.0 pg His-N protein samples were incubated with 10 000 cpm radiolabelled 
specific RNA for 20 minutes at 33°C. Samples were applied under vacuum to pre­
wetted individual filters. Filters were washed with 5% TCA and retained radioactivity 
measured in the scintillation counter.
RNA only and His-tag p-galactosidase (B-Gal) provided negative controls. 
Experimental conditions were performed in triplicate.
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expression of reporter genes LacZ and His3. Unlike the yeast two-hybrid system, the 
proteins do not interact directly but via a third moiety, a hybrid RNA (see schematic in 
Figure 5.3). It is the ability of protein to bind RNA that is measured by the reporter gene 
activity. The yeast strain L40-coat expresses the coat protein of bacteriophage MS2 
fused to Lex A DNA-binding protein. This fusion protein binds the Lex A operon in the 
genome and provides an anchor for the recombinant RNA. The latter is the MS2 coat 
protein RNA-binding site fused to the RNA sequence of interest. In this assay, the 
positive-sense RSV genome leader sequence was used as ‘specific RNA’ (designated 
L3-2 RSV) and the 3’ non-coding region of the hepatitis C virus genome was used as 
‘non-specific RNA’ (designated L40 HCV) (provided by J. Wood, MRC Virology 
Institute). N proteins were expressed as carboxy-terminal fusions of the GAL4p 
transcription activation domain from plasmids pACT2 (A2 strain N protein, provided by 
P. Yeo) and from pGAD424 (RSS-2 strain N protein, provided by A. Easton, University 
of Warwick).
Controls were employed to confirm the system was working as anticipated. L40-coat 
and L40-coat transformed with vector pACT2 lacking insert were used as negative 
controls. Control success was varied, as may be seen in Figure 5.4. With L40 coat (i.e. 
no RNA), the colony-lift filter assay with RSS-2 N (zero positive results out of five 
repeat experiments), PpACT2 (zero out of one) and pACT2 (zero out of one) were 
negative as expected. Flowever, more than half of those performed with RSV strain A2 
N (four out of seven) were positive. With pACT2 (i.e. no N), the colony-lift filter assays 
with L40-Coat (zero out of one) and L40-HCV (zero out of four) were negative. 
Flowever, one third of those performed with L3-2-RSV (two out of six) were positive.
Despite varying success of the controls, the N and P proteins of RSV were investigated 
using the yeast three-hybrid system. Duplicate experiments were performed with the P 
protein of RSV strain A2 in L3-2 RSV and in L40 FICV. The colony-lift filter assays were 
negative suggesting that P protein does not bind RNA. The N protein of RSV strain A2 
produced positive results when expressed in L3-2 RSV (seven out of 11) and L40 HCV 
(six out of six). Should this be representative of a true protein-RNA interaction, the 
results suggest that N protein is able to bind both specific and non-specific RNA. 
However, N pACT2 also produced positive results when present in L40 coat (four out of 
seven). Upon transfection with PpACT2 or pACT2, L40-coat produced only negative 
results. This would suggest positive results obtained with N pACT2 were due to the N
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Figure 5.3: A cartoon depicting the yeast three hybrid system.
In the yeast three-hybrid system, two recombinant proteins form a transcriptional 
activator, when in close proximity to one another, that induces expression of reporter 
genes LacZ and His3. The proteins do not interact directly but via a third moiety, a 
hybrid RNA. It is the ability of protein to bind RNA that is measured by the reporter 
gene activity.
The yeast strain L40-coat expresses the coat protein of bacteriophage MS2 fused to 
Lex A DNA-binding protein. This fusion protein binds the Lex A operon in the genome 
and provides an anchor for the recombinant RNA, MS2 coat protein RNA-binding site 
fused to the RNA sequence of interest (X). The second fusion protein is the Gal4p 
transcription-activation domain fused to the protein sequence of interest (Y), expressed 
from plasmid DNA. Direct interaction between RNA X and protein Y enables reporter 
gene expression.
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Figure 5.4: A scatter graph of data obtained with the yeast three hybrid system.
The transformed yeast strains L3-2-RSV and L40-HCV each carry a plasmid encoding 
different fusion RNAs. L3-2-RSV transcribes fusion RNA derived from RSV. L40-HCV 
encodes fusion RNA derived from hepatitis C virus. These yeast and their parent strain 
L40-Coat were transformed with plasmids encoding different fusion proteins. 
Interaction between the recombinant fusion protein and fusion RNA results in 
expression of the reporter gene p-galactosidase. The expression of p-galactosidase 
was investigated using the colony-lift filter assay and the extent of expression was 
estimated on a scale of between 0 and 3.
Fusion proteins were expressed from plasmids pGAD424 and pACT2. The N protein of 
RSV strain RSS2 was present in pGAD424. The N and P proteins of RSV strain A2 
were present in pACT2. The plasmid pACT2 alone provided a negative control.
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protein fusion. These observations may result from N protein association with the Lex A 
DNA-binding fusion protein or perhaps the bridging of both proteins with a non-specific 
RNA. Both situations would bring the transcription activation domain fused to N into 
close proximity with the reporter gene promoters. Upon expression in bacteria and 
subsequent purification, the N protein was observed to adhere to surrounding proteins. 
This would lend credibility to the explanation of non-specific protein-protein 
associations causing the observed positive results. Indeed, in a yeast two-hybrid 
screen with A2 N, performed concurrently with these experiments, it was noted that 
most of the interactions observed were non-specific in nature (C. Loney, personal 
communication).
In contrast, the N protein of RSS-2 produced predominantly negative results upon 
expression in yeast. Only one out of nine experiments was positive with L3-2 RSV and 
one out of six, positive with L40 HCV. The sequences of the N proteins of strains A2 
and RSS-2 are very similar (A. Easton, personal communication). However, without 
knowing the position of the important domains on N it is difficult to conclude which 
residues contribute to binding RNA. Primary protein differences are unlikely to provide 
an explanation for the contrasting results. A possible explanation is that there was a 
difference in the level of protein expression. This was not investigated directly. 
However, in the yeast two-hybrid system, an interaction was demonstrated between 
the A2 P and the N proteins of both A2 and RSS-2 indicating an acceptable expression 
level of both proteins with no discemable differences in reactivities (C. Loney, personal 
communication).
The erratic nature of the results and the unreliability of the controls led to the assay 
being pursued no further. This system appears to preferentially enable the study of 
RNAs with a high degree of structure, such as the HCV IRES. The RSV leader has no 
significant structure. Recently the role of secondary structure was discounted by work 
on hPIV3 (Hoffman & Banerjee, 2000). In addition, there is the possibility that both the 
leader and trailer sequences must be present for functionality. These points may 
contribute to the lack of success observed in this assay. However, the data obtained 
suggested that the N protein of RSV is able to bind RNA in a non-sequence specific 
manner.
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5.4 Gel Mobility Shift Assay
The interaction between His-N protein and radiolabelled RNA was investigated by gel 
mobility shift assay (GMSA). In a similar manner to the filter-binding assays, 
recombinant protein and RNA were combined and allowed to associate (Section 
2.11.3). Samples were analysed by non-reducing polyacrylamide gel electrophoresis 
and visualised by phosphorimagery. When bound by protein, migration of RNA through 
the gel would be retarded. Therefore, a shift may be observed from free radioactive 
RNA at the gel bottom to a higher position within the gel. The assay was initially 
performed using bacterial lysates of BL21 (DE3) pLysS expressing His-N protein from 
pET16b N (Figure 5.5). Bacteria lacking the plasmid were employed as a negative 
control. Samples 1 to 5 represented increasing volumes of bacterial culture, ranging 
from 0.1 to 25 ml. As may be seen in Figure 5.5, lanes containing N protein and control 
bacterial lysates shared several features. In each group, there was an increasing shift 
of radioactivity from the gel bottom to the upper gel as culture volume increases. This 
represented the reduction in free RNA and accumulation of RNA complexed with 
protein. In each sample there were three such bands visible in the upper region of the 
gel. Migration of each of these bands was progressively retarded as culture volume 
increased. This was caused by additional proteins associating with the established 
RNA-protein complex, shifting the band step-wise up the gel. The presence of the 
bands in both groups identified the responsible proteins as being bacterial in origin. In 
those lanes with N protein there was greater radioactivity retained within the wells, 
potentially the result of N protein-RNA complexes too large to allow migration into the 
gel. However, this hypothesis is questionable due to the radioactivity trapped in the well 
of the lane with probe alone. There was a very faint band visible just below each well in 
N protein lanes 3 to 5. These bands could potentially represent RNA associated with N 
protein of a size able to pass into the gel. These bands were absent from the negative 
control. Additional controls used were Bsc cell lysate as a positive control and purified 
His-p-galactosidase as a negative control. The shift observed with the Bsc cell lysate 
was routinely obtained but the cell protein involved is unknown. No bands are visible in 
the lane with purified His-tag p-galactosidase.
The assay was performed using purified His-tag N protein in place of bacterial lysates. 
10 000 cpm radiolabelled RNA was combined with samples of N protein ranging from 
10 ng to 10 pg (Figure 5.6). There were no bands visible in lanes containing the N 
protein. However, there was a reduction in radioactivity at the gel bottom (free probe)
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Figure 5.5: A gel mobility shift assay with bacterial cell lysates and specific 
radiolabelled RNA.
Lanes 1 to 5 represent volumes of bacterial culture, ranging from 0.1 ml to 25 ml. 
Volumes were centrifuged, the supernatants discarded and the bacterial pellets each 
resuspended in 500 pi PBS. Bacteria were lysed by freeze / thaw, chromosomal DNA 
shredded by passing through a needle and syringe and the lysate clarified by ultra­
centrifugation. Bacterial RNA was removed from the clarified lysate by digestion with 
75 units micrococcal nuclease in the presence of 1 mM CaCI2. Ca2+ ions were chelated 
and hence enzyme activity halted upon addition of EGTA. 38 pi of each sample was 
incubated with 10 000 cpm radiolabelled RNA for 15 minutes at 33°C. Samples were 
separated in a 5% polyacrylamide TBE gel. The gel was dried and radiolabelled bands 
visualised by phosphorimagery.
Bsc cell lysate provided a positive and His-tag p-galactosidase, a negative control.
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Figure 5.6: A gel mobility shift assay with purified His-tag N protein and specific 
radiolabelled RNA.
10 ng to 10 000 ng purified His-N protein was incubated with 10 000 cpm radiolabelled 
specific RNA for 15 minutes at 33°C. Samples were separated on a 5% polyacrylamide 
TBE gel. The gel was dried and radioactive bands visualised by phosphorimagery.
Bsc cell lysate provides a positive control and His-tag p-galactosidase and imidazole 
provide negative controls.
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as protein concentration increased. In contrast, there was a gradual increase of 
radioactivity in the wells. This movement of radiolabelled RNA from the gel bottom to 
the wells was affected by N protein concentration. The N protein-RNA complexes were 
apparently too large to pass into the gel. This may be the result of the primary N 
protein-RNA complexes being bound and bridged by additional N proteins, either by 
protein-RNA or protein-protein associations, creating large aggregates. This 
phenomenon of protein-RNA retention in the wells has also been observed with HCV 
core protein and with the hantavirus nucleocapsid (J. Wood personal communication; 
Severson et al., 1999).
The positive and negative controls described in Figure 5.5 were duplicated and 
behaved as expected. Imidazole was included as an additional negative control due to 
trace amounts being present in the purified protein. No bands were present in this 
control.
The assay was repeated several times in the attempt to pass radiolabelled RNA-protein 
aggregates from the wells into the gel. Various gel compositions were investigated. The 
acrylamide percentage was varied between 3.5 and 5% and agarose was used in place 
of acrylamide. Despite altered matrix conditions, the radioactive complexes would not 
migrate into the gel. Therefore, the question of RNA sequence specificity by the N 
protein was not addressed using this assay. The gel mobility shift assay again confirms 
the ability of recombinant N protein to bind RNA in vitro.
5.5 North-Western Blot Assay
North-western blot analysis provided an alternative approach in the investigation of 
RNA-binding specificity by His-tag N protein (Section 2.11.4). In brief, the protein 
sample was separated by SDS-PAGE and transferred to nitrocellulose membrane. The 
membrane-bound protein was renatured by incubation in HBB buffer and then probed 
with radiolabelled RNA. The membrane was washed and bound radioactivity visualised 
by phosphorimagery.
The assay was performed on bacterial lysates of BL21 (DE3) pLysS expressing His-N 
(Figure 5.7). There were several bands common to both His-N protein and control 
samples, as observed in the gel mobility shift assay (Figure 5.5). Lanes containing N
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Figure 5.7: A north-western blot with bacterial cell lysates and specific 
radiolabelled RNA.
Volumes of 1 ml to 25 ml bacterial culture were centrifuged, the supernatants discarded 
and the bacterial pellets each resuspended in 500 \x\ PBS. Bacteria were lysed upon 
addition of sample buffer and boiling. 30 jil of each bacterial lysate was separated by 
10% polyacrylamide SDS-PAGE. Proteins were transferred to nitrocellulose 
membrane, blocked with PBS containing 5% Marvel and 1 mM DTT and probed with 
50 000 cpm ml'1 radiolabelled specific RNA. The membrane was washed with HYB100 
buffer and radiolabelled bands visualised by phosphorimagery.
Purified His-tag p-galactosidase provided a negative control and may be seen as a 
very faint band at 116 kDa. p-galactosidase does not bind RNA. The band may result 
from either weak binding of RNA to the histidine-tag or from the assay being inherently 
sticky. In this instance, the protein bands of His-N are more intense than other protein 
bands, perhaps indicating the occurrence of a specific RNA interaction.
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protein lysates also possessed a band of 46 kDa, the expected size of His-tag N. The 
intensity of these bands increased with increasing culture volume. Bands of this size 
were absent from the control samples.
Following the success of this preliminary experiment, north-western analysis was used 
to investigate the ability of purified His-N to bind RNA. Varying amounts of purified 
protein were separated by SDS-PAGE and transferred to nitrocellulose membrane. The 
membranes were probed with 50 000 cpm ml'1 of either specific or non-specific 
radiolabelled RNA. In Figure 5.8 (a), His-N protein was present in a range from 10 ng 
to 10 pg and was probed with specific RNA. In Figure 5.8 (b), His-N was present in a 
range of between 100 ng and 2.4 pg and was probed with the non-specific RNA 
transcript. In each blot, bands of 46 kDa in size were visible, representing His-N bound 
by radiolabelled RNA. In both (a) and (b), band intensity increased with the increase in 
protein concentration. The presence of such bands in each blot indicated that His-N 
was able to bind both specific and non-specific RNA. This confirmed the observation 
from the yeast three-hybrid experiments that N protein bound RNA in a non-sequence 
specific manner.
A north-western blot was performed with a titration of His-tag p-galactosidase and 
specific radiolabelled RNA to confirm protein suitability as a negative control and to 
determine the inherent stickiness of the assay (Figure 5.8 c). No bands of radioactivity 
were visible in lanes with His-p-galactosidase. BSA provided an additional negative 
control and may be seen as a very faint band at 66 kDa. Upon comparison with (a) and 
(b), the blot in (c) demonstrated that only a low level of background binding occurred in 
the north-western assay. This reinforces the specificity of the interaction occurring 
between His-N and RNA.
Figure 5.9 confirms the non-sequence specificity of N protein-RNA association. The 
concentration of purified protein present in the strips of each blot was uniform. The 
strips were exposed to varying amounts of either specific (a) or non-specific (b) 
radiolabelled RNA. As radioactivity was increased from 80 to 50 000 cpm, a step-wise 
increase in band intensity was observed in both blots. The kinetics of RNA capture 
appear similar for both RNA species suggesting that the N has a similar affinity for both
i.e. N protein lacks sequence specificity. However, this experiment serves only as an
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Figure 5.8: A north-western blot of purified Histidine-tag N protein with specific
(a) and non-specific (b) radiolabelled RNA.
0.01 ng to 10 purified His-N protein was separated by 10% polyacrylamide SDS- 
PAGE. Proteins were transferred to nitrocellulose membrane, blocked with PBS 
containing 5% Marvel and 1 mM DTT and probed with specific (a) and non-specific (b) 
radiolabelled RNA. Membranes were washed with HYB100 buffer and radioactivity 
visualised by phosphorimagery.
A blot with purified His-tag p-galactosidase (His-p-Gal) and specific radiolabelled RNA 
provided a negative control (c). Bsc cell lysate was used as positive control (a) and His- 
P-gal (a), imidazole (a) and BSA (b & c) were used as negative controls. In (c), bands 
were absent from His-p-Gal lanes, however, a faint band of 66 kDa appeared in the 
BSA control. The band may be visible compared with His-p-Gal due to the higher 
protein concentration.
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Figure 5.9: A north-western blot with Histidine-tag N protein and varied amounts 
of radiolabelled specific (a) and non-specific (b) RNA.
Purified His-N protein was separated by 10% polyacrylamide SDS-PAGE. Proteins 
were transferred to nitrocellulose membrane and blocked with PBS containing 5% 
Marvel and 1 mM DTT. The membrane was then vertically sliced resulting in 3 pg His- 
N protein per strip. Each strip was probed with 80 to 50 000 cpm specific (a) or non­
specific (b) radiolabelled RNA. Membrane strips were washed with HYB100 buffer and 
radioactivity visualised by phosphorimagery. His-N protein may be observed in each 
strip at approximately 46 kDa. A second band of approximately 30 kDa in size is 
present in strips with 50 000 cpm radiolabelled RNA. This may represent truncated His- 
N previously observed during protein expression and purification.
His-tag (3-galactosidase with 50 000 cpm radiolabelled RNA provided a negative 
control. In the control lane probed with specific RNA, a very faint band is detected.
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indication as it considers RNA radioactivity and not molarity. The specific activity of 
each probe was not calculated for this experiment.
5.5.1 North-Western Competition Assay
The north-western competition assay compares the molar ratios at which specific and 
non-specific radiolabelled RNA are removed from membrane-bound N protein by a 
different non-specific RNA cold competitor (Section 2.11.5). To perform this analysis, a 
modified north-western protocol was devised. Such studies are normally performed in 
solution and analysed by GMSA. However, as previously observed, this assay may be 
unsuitable due to protein aggregation.
In the modified north-western assay, individual pieces of nitrocellulose with His-N 
protein were incubated in a solution containing radiolabelled RNA with cold (un­
labelled) competitor. Different ratios of competing species were used, and the bound 
radioactivity determined by phosphorimaging and densitometry. The north-western 
competition assay compares the molar ratios at which specific and non-specific 
radiolabelled RNA are removed from membrane-bound N protein by the cold RNA 
competitor (Figure 5.10). Radiolabelled RNA molarity was the same for each piece of 
membrane. The molar ratio of competitor RNA was increased from 0 to 729. The 
radiolabelled band intensity decreased as the concentration of cold competitor RNA 
increases, a feature common to both specific and non-specific radiolabelled RNA. The 
faint band obtained upon probing His-tag (3-galactosidase with specific RNA 
disappeared at a low ratio of cold RNA competitor; the band was no longer detectable 
by the ratio 1:27 compared with a ratio of 1:729 for His-N.
N protein band intensities differ greatly with specific and non-specific radiolabelled 
RNA. This is the result of differences in probe specific activity. 32P-labelled CTP was 
used in the synthesis of each probe. Nine C residues are present in specific RNA 
compared with 11 C residues in non-specific RNA. Therefore, non-specific RNA 
potentially has a higher specific activity than specific RNA, which accounts for the 
difference in band intensity observed in the assay.
The purpose of the competition assay was to investigate whether or not N protein 
possessed RNA sequence preference. To address this question, densitometric 
analysis using Quantity One software (BioRad) was performed on each band in the
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32P-labelled Specific / Non-Specific RNA : cold tRNA 
1:0 1:1 1:3 1:9 1:27 1:81 1:243  1:729
His-N + Specific RNA
His-N + Non-Specific RNA
His-p Gal + Specific RNA
Figure 5.10: A north-western blot competition assay with Histidine-tag N protein 
and specific and non-specific radiolabelled RNA.
Purified His-N protein was separated by 10% polyacrylamide SDS-PAGE. Proteins 
were transferred to nitrocellulose membrane and blocked with PBS containing 5% 
Marvel and 1 mM DTT. The membrane was then sliced into strips and the protein band 
isolated by alignment with Rainbow marker resulting in 2 fig His-N protein per 
membrane piece. Each membrane slice was probed with specific or non-specific 
radiolabelled RNA in the presence of increasing molar ratios of cold competitor tRNA. 
Membrane slices were washed with HYB100 buffer and radioactivity visualised by 
phosphorimagery.
His-tag p-galactosidase with specific radiolabelled RNA provided a negative control.
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resulting blots. Both actual measurements and percentages are listed in Table 5.1 and 
Figure 5.11. Analysis showed that the competition between specific or non-specific 
RNA and the cold competitor followed similar patterns. The similarity in rates at which 
specific and non-specific radiolabelled probe were competed from His-N by cold RNA 
suggested that the strength of association for each RNA was similar. The decrease in 
binding is rapid initially but a small amount of radiolabelled RNA appears to have 
resisted being dislodged by the cold competitor. It is possible that the majority of the 
association was not due to RNA binding to a particular site on His-N but rather that the 
acidic RNA bound basic residues on the protein surface. RNA bound in this manner 
may have been easily dislodged by the competitor. However, a small amount was 
captured by the genuine RNA-binding site on N, the binding to which may be 
irreversible, at least in vitro.
5.6 Discussion
The association between purified N protein and RNA was investigated in vitro by a 
number of assays. The approaches selected to address the question of RNA sequence 
specificity of the N protein had varying success. However, collectively, the assays 
demonstrated that recombinant histidine-tagged N protein possessed the ability to bind 
RNA in vitro.
Filter-binding and gel mobility shift experiments demonstrated the association between 
radiolabelled RNA and N protein. Frequently, the former assay was not greatly 
successful with little radioactivity captured on the membrane. Retention of protein was 
confirmed by western blot. Therefore, it was concluded that the RNA-protein complex 
frequently dissociated under assay conditions. The gel mobility shift assay similarly 
demonstrated association between N and RNA. In Figure 5.6, the protein-RNA 
complex was retained within the wells of the gel, an inescapable feature of this assay 
with the N protein. Such retention arises from protein-protein and protein-RNA 
interactions creating aggregates too large to migrate into the gel. From subsequent 
experiments, it may also be considered that bacterial RNA, remaining from 
recombinant protein expression, exacerbates this situation. Similarly, the presence of 
contaminating bacterial RNA could explain poor protein-radiolabelled RNA association 
in the filter-binding assays. Protein-RNA interactions observed by these assays were 
confirmed as true by inclusion of histidine-tag (3-galactosidase as negative control. The
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Molar Ratio of 
Radiolabelled RNA 
to Cold Competitor
Band Intensity % of Total Radioactivity
Specific RNA Non-specific RNA Specific RNA Non-specific RNA
1:0 782 4184 100 100
1:1 675 2364 86.32 56.5
1:3 253 1403 32.35 33.53
1:9 149.7 1574 19.14 37.62
1:27 43.45 703.7 5.56 16.82
1:81 32.42 568.4 4.15 13.59
1:243 24.65 226.7 3.15 5.42
1:729 19.14 160.7 2.45 3.84
Table 5.1: A table of band intensities and percentages of radioactivity obtained 
from a north-western competition assay of His-N protein with specific and non­
specific RNA sequences.
Densitometric analysis of the bands obtained in the north-western competition assay in 
Figure 5.10 was performed using Quantity One software (BioRad). Band intensities, 
normalised to background, are listed above.
With each radiolabelled probe, the band created in the absence of cold competitor (i.e. 
ratio 1:0) was considered 100%. Measurements of subsequent bands were calculated 
as a percentage of this intensity.
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Figure 5.11: Graphs of percentages of total radioactivity obtained from the north­
western competition assay.
The graphs represent north-western blot competition assay data presented in Figure 
5.10 and Table 5.1. They depict the percentage of total radioactivity of each His-N 
band upon increasing molar ratio of cold competitor RNA.
All competitor ratios are present in (a). Competitor ratios 1 to 243 only are present in
(b). Competitor ratios represent the molar excess of cold competitor with respect to 
radiolabelled RNA.
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protein confirmed the specificity of the His-N-RNA interaction and the absence of 
contribution by the His-tag.
The ability of His-N protein to bind sequences other than the RSV leader was 
demonstrated by the yeast three-hybrid system and north-western blot analysis. The 
yeast system met with varied success. Though the controls were not absolute, the 
assay strongly indicated that the N protein of RSV strain A2 was able to bind with a 
non-specific RNA, in this instance, the 3’ non-coding region of the HCV genome. The N 
protein of RSV strain RSS-2 failed to bind RNA. Previously, expression and biological 
activity of this clone had been demonstrated by its ability to bind P in the yeast two- 
hybrid system (C. Loney, personal communication). Therefore, the lack of success of 
RSS-2 N in the yeast three-hybrid system is probably due to reduced RNA-binding 
ability of the clone.
North-western blot analysis provided the most convincing evidence for the ability of 
His-N protein to bind both specific and non-specific RNA. In this procedure, protein was 
denatured upon separation by SDS-PAGE. Therefore, any bacterial RNA remaining 
from recombinant protein expression was dissociated from His-N. Following transfer to 
nitrocellulose membrane, protein was renatured by incubation in HBB buffer. 
Therefore, unlike several of the in vitro assays so far employed, north-western blots 
investigated the renatured protein, free from contaminating RNA.
During these studies, a protein band of approximately 30 kDa was identified as binding 
RNA (Figure 5.9; strips probed with 50 000 cpm). This band was the same size as that 
observed during the purification of His-N in Chapter 4. The 30 kDa band was identified 
as representing the amino-terminus of the N protein. Its detection in this assay 
suggests that the RNA-binding domain may be present within the amino terminus of 
the N protein (see Chapter 6).
Modification of north-western blot analysis led to development of the competition 
assay. This assay enabled semi-quantitative analysis of the preference of RNA binding 
by N. Results indicated that the N protein does not posses RNA sequence preference, 
confirming observations made from the yeast three-hybrid system.
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From the studies presented in this chapter, it was concluded that recombinant His-tag 
N protein was able to bind RNA in vitro. In addition, the protein possessed the ability to 
bind RNA sequence of both viral and non-viral origin and displays an apparent lack of 
sequence preference. Also various conditions were determined that may be of use in 
future studies on the N-RNA interaction. A novel assay to overcome the inherent 
difficulties of working with N proteins was devised and successfully employed.
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6 A Study of the RNA-Binding Domain of N Protein (I)
6.1 Introduction
The purpose of this study was to identify regions in N protein responsible for interacting 
with RNA. The first approach selected to identify this RNA-binding domain, or domains, 
required the creation of a series of deletion mutants of N protein. The ability of mutant 
protein to bind RNA was investigated by the use of established assays such as north­
western blotting. If interesting domains were identified, the mutant proteins would be 
further refined, with the ultimate aim of focussing on individual amino acids.
6.2 Mutant N Protein Synthesis
6.2.1 Mutant His-N Generation by Site-Directed Mutagenesis
Two histidine-tag N protein mutants with internal deletions were created using the site- 
directed GeneEditor mutagenesis kit (Promega) using pET16b N as template. The 
deletion mutants NA1-200 and NA121-160 were generated by this method. Mutant 
DNA excised from plasmid pET16b by digestion with Bam HI is presented in Figure 
6.1. The mutant sizes of NA1-200 and NA121-160 were of the expected lengths (620 
bp and 1100 bp, respectively). The deletions, and maintenance of the ORF, were 
confirmed by manual and automated DNA sequencing.
Attempts were made to expand the repertoire of mutants generated by site-directed 
mutagenesis however cloning difficulties prevented extension of this mutant range.
6.2.2 Mutant His-N generation by PCR
N protein deletion mutants were generated by PCR to compliment those created by 
site-directed mutagenesis. Internal mutation primers were designed to introduce a 
premature stop codon and restriction site into the N protein gene creating a series of 
carboxy terminus deletions. Truncations were made in increments of 50 amino acids.
PCR was performed with pET16b N template DNA and mutation primers following the 
method described in Section 2.9.2. DNA amplification was confirmed by ethidium 
bromide-stained agarose gel electrophoresis (data not included). Following limited 
exposure to long wave UV light, the DNA bands were located, excised and extracted
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Figure 6.1: Bam HI digestion of N mutants with internal deletions generated by 
Site-Directed GeneEditor mutagenesis.
Samples were separated in a 1% agarose TAE gel, stained with ethidium bromide and 
visualised under UV light. Full-length N is 1220 bp in size. Mutants NA1-200 and 
NA121-160 are approximately 620 bp and 1100 bp, respectively. Linearised pET16b 
(5711 bp) is present in each lane. (Marker, M).
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from agarose gel by Gene Clean. DNA was digested with Bam HI to enable 
subsequent ligation into pET16b. The products of digestion were visualised by ethidium 
bromide-stained agarose gel electrophoresis (Figure 6.2 a). A single discreet band was 
present within each sample lane. Each band was of the expected size for the particular 
mutant, ranging from 1070 bp for NA342-391 to 170 bp for NA42-391.
Each PCR product was combined with Bam Hl-digested plasmid pET16b in a ligation 
reaction. The ligation products were ethanol precipitated followed by introduction into 
DH5 cells by electroporation. Transformed bacteria were selected on L-broth agar. 
Individual colonies were picked and cultured in selective liquid growth medium. 
Amplified plasmid DNA was prepared and insert size and orientation determined by 
restriction digestion patterns in ethidium bromide-stained agarose gel electrophoresis. 
The digestion products of NA342-391 to NA142-391 may be seen in Figure 6.2 (b). 
Bam HI DNA fragments excised from plasmid were of the size expected for each 
particular deletion, ranging from 1070 bp for NA342-391 to 470 bp for NA142-391. Hind 
III was used to digest pET16b NA242-391 to determine insert orientation. An excised 
band of 702 bp was produced demonstrating the correct orientation of insert in plasmid. 
All other plasmids were digested with Xba I with which a band of 509 bp was expected 
if the mutant gene was present in the correct orientation. Bands of similar size were 
excised from NA292-391, at least one clone of NA192-391 and from NA142-391. 
Therefore in this example, mutant clones were present in the correct orientation in all 
but NA342-391. Upon re-ligation, plasmids carrying NA342-391 and NA92-391 in the 
correct orientation were obtained (data not included).
6.3 Mutant Protein Expression
Mutant DNA clones, generated by site-directed mutagenesis and by PCR, were 
introduced into E.coli strains BL21 (DE3) pLysS and NovaBlue (DE3) by 
electroporation. The eight mutants successfully created are depicted in Figure 6.3.
The temperature and length of incubation for optimal mutant protein expression in 
BL21 (DE3) pLysS were investigated. Culture temperatures of 30°C and 37°C were 
compared and the length of incubation following induction of protein expression was 
varied from three hours to overnight. It was determined that conditions previously 
identified as optimal for full-length N protein expression were suitable for expression of
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Figure 6.2: Restriction endonuclease digestion of gene-cleaned mutant N PCR 
products (a) and of N PCR mutants in pET16b (b).
DNA samples were separated by 2% agarose TAE gel electrophoresis, stained with 
ethidium bromide and visualised by UV light. Bam HI was used to digest gene-cleaned 
mutant N PCR products (a). It was also employed in the plasmid-insert digestions 
visible in (b). In both (a) and (b), Bam HI digestion created bands of mutant DNA of the 
following approximate sizes: NA342-391 (1070 bp), NA292-391 (920 bp), NA242-391 
(770 bp), NA192-391 (620 bp), NA142-391 (470 bp), NA92-391 (320 bp), NA42-391 
(170 bp). In (b), orientation digestions were performed with Xba I and with Hind III 
(NA242-391). With the exception of NA342-391, each mutant was present in the correct 
orientation within pET16b. Linearised plasmid (5711 bp) is present in each sample 
lane. (Marker, M).
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NH2 COOH Protein Size, kDa
N 44.0
NA1-200 21.5
NA121-160 39.5
NA342-391 38.4
NA292-391 32.7
NA242-391 27.1
NA192-391 21.5
NA142-391 15.9
NA92-391 10.2
Figure 6.3: A cartoon of Histidine-tag N protein mutants.
Mutants are compared with full-length protein and their deletions indicated by dotted 
line in place of the coloured box. The amino terminus box surrounded by dotted line 
represents the histidine-tag. Expected sizes of mutant protein (kDa) are approximate 
and are calculated disregarding the His-tag.
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mutant proteins. Therefore, bacterial cultures were incubated at 37°C until an O.D.eoo 
0.8 was obtained. Recombinant protein expression was induced with 1 mM IPTG for a 
further three hours at 37°C.
Mutant protein expression from BL21 (DE3) pLysS and NovaBlue (DE3) was compared 
under these culture conditions. Expression was reasonable from NovaBlue (DE3) 
bacteria but was more uniform and at a higher level in BL21 (DE3) pLysS. Therefore, 
the latter was routinely used for mutant protein expression.
Bacterial expression of the histidine-tag N mutant proteins was confirmed by western 
blot (Figure 6.4). Purified His-N was used as a positive control and was visible as a 
band of approximately 46 kDa. A band of approximately 90 kDa was also present 
within this lane possibly representing His-N protein dimers. Mutant protein of the 
expected size was present in each lane (sizes are listed in Figure 6.3). There was 
considerable variation in the level of expression which resulted in some lanes being 
overloaded, particularly those with the amino-terminal deletion mutants NA1-200 and 
NA121-160. In addition to the full-length mutant proteins, breakdown products of 
approximately 21.5 kDa and 30 kDa were visible in lanes with NA121-160 and NA342- 
391, respectively. The additional band, present in NA121-160, was similar in size to 
NA1-200 and may result from sample overflow from the adjacent lane. Similarly, the 
extra band in NA342-391 was similar in size to NA292-391 and may represent 
contamination from the adjacent lane. Alternatively, it may be the amino-terminal 
truncation product previously observed in samples of full-length N protein, resulting 
from proteolytic degradation.
The mutant proteins were extremely prone to degradation. Storage conditions were 
varied in temperature (-70°C, -20°C, +4°C), by the addition of protease inhibitors and of 
stabilisers such as glycerol but with little effect. The proteins could be maintained in 
bacterial lysates or in purified state at 4°C for up to two weeks but use of freshly 
synthesised protein proved much more reliable.
6.4 RNA-binding properties of N protein mutants
The ability of His-N deletion mutants to bind RNA was investigated by north-western 
blot analysis. Initial experiments were performed with clarified bacterial lysates (Figure
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Figure 6.4: A north-western (a) and associated western blot (b) of clarified 
lysates of bacteria expressing histidine-tag N mutants.
The bacterial lysates were separated by 12% polyacrylamide SDS-PAGE. Proteins 
were transferred to nitrocellulose membrane, blocked with 5% Marvel in PBS and 
probed with either 50 000 cpm ml'1 specific radiolabelled RNA (a) or HRP-conjugated 
antibody directed against the Histidine-tag (b). The north-western blot (a) was washed 
with HYB100 buffer and the radiolabelled bands visualised by phosphorimagery. The 
western blot (b) was washed with TPBS and protein bands detected by ECL and 
autoradiography.
In (a), untransformed bacterial lysate (1) and purified His-p-galactosidase (2) provided 
negative controls. Purified His-N (~46 kDa) (1) and His-N bacterial lysate (2) were used 
as positive controls. In (b), untransformed bacteria provided a negative control and 
purified His-N and His-p-galactosidase (116 kDa) were used as positive controls.
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6.4). However, considerable background radioactivity was obtained by this method due 
to bacterial contaminants. Background radioactivity obscured the signal of potential 
bands created by the association of RNA with mutant N protein. However, possible 
bands were observed in some sample lanes providing encouragement for further 
investigation.
Mutant proteins were purified from bacterial lysate in an attempt to reduce background 
in the resulting north-western. The most successful method of His-tag mutant 
purification was by addition of nickel-NTA agarose to clarified bacterial lysates with 
incubation for 90 minutes at 4°C. The agarose was pelleted by centrifugation and 
washed successively with 10 mM, 20 mM, 40 mM, 60 mM and 100 mM imidazole 
phosphate buffer. The agarose was then combined with sample buffer to remove 
bound His-tag protein, centrifuged and the supernatant investigated by SDS-PAGE. 
Gels stained with coomassie blue demonstrated that bacterial contaminants were 
considerably reduced and western blot confirmed recovery of the His-tag mutant 
proteins (data not included).
North-western blot analysis was performed using purified proteins. However, 
considerable background radioactivity was still obtained. To counteract this, the 
number and duration of membrane washes was increased and an unlabelled 
competitor RNA was added.
A north-western assay was performed with purified mutant proteins and with 
radiolabelled specific RNA (i.e. leader RSV) and un-labelled non-specific competitor 
RNA at a molar ratio of 1: 5 (Figure 6.5 (a)). Recovery of mutant proteins following 
purification was confirmed by western blot (Figure 6.5 b). In Figure 6.5 b, the protein 
band intensities were quite varied ranging from the total absence of NA292-391 and 
low concentrations of NA342-391 to high concentrations of full-length N protein, the 
amino-terminus deletion mutants and NA142-391. In Figure 6.5 (a), the background 
radioactivity was improved by the addition of competitor RNA but was still high and the 
few protein-RNA bands observed were diffuse. Banding similar to that in the negative 
control (purified lysate of bacteria lacking His-tag protein) was present in each lane of 
purified protein. A strong band of approximately 46 kDa was visible with purified full- 
length N. There was a distinct band observed with NA121-160 and potential bands in 
lanes with NA1-200 and NA142-391 though these were of lower intensity. Each band
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Figure 6.5: A north-western (a) and associated western blot (b) of purified mutant 
N proteins.
Purified His-N mutant proteins was separated by 12% polyacrylamide SDS-PAGE. 
Proteins were transferred to nitrocellulose membrane and probed with specific 
radiolabelled RNA and unlabelled bovine tRNA in a molar ratio of 1:5 (a) or with HRP- 
conjugated antibody directed against the histidine-tag (b). The north-western blot (a) 
was washed with HYB100 buffer and the radiolabelled bands visualised by 
phosphorimagery. The western blot (b) was washed with TPBS and protein bands 
detected by ECL and autoradiography.
In both (a) and (b), purified His-tag N protein provided a positive control. Purified lysate 
of bacteria lacking His-tag protein was used as negative control. In (b), faint bands at 
46 kDa, >30 kDa and >14.3 kDa are present in the negative control. There are 
potential RNA-protein bands in the lanes His-N, NA121-160, NA1-200 and NA142-391 
in the north-western blot (a).
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was of the expected size for the mutant protein. As demonstrated in the western blot, 
these proteins were present at high concentrations. The faint bands observed with 
NA1-200 and NA142-391 may be the result of non-specific association of RNA to high 
concentrations of protein, a feature previously observed in north-western blots. 
However, the intensity of the band present in NA121-160 suggests the occurrence of a 
specific protein-RNA interaction. No bands could be distinguished in the remaining 
lanes.
Despite numerous repeats of the assay, background radioactivity remained too high to 
reliably determine which mutants retained the ability to bind RNA. Further protein 
purification was attempted using HiTrap chromatography. This gained little advantage 
in the resulting north-western blot. Therefore, the assay was discontinued having only 
concluded that NA121-160 and full length N protein bind RNA.
6.5 Discussion
Having previously established the general nature of association between RNA and the 
N protein of RSV, the next stage of investigation was to identify domains within the 
protein responsible for such interaction. In this chapter, this aim was addressed by the 
generation of N protein mutants and analysis of their ability to bind radiolabelled RNA.
Eight histidine-tag N protein mutants were successfully created. A series of six 
carboxy-terminal deletion mutants, with truncations in increments of 50 amino acids, 
were generated by PCR. Two mutants with internal deletions in the amino terminus 
were created by site-directed mutagenesis using the GeneEditor kit (Promega). Further 
attempts to create more mutants by site-directed mutagenesis were unsuccessful. This 
was probably the result of putting too great a demand on the system by attempting to 
create internal deletions of too large a size. The size and orientation of mutants within 
the plasmid pET16b were confirmed by restriction enzyme digestion. Partial 
sequencing of each mutant sequence confirmed the nature of each mutation.
Conditions optimal for the expression of full-length His-N from BL21 (DE3) pLysS were 
found to be suitable for the expression of the mutant proteins. Protein production in 
NovaBlue was compared with that from BL21 (DE3) pLysS. Mutant expression was 
more consistent from the latter host. Unlike the full-length protein, mutants of His-N
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were found to be very sensitive to degradation enabling only short-term storage. This 
lack of stability may result from the absence of specific amino acid sequences or of 
larger protein domains, thereby creating less stable protein conformations and causing 
proteins to fall apart with greater ease. In Figure 6.4 (b), N protein mutants in clarified 
bacterial lysates are visualised in a western blot. In addition to the mutant protein, 
lanes containing NA121-160 and NA342-391 posses smaller bands of 21.5 kDa and 30 
kDa, respectively. Additional bands could represent the overflow of protein from 
adjacent wells that would create bands of the appropriate sizes. Alternatively, they may 
result from mutant protein breakdown. Bands were visible by western blot analysis with 
antibody specific to the His-tag therefore the amino terminus of N protein was present 
in each. The band present in NA342-391 is similar in size to the amino terminus 
breakdown product observed during full-length His-N purification (Chapter 4). If this 
band also represents a breakdown product of mutant protein, it would suggest that the 
N is rather susceptible to degradation in a region approximately two-thirds along its 
length.
Purification was reasonably successful with recovery of most mutant proteins (Figure
6.5 a). The protein concentration recovered appeared to reflect the abundance of the 
original protein present in the clarified lysate.
The success of mutant protein analysis by north-western blot was disappointing. 
Despite the use of purified protein, an increased number of membrane washes and the 
addition of unlabelled RNA to saturate non-specific RNA association, high background 
radioactivity was routinely obtained (Figure 6.5 b). An intense band of the expected 
protein size was obtained in the NA121-160 lane representing a specific interaction 
between mutant protein and radiolabelled RNA. Faint bands of the correct protein size 
were also present in lanes with NA1-200 and NA142-391. However, visualisation of the 
latter proteins, which were present at high concentrations, may result only from non­
specific association with radiolabelled RNA, although steps were taken to counteract 
this effect. Bands were not visible in the remaining lanes. This may indicate that the 
remaining mutants are unable to associate with RNA. However, it is probable that 
potential bands were obscured by high background radioactivity. Indeed, it is probable 
that several remaining mutants posses the ability to bind RNA as the RNA-binding site 
in the N protein of related viruses occurs within the amino-terminal two-thirds of the 
protein, for example, in Sendai virus (Buchholz et al., 1993). The RNA-binding ability of
87
Chapter 6
the 30 kDa fragment, identified in earlier chapters, should also be considered. It has 
been demonstrated to represent the amino-terminal region of the N protein and to 
retain the ability to bind RNA. Thus, like Sendai virus, the N protein of RSV appears to 
have an amino-terminal for nucleocapsid formation and a carboxy-terminal for 
association with the P protein (Murray et al., 2001).
Despite repeated efforts to employ His-N deletion mutants to identify the RNA binding 
domain, the inherent difficulties in working with N were all too apparent. It would appear 
that the mutant proteins were unstable and prone to degradation. In addition, the 
deletions may affect the conformation of the remaining protein rendering it inactive. 
Concurrent work within the laboratory using N deletion mutants in the yeast two-hybrid 
system also encountered the problem that some deletions would prevent the N: P 
interaction. However, larger deletions, that encompassed smaller ones, regained the 
ability to bind P thus making any deduction speculative (C. Loney, personal 
communication). Indeed, Garcia-Barreno et al. (1996) were unable to map regions on 
N protein responsible for the formation of Cl bodies using deletion mutants, yet could 
readily do so with P. This suggests that the tertiary structure of N might be quite 
complex. Similarly, data from Krishnamurthy & Samal (1998) would indicate that 
deletions within N protein may have other effects than the simple removal of binding 
sites.
Despite the reliability and success of the north-western blot assay with full-length N, it 
proved an unsuitable approach for the analysis of the mutant proteins. This may be due 
to the limited level of purity obtained with the mutant proteins. However, this is unlikely 
as successful north-western blot analysis was performed on transformed bacterial cell 
lysates (Chapter 5).
An alternative approach such as gel mobility shift analysis may have been employed to 
investigate the RNA-binding ability of the mutant proteins. Though by this method, 
protein purity may have presented a problem. However, due to time restraints, further 
analysis of the mutants was halted in preference of an alternative approach to 
investigate the N protein RNA-binding domain.
88
Chapter 7
7 A Study of the RNA-Binding Domain of N Protein (II)
7.1 Introduction
The interaction between N protein and RNA was investigated by crosslinking studies 
and subsequent manipulation. His-N and radiolabelled RNA were crosslinked by 
exposure to UV radiation and the product separated by SDS-PAGE and visualised by 
phosphorimagery. Proteolytic and nucleic acid digestion enabled those peptides 
associated with radiolabelled nucleotides to be visualised. Analysis then progressed to 
the use of unlabelled RNA to enable investigation of peptides by mass spectrometry. 
The purpose of such analysis was to identify the sequences of N peptides modulated 
by the presence of RNA and thereby indicate regions of N protein involved in binding 
RNA.
To enable execution of crosslinking studies, greater purity of His-N than that so far 
achieved by affinity chromatography was required (Section 2.10.1). Therefore, further 
methods of protein purification were investigated using nickel affinity purified His-N as 
the starting material.
7.2 N Protein Purification by Ion-Exchange Liquid Chromatography
7.2.1 Determination of His-N Protein Iso-Electric Point
Ion-exchange liquid chromatography was chosen to further purify recombinant N 
protein. This required knowledge of the iso-electric point (pi) of His-N. The pi is defined 
as the pH value at which an amphoteric protein has a net zero charge.
The pi of His-N was investigated using the Phast System (Pharmacia Biotech). The 
pre-formed gels of Phast Gel IEF media are composed of homogenous polyacrylamide 
and contain Pharmolyte® Carrier Ampholytes, able to generate a stable, linear pH 
gradient within the gel. Proteins migrate under an electric field, relatively unhindered by 
the porous gel, to a point in the pH gradient that corresponds to their pi. His-N was 
separated in a Phast gel (pH 3 to 9) and visualised by silver-stain (Figure 7.1). The 
position within the gel to which His-N migrated suggests its pi is approximately 7.35 -  
7.5. This pi range was confirmed by IEF software available in the SEQLab package 
(GCG). The protein sequences of His-N and native N were entered into the programme
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Figure 7.1: An iso-electric focussing gel of Histidine-tag N protein.
100 ng purified His-N protein was separated by electrophoresis in a pre-formed gel of 
Phast IEF media (Pharmacia Biotech). His-N was visualised by silver-stain and its pi 
value estimated between 7.35 and 7.5. (Marker, M).
Chapter 7
and their theoretical pi values calculated. That of His-N was 7.63, close to that obtained 
experimentally. The theoretical pi of native N was 8.37; thus, the addition of the 
polyhistidine-tag, and inter-linking amino acids, appeared to have made the 
recombinant protein more acidic than unmodified N protein. However, despite the 
slightly more acidic nature of His-N it was still able to bind RNA, suggesting that the 
over-all basic charge of N is not required for binding RNA.
7.2.2 N Protein Purification by Cation-Exchange FPLC
The basic pi of His-N suggested the use of a cation-exchange resin. The Mono-S 
cation-exchange column (Pharmacia Biotech) contains the negatively-charged group 
methyl sulphonate (SP) bound to beaded polystyrene resin. This was selected for use 
in the purification of His-N. The recombinant protein was dialysed into 0.2 M Tris HCI 
(pH 6.5), loaded onto the SP column and eluted with a sodium chloride gradient (up to 
1 M). Western blot analysis revealed the presence of His-N in the flow-through only, 
prior to application of the elution gradient. This suggested that His-N did not bind to the 
column. Rather than attempt to optimise this calculated purification step, the use of 
different ion-exchange resins was investigated.
7.2.3 Investigation of Ion-Exchange Resins
Sepharose-bound ions SP (strong anion) and DEAE (weak cation) were investigated to 
establish which was better able to bind His-N.
Purified His-N protein was combined with each resin in 0.2 M Tris (pH 6.5) and briefly 
shaken. The mixture was centrifuged for one minute at 6000 xg and the supernatant, 
removed and retained. His-N protein was eluted from the ion-exchange beads with a 
series of sodium chloride steps ranging from 0 to 2.5 M in 0.2 M Tris (pH 6.5) (Figure 
7.2). With SP-resin, His-N protein was detected in each sample. A considerable 
amount of protein was present in the flow-through fraction. A major peak in protein 
elution occurred at 1 M NaCI and above, although a significant amount of His-N 
remained associated with the SP-resin. In contrast, with DEAE-resin only a small 
amount of protein was present in the flow-through fraction. Protein elution occurred at 1 
M sodium chloride but again a small amount of His-N remained bound to the resin. 
Other protein bands were visible in the majority of lanes. A band of approximately 80 
kDa may represent His-N protein dimers. Additional larger bands are visible in lanes 
overloaded with His-N demonstrating protein oligomerisation, able to survive the
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Figure 7.2: A comparison in the ability of ion exchange resins DEAE- and SP- 
agarose to associate with Histidine-tag N protein.
10 fig purified His-N was combined with each resin in a volume of 100 pi 0.2 M Tris (pH
6.5) (wash buffer). The resin was centrifuged and the supernatant removed and 
retained (flow-through, FT). His-N was eluted with a gradient from 0 to 2.5 M sodium 
chloride (NaCI) in wash buffer. Elutants were analysed by western blot with HRP- 
conjugated antibody directed against the Histidine-tag. Protein bands were visualised 
by ECL and autoradiography.
In addition to monomeric His-N (M), larger protein bands are present in several lanes, 
possibly representing His-N dimer (D) and trimer (T).
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reducing conditions of SDS-PAGE. On the basis of these observations DEAE was used 
for further purification of His-N.
7.2.4 N Protein Purification by Ion-Exchange FPLC
A DEAE column was connected to an Akta purifier chromatography system and 
washed with 0.2 M Tris buffer (pH 6.5) in preparation for His-N purification. The protein 
sample was applied to the column, washed with start buffer and eluted with a salt 
gradient from 0 to 1 M sodium chloride in 0.2 M Tris (pH 6.5). In Figure 7.3 (a), a 
single, tight protein peak was obtained in elution fractions 3 to 6. Unexpectedly, the 
peak occurred at an elution buffer concentration of 0.2 M sodium chloride, considerably 
lower than that observed in Figure 7.2. As observed in metal ion chelate 
chromatography, the nucleic acid trace imitated that of protein (Figure 4.8).
Protein in fractions 3 to 8 was separated by SDS-PAGE and visualised by silver-stain 
and by western blot (Figure 7.3 b). In the silver-stained gel, His-N was present as a 
band of 46 kDa in size and the highest protein concentration occurred in samples 3 to 
5. In fractions 4 and 5, a larger band is visible, possibly resulting from N protein 
oligomerisation. In fractions with a high concentration of N, smaller protein bands were 
visible. A similar distribution of protein band intensity was observed by western blot, 
performed with antibody directed towards the histidine tag. Smaller protein bands (< 30 
kDa) were again observed. This suggests that they result from His-N breakdown and 
possess the amino terminus of the protein. This figure suggests that recombinant N 
protein is free from contaminating proteins but possesses self-breakdown products, 
more evident since ion-exchange purification. To further improve His-N protein 
purification, size-exclusion liquid chromatography was performed.
7.3 Size-Exclusion Liquid Chromatography
A Superdex 6 column (Pharmacia Biotech) was used to further purify DEAE His-N 
protein. The column and Akta purifier chromatography system were connected and 
washed with Tris-based RNA binding buffer, used in the gel mobility-shift and UV 
cross-linking experiments. The His-N protein sample was applied and washed through 
the column with RNA binding buffer. The elution profile in Figure 7.4 (a) showed a 
relatively large peak in fraction 13 followed by several small peaks. The large peak may 
represent full-length His-N and subsequent peaks, the smaller breakdown products of
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Figure 7.3: DEAE ion exchange FPLC of Histidine-tag N (a) and subsequent 
analysis of the purified protein (b).
His-N protein, purified by HiTrap affinity chromatography, was applied to the DEAE 
column, washed with 0.2 M Tris (pH 6.5) and eluted with a NaCI gradient (a). Fractions 
were separated by 10% polyacrylamide SDS-PAGE and analysed by silver-staining 
and by western blot with HRP-conjugated antibody directed against the Histidine-tag 
(b).
Chapter 7
(a)
mAU
1000
500
0
%B
60
« -
ml0.0 10.0 20.0
% Elution Buffer 
Protein, 280 nm
Nucleic Acid, 260 nm
(b)
kDa Silver-Stain
46 —
* 4*
Western Blot kDa
3 4 5 6 7 8  3 4 5 6 7 8
— 46
Chapter 7
(a)
mAU
100
0
1314101
30.0mi20.010.00.0
Protein, 280 nm
His-N Samples
Figure 7.4: Size-exclusion FPLC of Histidine-tag N (a) and subsequent analysis of 
the purified protein (b).
His-N protein, purified by DEAE ion exchange chromatography, was applied to the 
size-exclusion column and eluted with Tris-based binding buffer (a). Fractions were 
separated by 10% polyacrylamide SDS-PAGE and analysed by silver-staining (b).
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the protein. To confirm the identity and purity of the protein, fractions 11 to 15 were 
separated by SDS-PAGE and visualised by silver-stain (Figure 7.4 b). The His-N 
protein of approximately 46 kDa was present in each sample. At higher concentrations, 
there appears to be a second protein band visible immediately beneath the His-N band, 
although this may be an artefact of the gel or of image processing. The breakdown 
products of His-N protein were not detected.
The final product of affinity, ion-exchange and size-exclusion chromatography was 
considered of acceptable purity for use in UV crosslinking experiments and mass 
spectrometry.
7.4 UV Crosslinking Assay
7.4.1 Optimisation of assay conditions (i) UV crosslinking
The association between N protein and RNA was investigated using the UV 
crosslinking assay. The temperature, and duration, of incubation and the energy level 
of UV radiation were investigated to determine optimal reaction conditions. The most 
favourable conditions were an incubation of 20 minutes at 33°C followed by exposure 
to 25 000 fijoules cm'2 x100 UV radiation (Figure 7.5). In lane 1, 0.6 pg His-N was 
combined with 6500 cpm radiolabelled specific RNA, whereas 0.3 pg His-N was used 
in lane 2. A single band of approximately 60 kDa was present in each lane and 
represented crosslinked RNA and protein. Band intensity decreased as N protein 
concentration was reduced confirming the presence of N within the band complex.
The third sample lane in Figure 7.5 was generated by combining sodium hydroxide- 
treated N protein with RNA. In Chapter 5, it was determined that N protein binds RNA 
in a non-sequence specific manner. It is possible that the His-N may associate with 
bacterial RNA during expression; this has been alluded to before, as being problematic 
in the initial RNA-binding studies. Sodium hydroxide treatment was attempted to 
remove potential bacterial RNA from the protein. N protein was separated from 
associated RNA by SDS-PAGE and transferred to nitrocellulose membrane. The 
protein band was located by coomassie blue staining and eluted from the membrane 
by overnight incubation with 0.2 mM sodium hydroxide. RNA-free N protein was then 
combined with radiolabelled RNA and UV crosslinking performed. Full-length His-N 
was notably absent and only a single band of approximately 30 kDa was routinely
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Figure 7.5: UV crosslinking assay of Histidine-tag N and radiolabelled RNA.
The UV crosslinking assay was performed with purified His-N and with sodium 
hydroxide (NaOH) -treated His-N protein. The latter was generated by separating 
purified His-N by SDS-PAGE, transferring to nitrocellulose membrane and from there 
releasing the protein by incubation with 0.2 mM sodium hydroxide (NaOH). This 
treatment was performed to disrupt any existing association between His-N and 
bacterial RNA, remaining from recombinant protein expression.
Protein and 10 000 cpm specific radiolabelled RNA were incubated for 20 minutes at 
33°C and crosslinked by exposure to UV radiation. Protein:RNA complexes were 
separated by 10% polyacrylamide SDS-PAGE and visualised by phosphorimagery. 
(Marker, M).
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obtained. This may be the result of sodium hydroxide cleavage of the N protein, 
creating a peptide that was able to bind RNA. The band was investigated by silver- and 
coomassie blue-stained protein gels and by western blot analysis with various N 
protein MAbs, which were previously mapped (Murray et al., 2001), and the histidine- 
tag MAb. The band was absent from each assay and therefore remained unidentified, 
however due to the reactivities of the MAbs we can exclude certain regions of the N in 
being involved in RNA binding (see Discussion Chapter 9).
7.4.2 Optimisation of assay conditions (ii) RNase A concentration
Individual N proteins probably associate with only a few nucleotides within an RNA 
sequence. For example, the N proteins of rabies and Sendai virus each bind eight and 
six nucleotides respectively (Egelman et al., 1989; Iseni et al., 1998; Vulliemoz & Roux, 
2001). Therefore, either the probe (47 nt) may be bound by more than one N protein or 
regions of the RNA probe may remain unbound by protein. In the UV crosslinking 
assay, RNA not protected by protein was removed by RNase A. The protein may only 
be visualised when it is bound to radiolabelled RNA therefore observation of an RNase 
A-treated protein band is dependent on the presence of labelled nucleotides. In Figure
7.6 (a), a noticeable decrease in size was observed following RNase A digestion of the 
His-N:RNA complex, with a reduction from 60 kDa to 46 kDa. Decrease in mass was 
accompanied by a reduction of the band intensity, as a result of the removal of 
unbound nucleotides. At the gel bottom, the intense band of free RNA probe 
disappeared completely upon addition of RNase A.
RNase A was titred to determine its optimal concentration. N protein and radiolabelled 
RNA were each used at approximately half the concentrations used in Figure 7.6 (a) 
resulting in lower band intensities (Figure 7.6 b). The N protein-RNA band intensity and 
to a limited extent its size, increased as the concentration of RNase A was decreased 
from 10 jig to 1 ng. Free RNA was absent at RNase A concentrations of 10 jig and 1 
pg. Thus, 1 jig of RNase A was used in subsequent experiments as the N protein-RNA 
band was visible but minimal full-length free probe was present.
The success of RNase A treatment suggests that, unlike the viral nucleocapsid, the 
protein-RNA complex generated was not resistant to RNase digestion. This may
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Figure 7.6: RNase A digestion of UV crosslinked Histidine-tag N and 
radiolabelled RNA.
0.6 pg (a) or 0.3 jig (b) purified His-N protein was incubated with 10 000 cpm specific 
radiolabelled RNA for 20 minutes at 33°C and crosslinked by exposure to UV radiation. 
RNase A was added to the crosslinked samples and incubated for 15 minutes at 33°C. 
Digests were separated by 10% polyacrylamide SDS-PAGE and visualised by 
phosphorimagery. In (b), RNase A was titrated in a range from 0.001 pg to 10 pg. 
(Marker, M).
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suggest that probe is not encapsidated along its entire length but instead is bound by N 
protein in a less structured conformation.
7.4.3 Optimisation of assay conditions (iii) Radiolabel
In initial experiments, radiolabelled CTP was used to generate the RNA probe. 
However, only nine CTP residues are present in the RNA sequence used in 
comparison with 24 ATP residues. Therefore, probes with 32P-CTP and with 32P-ATP 
were synthesised and the intensity of the resulting N protein-RNA bands was 
compared. A range from 2500 cpm to 20 000 cpm of labelled RNA was combined with 
0.6 pg N protein, crosslinked and digested with 1 pg RNase A prior to separation by 
SDS-PAGE (Figure 7.7 a). RNase A treatment was omitted in Figure 7.7 (b). An His-N- 
RNA band at 46 kDa was present within each lane. Band intensity increased as the 
concentration of both CTP- and ATP-radiolabelled RNAs were increased. Bands 
created with the labelled-ATP probe were more intense than those with CTP-labelled 
probe. Band intensities appeared to approximate to the expected ratio of 8 : 3, that is, 
24 ATP residues to nine CTP residues. Due to the improved band intensity, specific 
probe created with radiolabelled-ATP was used in subsequent experiments.
7.4.4 Optimisation of assay conditions (iv) Proteolytic digestion
To detect specific regions of N protein responsible for binding RNA, proteolytic analysis 
of N, bound to RNA, was performed. Initially, various means of N protein digestion 
were investigated in the absence of RNA. Digestion was performed with the 
endoproteinases V8, clostripain, LysC and trypsin (Promega). Their individual digestion 
products were predicted by GCG software analysis to yield from 18 (clostripain) to 48 
(trypsin) peptides. Digestions were performed in UV crosslinking binding buffer and 
were incubated overnight at either room temperature or 37°C. The extent of N protein 
digestion was investigated by 10% SDS-PAGE and by silver-staining (Figure 7.8 a). 
Protein digestion had occurred with each enzyme, though with varied success. Full- 
length protein remains in each sample, though at a low concentration with trypsin. 
Clostripain digestion was the least successful with only two faint product bands visible, 
the majority of protein remained as full-length. Many digestion products were created 
with V8 protease but several were only a little shorter than full-length His-N protein. 
The products of LysC digestion were smaller but limited in number, the major bands 
were 27 kDa and 20 kDa. N protein digestion with trypsin was the most complete with
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Figure 7.7: UV crosslinking assay of Histidine-tag N and RNA labelled with either 
32P-ATP or 32P-CTP.
0.6 f.ig His-N protein was combined with a range from 2500 cpm to 20 000 cpm specific 
32P-ATP or 32P-CTP radiolabelled RNA, incubated for 20 minutes at 33°C and 
crosslinked by exposure to UV radiation. RNA was digested with 1 jag RNase A for 15 
minutes at 33°C (a). Samples were separated by 10% polyacrylamide SDS-PAGE and 
visualised by phosphorimagery. In (b), RNase A digestion was not performed. (Marker, 
M).
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Figure 7.8: Protease digestion of Histidine-tag N protein.
The proteases V8, clostripain and trypsin were used in a weight ratio of 1: 20 with His- 
N protein. LysC and His-N were used in a weight ratio of 1: 100. Digestion was 
performed overnight at either room temperature or at 37°C (clostripain). Products were 
separated by 10% polyacrylamide SDS-PAGE and visualised by silver-stain (a). The 
total possible number of digestion products with each protease are as follows: 29 (V8 
protease), 18 (clostripain), 31 (LysC) and 48 (trypsin). However, fewer fragments were 
expected as N protein conformation may make certain protease digestion sites 
inaccessible.
The products of His-N protein digestion with trypsin were separated by 16% 
polyacrylamide Tris-tricine gel electrophoresis and visualised by silver-stain (b) and by 
western blot, with polyclonal antibody directed against the N protein (c). (Marker, M).
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only minimal full-length protein remaining. Many peptides were generated including 
several at approximately 21.5 kDa and smaller. Digestion products of this size are most 
desirable for eventual analysis by mass spectrometry.
The products of trypsin digestion were further analysed by silver-stain and by western 
blot. His-N was treated with trypsin for three hours at 37°C and the digestion products 
separated by 16% polyacrylamide gel and visualised by silver-stain (Figure 7.8 b). 
Trypsin digestion removed full-length N protein and created a number of peptides 
smaller than 30 kDa. Eight discrete bands were clearly visible, though additional 
peptides may also be present. Several bands with a mass of 14.3 kDa or less may be 
seen. A western blot of His-N, digested with trypsin, was performed using a polyclonal 
antiserum specific to the N protein (Figure 7.8 c). In this example, full-length protein 
remained at 46 kDa. An intense band of a digestion product was visible at 
approximately 30 kDa. In addition, very faint bands of approximately 21.5 kDa and 
smaller than 14.3 kDa were present. However, many of the smaller peptides visible by 
silver-stain were not detected by the antibody. The peptides detected by silver-stain 
and by western blot are relatively large suggesting that incomplete digestion of N 
protein has occurred. Should digestion proceed to completion, 48 peptides would be 
generated, the majority of which would be undetectable by these means.
The small number of relatively large digestion products visible in the silver-stained gel 
suggests that many sites are not available due to N protein conformation. Protein 
denaturation was attempted to make more trypsin sites available and thereby generate 
smaller digestion products. This was achieved by either heating His-N to 95°C for 20 
minutes, or chemically denaturing the protein with guanidine hydrochloride, prior to 
crosslinking. Denatured N protein-RNA association occurred, however, in the absence 
of trypsin, the complex was retained in the well and did not migrate into the gel. Upon 
trypsin treatment, no bands were visible, possibly as a result of complete digestion. 
The RNA-binding site of N may be conformational, created by folding of the protein. 
Therefore, use of the denatured protein to bind RNA may not be an appropriate method 
to investigate the RNA-binding site. Trypsin digestion of native protein generated 
relatively small peptides (Figure 7.8 b), this was considered sufficient for initial 
experiments and denaturation of the N protein was pursued no further.
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7.4.5 Optimisation of assay conditions (v) UV crosslinkinq and protease digestion of 
His-N:RNA.
Trypsin digestion of N was combined with the UV crosslinking assay. Protease 
digestion was performed for three hours at 37°C following N protein-RNA exposure to 
UV radiation and RNase A digestion. The radiolabelled products were separated by 
16% polyacrylamide gel and visualised by phosphorimagery (Figure 7.9). In Figure 7.9, 
three groups of samples [RNA only], [N protein and RNA only] and [N protein, RNA and 
trypsin], digested with 0 pg, 0.1 pg or 1 pg RNase A, are present. As previously 
observed, the N protein:RNA complex forms a band of approximately 60 kDa that 
decreases to approximately 46 kDa upon addition of RNase A. In samples digested 
with trypsin, two novel bands replace that of full-length N protein. These bands are of 
approximate sizes 13.5 kDa and 10 kDa (N*1 and N*2, respectively) and persist upon 
the increase of RNase A concentration. These features, the intensity of the bands and 
their absence from other lanes, suggest that they represent N peptides associated with 
radiolabelled nucleotides.
7.5 Mass Spectrometry Analysis
Two N peptides bound by radiolabelled nucleotides were identified by UV crosslinking 
analysis of N protein and RNA, subsequent proteolytic and nucleic acid digestion and 
visualisation by SDS-PAGE. Mass spectrometry was attempted to identify the 
sequences of N peptides involved in nucleic acid binding.
Samples to be analysed by mass spectrometry were prepared with non-radiolabelled 
RNA. The preparation of these samples was performed in parallel with samples 
created with radiolabelled RNA. SDS-PAGE was performed to confirm recovery of the 
radiolabelled samples and was taken as an indication of the status of the unlabelled 
samples. Slide-A-Lyzer mini dialysis units were used to dialyse the nucleotide-bound N 
peptide samples against 0.1% tri-fluoroacetic acid (TFA). Samples were removed from 
the dialysis units and those with radiolabelled RNA were investigated by 16% 
polyacrylamide Tris-tricine gel electrophoresis (Figure 7.10). The expected bands of 
full-length N protein:RNA complex, both with and without RNase A, were visible (lanes 
3 and 4). A faint band, of approximately 13.5 kDa (N*), was visible in the lane with 
trypsinised sample (lane 5). This band was also present in the sample digested with 
RNase A alone (lane 4). However, the band was absent from lane 2 (digested RNA
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Figure 7.9: UV crosslinking assay of Histidine-tag N and radiolabelled RNA with 
subsequent RNase A and trypsin digestion.
2 jig purified His-N protein and 15 000 cpm specific radiolabelled RNA were incubated 
for 20 minutes at 33°C and crosslinked by exposure to UV radiation. 0, 0.1 fig or 1 pg 
RNase A was added and the samples incubated for 15 minutes at 33°C. Trypsin was 
added to certain samples in a ratio of 1: 20. The reactions were incubated overnight at 
37°C. Samples were separated by 16% polyacrylamide Tris-tricine gel electrophoresis 
and visualised by phosphorimagery.
A band of approximately 46 kDa is present in lanes of full-length His-N-RNA (N) treated 
with RNase A. In lanes of sample further treated with trypsin, bands of 13.5 kDa (N *1) 
and 10 kDa (N *2) are present. Intensity of digested RNA at the gel bottom is less in 
protein-RNA samples treated with both RNase A and trypsin. (Marker, M).
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Lanes 1 2 3 4 5 6
N - + + + +
RNA + + + + + +
RNase + - + + +
Trypsin - - - + +
Dialysis - - - - +
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21.5 — 
14.3 —
12.5 —
Figure 7.10: UV crosslinking assay of Histidine-tag N and radiolabelled RNA, with 
subsequent RNase A and trypsin digestion and dialysis.
1 fig purified His-N protein and 10 000 cpm specific radiolabelled RNA were incubated 
for 20 minutes at 33°C and crosslinked upon exposure to UV radiation. Samples were 
digested with 0.1 fig RNase A for 15 minutes at 33°C followed by digestion with 0.1 fig 
trypsin overnight at 37°C. Dialysis was performed in a Slide-A-Lyzer mini-dialysis unit 
(3000 mwco) against 0.1% TFA for 4 hours at 4°C. Samples were separated by 16% 
polyacrylamide Tris-tricine electrophoresis and visualised by phosphorimagery. A band 
of 13.5 kDa (N * ) was recovered from dialysis of the final digestion products.
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only) suggesting that it was of N protein origin. More importantly, the 13.5 kDa peptide 
and additional smaller bands were recovered from dialysis, indicating similar success 
with the unlabelled samples. Therefore, the latter samples were snap frozen in a dry 
ice-methanol bath and freeze-dried overnight at -60°C, under vacuum. They were then 
sent to A. Wilson at the Department of Microbiology, University of York and analysis by 
mass spectrometry performed by P. Ashton.
Four samples were prepared and analysed by MALDI mass spectrometry. Prior to 
analysis of each sample, the machine was calibrated using close external calibration 
leading to a mass accuracy of 0.2 Da. Within the preliminary study, a mass spectrum of 
less than 3800 m z'1 was investigated in each sample. This would not enable detection 
of the labelled peptides of sizes 13.5 kDa and 10 kDa observed in Figure 7.9.
Samples of [RNase A & Trypsin] and of [RNA & RNase A & Trypsin] provided negative 
controls enabling peaks contributed by RNA, trypsin and RNase A to be discounted 
from the experimental spectra. Peptides were not detected in either control suggesting 
that peaks obtained in the experimental samples originated from N protein alone. 
Spectra were obtained of samples [N protein & RNase A & Trypsin] (sample 1) and [N 
protein & RNA & RNase A & Trypsin] (sample 2). They were of good quality suggesting 
that trypsin digestion had gone largely to completion and that no buffer salts remained. 
The spectra of experimental samples are present in Figure 7.11 and the peak masses 
displayed in Table 7.1. The peak values listed are of the mono-isotopic mass of each 
peptide, that is, the mass of the peptide containing only 12C atoms. Peptides are 
usually represented by a series of peaks that differ by 1 Da or more as 13C atoms 
become incorporated.
The mass peaks of each list were used to search the NCBI ‘nr’ database using 
MASCOT, with a tolerance of 0.5 Da. The N protein was not retrieved from either list. 
However, there are several masses in each spectra that correspond to predicted 
products of tryptic-digestion of the N protein. Peptide positions within N protein are 
displayed in Figure 7.12. Of these peptide sequences, most were present in either both 
samples or in sample 2 only. There was only one peptide identified in sample 1 and 
absent from sample 2 that potentially represented sequence altered in mass due to 
association with nucleotides. The peptide sequence is AYAEQLK (352 to 358 amino 
acids) and has a mass of 822.4774 Da. In the nucleocapsid protein of related viruses,
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Figure 7.11: Graphs of the spectra obtained from the mass spectrometry of digested, 
UV crosslinked Histidine-tag N and RNA.
The control sample of His-N, RNase A and trypsin produced the mass spectrum in (a). The 
experimental sample of His-N, specific RNA, RNase A and trypsin produced the mass 
spectrum in (b). Arrows indicate masses that correlate with peptide sequences present in 
His-N. Black arrows indicate masses present in both samples. Red arrows identify masses 
unique to each spectrum. These masses correlate to the following peptide sequences:
1 AYAEQLK, 2 NQDLYDAAK, 3 MLKEMGEVAPEYR, 4 LCGMLLITEDANHK.
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Table 7.1: Particle masses of digested, UV crosslinked Histidine-tag N and RNA 
obtained by mass spectrometry.
Sample 1 is the control sample [His-N protein & RNase & Trypsin]. Sample 2 is the 
experimental sample [His-N protein & RNA & RNase & Trypsin]. Masses in m z \
Sample 1 Sample 2 N Peptide Sequence
759.442
766.3549
767.3994
787.4917
798.5936
815.4605
816.5365 816.5087 SGLTAVIR
822.4774 AYAEQLK
823.1333
827.6026
828.4718
839.0978 839.1085
842.5499
845.1173
855.0874
858.4345
859.3721
861.0729 861.5828
877.0553 877.0491
883.5024
893.028
918.3294
922.6907
938.515 938.4934
948.5035
952.4926
954.4809
963.6028
967.7312
976.4101
1013.5844
1034.1417
1036.5503
1037.5059 NQDLYDAAK
1050.1397 1050.0955
1052.0722
1065.5528
1066.0928
1066.6012 1066.544
1069.0783
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Table 7.1: continued.
Sample 1 Sample 2 N Peptide Sequence
1069.607
1084.7039
1088.1625
1114.6798
1140.5016
1162.5725
1179.5887
1180.5818 1180.5551 EMGEVAPEYR
1184.6323
1196.544
1198.7425
1231.6573
1233.6199
1289.6612
1300.751
1308.6354
1310.6927 1310.6898
1323.7349
1326.7204
1329.7413
1346.8352
1347.5231
1360.7487
1362.7044
1360.7679 1390.6666
1394.7285 1394.7306
1431.9245
1442.9607
1446.7023 1446.7691
1447.7832 1447.7662
1461.7486 1461.7008 DIANSFYEVFEK
1474.7444
1475.7749
1485.7084
1501.7906
1530.8932 1530.8506
1531.8512
1534.7367 MLKEMGEVAPEYR
1556.7914
1557.8808 LCGMLLITEDANHK
1566.5763
1567.9811
1568.8403
1572.6446
1620.7776 1620.8015
1628.8499
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Table 7.1: continued.
Sample 1 Sample 2 N Peptide Sequence
1629.9216 1629.8632 LGGEAGFYHILNNPK
1640.8078
1667.9294
1676.8248
1688.4504
1706.9847 1706.9136
1710.7809
1716.8162
1722.9355 1722.9209
1734.83
1751.4945
1793.9668 1793.9314
1796.8372
1802.9332
1841.8725
1845.8296
1857.1835
1960.6533
1993.9926
2076.0719
2077.1376
2118.2952
2130.0706
2131.0559
2136.7016
2200.0408
2202.1364
2239.3157 2239.2003
2248.1334
2255.6927
2270.1554 2270.0576
2273.9852
2299.0849
2300.1388
2320.3252 2320.3374 ENGVINYSVLDLTAEELEAIK
2321.267
2346.1578
2352.964
2435.8487
2511.4753 2511.3874
2515.1021
2527.3576
2548.2899
2706.2879
2718.5462
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Table 7.1: Continued.
Sample 1 Sample 2 N Peptide Sequence
2866.4886
2882.4656
2931.5098
2963.2653
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1 HHHHHHHHHHSSGHIEGRHMLEDPMALSKVKLNDTLNKDQLLSSSKYTIQ
51 RSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGR
101 EDTIKILRDAGYHVKANGVDVTTHRQDINGKEMKFEVLTLASLTTEIQIN
151 IEIESRKSYKKMLK/EMGEVAPEYRHDSPDCGMIILCIAALVITKLAAGDR
201 SGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKHPHFIDVFVHF
251 GIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHAS
301 VQAEMEQWEVYEYAQKLGGEAGFYHILNNPKASLLSLTQFPHFSSWLG
♦ #
351 n a a g lg im g e y r g tp r n q d ly d a a ^ /a y a e q l j^ /e n g v in y s v ld l ta e e le
401 AIKHQLNPKDNDVEL
Figure 7.12: The position of peptides identified by mass spectrometry within the 
Histidine-tag N protein sequence.
The Histidine-tag and plasmid-derived linkage amino acids are in blue type. Sites of 
potential trypsin cleavage are underlined. Peptides identified by mass spectrometry are 
in red type. The peptide present in [N protein & RNA & RNase & Trypsin] only is in 
green type.
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the region responsible for binding RNA occurs most frequently in the amino terminal 
two-thirds of the protein (Buchholz et al, 1993). However, this peptide sequence is 
present within the carboxy region of the N protein. Larger masses are present in 
sample 2 that approximately correspond to this peptide sequence associated with 
either one or two nucleotides.
The peptide identified as a candidate for modification by RNA is considerably smaller 
than radiolabelled peptides visualised by SDS-PAGE (Figure 7.9). These latter 
peptides were of approximate sizes 10 kDa and 13.5 kDa, ten-fold larger than the 
peptide sequences identified by mass spectrometry. Sequenced peptides were either 
too small to be retained by the gel or were masked by bands created by digestion of 
RNA probe. The larger peptides escaped detection by mass spectrometry due to the 
parameters of measurement being limited.
Initial investigation by the UV crosslinking assay and mass spectrometry has been 
successful in terms of retrieval of peptide sequences from the resulting samples. Their 
success in investigating the RNA-binding sequence has been more limited with the 
identification of only one peptide candidate. However, analysis by mass spectrometry 
has been performed only once due to time constraints and machine failure. The assay 
should be repeated to confirm results and to identify other sequences of N protein 
j involved in binding RNA. In addition, greater concentrations of N protein could be used,
additional methods of protein digestion investigated and the spectra of larger masses 
i analysed.
] 7.6 Discussion
j
| The purpose of work presented in this chapter was to investigate the domains of the N
j protein responsible for binding RNA. Analysis by UV crosslinking and by mass
spectrometry was performed to complement that achieved with N protein mutants, 
presented in Chapter 6.
The His-tag N protein had previously been purified by affinity chromatography, 
presented in Chapter 4. However, bacterial contaminants from recombinant protein 
expression remained in the purified protein sample (Figure 4.9). Therefore, to enable 
analysis by UV crosslinking and by mass spectrometry, further purification of the N
j
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protein was required. Ion-exchange and size-exclusion chromatography were 
performed to generate the final purified product, suitable for subsequent analysis. 
Initially, the experimental pi of His-N was obtained to enable selection of an appropriate 
resin-bound ion for ion-exchange chromatography. The value obtained (pH 7.35 -  7.5) 
was similar to the theoretical value of 7.63, obtained using IEF software available in 
SEQLab. This value is lower than the theoretical value obtained for N protein (pi 8.37). 
Despite the addition of 10 histidine residues in the protein tag, native N is more basic 
than the His-N protein. Determination of protein pi led to the selection of 0.2 M Tris (pH 
6.5) and SP as an appropriate buffer and ion-resin, respectively. The buffer pH was 
selected to maintain the protein with a net positive charge. However, under the buffer 
conditions selected, protein purification by cation-exchange chromatography was not 
achieved. In place, the weak cation DEAE was considerably more successful. His-N 
was purified by DEAE anion-exchange FPLC, with protein elution at 0.2 M NaCI 
forming a single, tight peak in the resulting trace (Figure 7.3). Upon investigation by 
silver-stain gel and western blot, bacterial proteins were no longer detected. However, 
His-N breakdown products were present. These smaller protein bands were removed 
by size-exclusion chromatography and their absence confirmed by silver-stain (Figure 
7.4).
Protein purity was considered sufficient for use in the UV crosslinking assay. Incubation 
at 33°C for 20 minutes followed by exposure to 25 000 jijoules cm'2 x100 UV radiation 
were determined as optimal conditions. In Figure 7.5, bands representing His-N- 
radiolabelled RNA association are 60 kDa in size. Also present in this figure is a band 
created by the crosslinking of RNA with His-N treated with 0.2 mM NaOH. The purpose 
of this treatment was to remove bacterial RNA from the recombinant protein. This was 
achieved by protein separation by SDS-PAGE, transfer to nitrocellulose and 
subsequent protein recovery from the membrane by NaOH treatment. The intensity of 
the band generated by UV crosslinking was very high, however, the protein fragment 
responsible could not be detected by silver-stain gel or by western blot (data not 
included). Presumably, the fragment was generated by NaOH chemical cleavage of 
His-N. The strong RNA interaction exhibited by this protein truncation makes further 
analysis desirable as it would aid identification of the N protein RNA-binding site.
Upon RNase A treatment of UV crosslinked His-N:RNA complex, the band decreases 
in both size (from 60 kDa to 46 kDa) and intensity as a result of nucleotide loss from
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the complex. 1 ng RNase A was selected for use in subsequent assays following 
enzyme titration (Figure7.6). Unlike viral nucleocapsids, the RNA:His-N complex is 
sensitive to RNase A digestion suggesting that the RNA probe is not encapsidated by 
His-N. Protein binding may perhaps be less structured with either individual or only few 
protein monomers binding along the length of the oligo. Indeed, the detection of only a 
single band upon RNA-N binding, irrespective of RNase A treatment, would suggest 
the occurrence of binding between individual N proteins and RNA. Otherwise, a series 
of bands of increasing size would be visible, created by the step-wise addition of 
protein monomers to RNA probe. This limited binding may be affected by the presence 
of bacterial RNA, remaining from recombinant protein expression. Also, it may result 
from the addition of RNA probe, post-His-N translation, and therefore, after possible 
protein maturation and potential alteration of RNA-binding domains.
His-N was digested individually with proteases V8, clostripain, LysC and trypsin (Figure 
7.8). Digestions with LysC and with trypsin were most successful with little full-length 
His-N remaining. LysC digestion generated only a limited number of products, including 
two main bands of 27 kDa and 20 kDa in size. Trypsin digestion was most successful, 
producing at least eight products, all of which were smaller than 30 kDa. Western blot 
analysis with polyclonal antibody directed against N detected an intense band of 
approximately 30 kDa. Faint bands of 21.5 kDa and less than 14.3 kDa were also 
visible.
UV crosslinking of N protein with RNA and subsequent digestion with RNase A and 
trypsin yielded two radiolabelled peptides N*1 (13.5 kDa) and N*2 (10 kDa) (Figure 7.9). 
The identity of these peptides remains unknown.
To further investigate nucleotide-bound N peptides, mass spectrometry was performed 
using a MALDI mass spectrometer. Spectra obtained for [N & RNase A & Trypsin] and 
[N & RNA & RNase A & Trypsin] were of good quality suggesting digestion had largely 
gone to completion and that buffer salt was absent (Figure 7.11). Masses from each 
sample were investigated in the NCBI ‘nr5 database using MASCOT. A number of N 
peptides generated by trypsin digestion were identified in both samples. However, only 
one peptide was unique to sample 1, possibly representing a peptide modified by the 
addition of RNA and hence, absent from sample 2. This peptide was AYAEQLK, 
present from amino acid 352 to 358 within the carboxy terminal of the N protein (Figure
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7.12). The peptide has a mass of 822.4774 Da, considerably smaller than those 
observed in gel analysis of the UV crosslinking assay. The lack of detection of peptides 
N*1 and N*2, identified by UV crosslinking, was due to the parameters of measurement 
of the mass spectrometer being unsuitable for the analysis of peptides of this size.
Masses of a size appropriate for peptide AYAEQLK bound by one or two nucleotides 
are present in sample 2. To investigate the presence of like sequence in these larger 
masses, the peptides could be fragmented and the resulting fragmentation patterns 
compared with that of the 822.4774 Da peak, allowing for possible mass shifts that 
correspond to presence of one or more nucleotide. Alternatively, the peptides may be 
sequenced on a Q-To-F mass spectrometer. However, peptide analysis by these 
means would require considerably higher concentrations of N protein. In addition, the 
original analysis by MALDI mass spectrometry should be repeated to identify other 
possible sites of RNA binding.
In conclusion, UV crosslinking analysis of N protein and RNA identified two RNA- 
binding peptides. An additional peptide sequence possibly involved in N protein-RNA 
interaction was identified by mass spectrometry.
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8 A Study of Ribonucleoprotein Structure
8.1 Introduction
The nucleocapsid protein of RSV is able to bind RNA in a non-sequence specific 
manner. Therefore, it is possible that His-N protein associates with bacterial RNA 
during expression and is able to form nucleocapsid-like structures, as reported for the 
expression of N proteins from other Mononegavirales in heterologous expression 
systems (Iseni et al., 1998; Masters & Banerjee, 1988; Meric et a/., 1994, Spehner et 
al., 1991). The occurrence of potential ribonucleoproteins (RNPs) in bacteria 
expressing His-N or mutant derivatives was investigated by caesium chloride (CsCI) 
gradients and electron microscopy (EM). The presence of RNA was investigated. 
Therefore, this study may give more insight to the domain, or domains on N 
responsible for binding RNA.
8.2 CsCI Gradient Isolation of Nucleocapsid-like Structures
Two buoyant density gradient types were employed. Preformed gradients with a CsCI 
range from 20% (w/w) to 40% (w/w) provided a relatively quick method of separation. 
Though sample equilibrium was not obtained, separation was sufficient to enable 
potential RNPs to be investigated by EM. CsCI buoyant density equilibrium gradients 
provided more refined separation allowing the components to better reach their 
equilibrium buoyant density. The samples analysed were the clarified lysates of cells 
expressing the N protein of interest. All bacterial lysates were digested with DNase and 
RNase A to reduce sample viscosity prior to centrifugation and subsequent density 
gradient separation (Sections 2.12.1 & 2.12.2). Retention of RNA following RNase 
treatment is taken as a defining feature of Paramyxoviridae nucleocapsids (Fearns et 
al., 1997).
8.2.1 Buoyant Density Equilibrium Gradients
Initial density gradients were performed to compare the behaviour of RSV N protein 
prepared from different sources. These included clarified lysates of bacteria expressing 
histidine-tag N protein, Sf21 cells infected with recombinant baculovirus (Bac-N) 
expressing N protein (provided by P. Yeo) and CV-1 cells infected with RSV. 
Equilibrium gradients were fractionated and investigated by western blot (Figure 8.1). 
The blot with bacterially derived His-N protein (Figure 8.1 a) was probed with antibody
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Figure 8.1: A western blot of N proteins separated by equilibrium gradient.
The clarified lysates of bacteria expressing Histidine-tag N protein (a), Sf21 cells 
infected with Bac-N expressing baculovirus-N (b) and CV-1 cells infected with RSV (c) 
were separated by step gradient. The RNP band was isolated from the 30% (w/w) CsCI 
region of the gradient and combined with additional 30% CsCI to form an equilibrium 
gradient. Gradients were fractionated and investigated by western blot. Histidine-tag N 
protein was probed with antibody specific to the His-tag (a). Baculovirus-N (b) and 
native N from RSV (c) were each probed with the polyclonal anti-N antibody aN015. 
Protein bands were visualised by ECL and autoradiography.
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specific to the histidine-tag. Blots with baculovirus-N protein (Figure 8.1 b) and with 
RSV-N (Figure 8.1 c) were probed with the rabbit polyclonal antiserum, aN015, specific 
to the N protein. In each gradient, the density at which protein concentration peaked 
was approximately 1.29 g / cm3. This is within the equilibrium density range of viral 
RNPs, buoyancy being a feature of RNA-bound protein (Ghosh & Ghosh, 1982; 
Masters & Banerjee; 1988, Myers et al., 1999). Therefore, it is probable that, within 
these fractions, N protein was associated with RNA derived from a source other than
r,
| RSV. The blots of recombinant proteins His-N and baculovirus-N were similar. Protein
f
| was at its most concentrated in fractions 17 and 18. Products of both oligomerisation
and of protein breakdown were present in fractions with high protein concentration. In 
contrast to the recombinant proteins, RSV-N was detected in fractions 16 to 18 
inclusive, and was present at considerably lower concentration as a single band of full- 
length protein when compared to the heterologously expressed N proteins. The 
absence of additional bands may be due to the lower N protein concentration applied to 
the gradient or perhaps greater stability of virus-derived protein. An equilibrium gradient 
of BSA, which does not bind RNA and therefore provides a negative control, was also 
performed and protein distribution analysed by SDS-PAGE stained with coomassie 
blue.
I Densitometry analysis of the western blots in Figure 8.1 (a to c) demonstrated similar
! distribution of His-N and Bac-N in the equilibrium gradients, with a peak density ofis
; 1.3045 g / cm3 common to both (Figure 8.2). The RSV-N gradient was slightly
f
! displaced from those obtained with the recombinant proteins. The RSV-N protein peak
j occurred at a density of approximately 1.29 g / cm3. Despite subtle differences, the
-
j fraction density at each N protein peak was approximately 1.29 g / cm , again
indicating that each protein was probably associated with RNA within the gradient. The 
slight differences may be the result of overloading and sample error.
Further equilibrium density gradients were performed to investigate the mutant N 
proteins described in Chapter 6. The peak protein densities of His-N and its mutant 
proteins occurred in a range from 1.2629 g / cm3 (NA342-391) to 1.3023 g / cm3 (His-N) 
(Figure 8.3). The highest densities were obtained with proteins His-N, NA121-160 and 
NA142-391. Peak protein fractions of gradients with NA1-200 and NA342-391 had the 
lowest densities, of 1.2659 g / cm3 and 1.2629 g / cm3, respectively. It is difficult to 
conclude whether these differences in peak protein fraction densities represent a
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Figure 8.2: A graph showing the distribution of N proteins within buoyant density 
equilibrium gradients.
Traces represent native RSV-N and the recombinant proteins, histidine-tag N and 
baculovirus-N. The western blots of fractionated equilibrium gradients featured in 
Figure 8.1 were scanned and the band intensities quantified using densitometry 
software Quantity One (BioRad). The percentage of total protein present in individual 
fractions was calculated and plotted against fraction density. The traces of His-N and of 
baculovirus-N each display a peak in protein percentage at a density of approximately 
1.3 g / cm3. With RSV-N, this peak occurs at the lower density of approximately 1.28 g / 
cm .
Purified BSA provides a negative control.
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Figure 8.3: Density at which highest concentration of Histidine-tag N protein and 
its mutant derivatives occur in CsCI equilibrium gradients.
His-N and its mutant derivatives were separated by CsCI equilibrium gradient. 
Gradients were fractionated and investigated by western blot with antibody directed 
against the Histidine-tag. Protein bands were visualised by ECL and autoradiography. 
The refractive indices of gradient fractions containing the highest protein 
concentrations were measured and are presented in the above graph. His-N is 
presented in green and provides a positive control. Mutant proteins with amino-terminal 
deletions are presented in red. Carboxy-terminal deletion mutants are presented in 
blue. Peak densities range from 1.2629 g / cm3 (NA342-391) to 1.3023 g / cm3 (His-N).
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difference in protein-RNA association of the mutants or result only from experimental 
variation. A negative control was omitted from the bar graph due to an even distribution 
of BSA through the gradient without a detectable peak in protein concentration (see 
Figure 8.2).
Differences in protein density of the His-N mutants showing significantly lower densities 
(NA1-200 and NA342-391) were investigated further by equilibrium gradients. The 
density of NA1-200 was compared with that of the other amino-terminus deletion 
mutant NA121-160, whose density was equivalent to His-N. Protein samples and 
gradients were prepared and performed concurrently. In Figure 8.4 (a), the peak in 
NA1-200 protein intensity occurred at fraction 12, considerably lower than that 
observed with NA121-160, which occurred at fraction 15. These gradients suggest that 
NA1-200 has a lower density than NA121-160, confirming previous observations 
(although in these experiments the density readings were not measured), and indicate 
that there may be a difference in protein-RNA binding behaviour. A similar pair-wise 
comparison was performed with NA342-391 and NA292-391 (Figure 8.4 b). Peaks in 
protein concentration occurred in the same fraction indicating that NA342-391 density 
is the same as NA292-391 and, presumably, as the other mutants, with the exception 
of NA1-200.
8.2.2 Preformed CsCI Gradients
Preformed density gradients (20 to 40% (w/w) CsCI) were performed with His-N and its 
mutant proteins. Gradients were fractionated and analysed by western blot (see Figure
8.5 for an example). In Figure 8.5, NA292-391 was first detected in fraction 12 and was 
present in all subsequent fractions. Protein concentration increased gradually until 
fraction 33 after which there was a dramatic increase in concentration until fraction 36. 
Protein concentration then decreased until the final fraction 40.
The density at which peak protein concentration occurred within preformed gradients 
was measured for each mutant (Figure 8.6). Variation in density occurred, with a range 
from 1.2561 g / cm3 (NA121-160) to 1.2919 g /  cm3 (NA192-391). The fraction density 
obtained for His-N was 1.2668 g / cm3, considerably lower than the value of 1.3023 g / 
cm3 presented in Figure 8.3. There was notable variation between mutant densities 
within gradients. An explanation may be that the gradients were performed at different
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Figure 8.4: Pair-wise comparisons of His-N mutant protein distribution within 
equilibrium density gradients.
His-N mutant proteins were separated by CsCI equilibrium gradient. Gradients were 
fractionated and protein distribution analysed by western blot with antibody directed 
against the histidine-tag. Protein band intensities were quantified using densitometry 
software Quantity One (BioRad). The percentage of total protein present in individual 
fractions was calculated and plotted against fraction number. Proteins NA121-160 and 
NA1-200 were analysed in (a). Proteins NA342-391 and NA292-391 were compared in 
(b). In (a), NA121-160 forms a tight protein peak in fraction 15. The NA1-200 protein 
peak occurs in fraction 12 and is relatively broad. This may suggest separation of 
distinct protein structures of different densities. A shoulder is present immediately 
before the peak in each trace, the significance of which is unknown. In (b), NA342-391 
and NA292-391 share a similar distribution within each gradient suggesting a similarity 
in protein behaviour.
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Figure 8.5: A western blot demonstrating the distribution of mutant protein 
NA292-391 within a CsCI preformed gradient.
The clarified lysate of bacteria expressing the mutant protein NA292-391 was applied 
to a 20 to 40% (w/w) preformed CsCI gradient and centrifuged. The gradient was 
fractionated and analysed by western blot with antibody directed against the Histidine- 
tag. Protein bands were visualised by ECL and autoradiography.
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Figure 8.6: Density at which highest concentration of Histidine-tag N protein and 
its mutant derivatives occur in CsCI preformed gradients.
His-N and its mutant derivatives were separated by CsCI preformed gradient. 
Gradients were fractionated and investigated by western blot with antibody directed 
against the Histidine-tag. Protein bands were visualised by ECL and autoradiography. 
The refractive indices of gradient fractions containing the highest protein 
concentrations were measured and are presented in the above graph. His-N is 
presented in green and provides a positive control. A negative control is provided by 
BSA (purple). Mutant proteins with amino-terminal deletions are presented in red and 
carboxy-terminal deletion mutants are presented in blue. Peak densities range from 
1.2561 g / cm3 (NA121-160) to 1.2919 g / cm3 (NA192-391).
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times therefore introducing the possibility of differences in gradient preparation and 
conditions of centrifugation. For example, preformed gradients of NA1-200 and NA242- 
391 and of NA142-391 and NA92-391 were performed concurrently. Within each pair, 
density readings were found to be similar. In addition, centrifuge unreliability may have 
contributed to the variation in density, given its inclination to spontaneously stop. Upon 
comparison of the fraction densities at which His-N protein peaks occurred in the 
different gradient types, it appeared that protein analysed by preformed gradient did not 
\ reach equilibrium. However, separation by preformed gradient retained credibility upon
5
|! comparison of mutant proteins with the negative control, BSA. Unlike buoyant
f
•; equilibrium gradients, a peak in BSA protein concentration was observed in this
I gradient-type. There was a dramatic difference in fraction density between the mutants,
potentially bound to RNA, and BSA that does not associate with RNA.
Experimental variation and lack of buoyant density equilibrium may provide an 
explanation for the peak densities obtained for mutants NA1-200 and NA121-160. By 
preformed gradient, NA121-160 density (1.2561 g / cm3) was lower than that of NA1- 
200 (1.2738 g / cm3), the inverse of results obtained by buoyant equilibrium gradient. 
Both values would be considered acceptable for RNA-bound protein when compared
f.
with the negative control. By equilibrium gradient, the density at which NA1-200 
| concentration was at its peak suggested a difference in protein behaviour compared
j with the other mutants (Figures 8.3 and 8.4), possibly an alteration of RNA-binding
J ability. However, this supposition becomes less clear upon consideration of the
| preformed gradients. However, for a number of factors the use of preformed gradients,
at least in our hands, should not be used as a reliable indicator of density, as 
previously commented on by Masters & Banerjee, (1988). However, the preformed 
gradients provided a more convenient method for the isolation of potential RNPs and 
their analysis by EM.
8.3 Electron Microscopy of N Protein and its Mutants
N proteins from different origins (see Section 8.2.1) and His-N protein mutants were 
investigated by electron microscopy (EM). Aliquots of CsCI gradient fractions with 
densities of between 1.29 to 1.31 g / cm3 were adsorbed on carbon-coated copper 
grids, stained with 1% (w/w) phosphotungstic acid and analysed by EM (Figure 8.7). 
Nucleocapsid structures were visible in grids created with RSV-derived N. Structures
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Figure 8.7: Examples of structures observed by EM after isolation of N protein on 
CsCI gradients.
Histidine-tag N and its mutant derivatives were expressed in bacteria. Bac-N was 
expressed in Sf21 cells infected with recombinant baculovirus. Clarified cell lysates 
were separated by CsCI density gradient. The fractions containing high concentrations 
of N protein, identified by western blot, were investigated by EM.
A nucleocapsid obtained from RSV-infected CV-1 cells is present in the insert in Bac-N, 
demonstrating similarity in native and baculovirus-derived nucleocapsid form. Nwt refers 
to an untagged form of N, expressed and purified from bacteria (construction details 
not included). The mutant NA242-391 was difficult to purify and frequently contained a 
high amount of contaminating bacterial debris. A picture of NA242-391 nucleocapsid- 
like structures was therefore unavailable.
His-N
Bac-N
NA 342-391 NA 292-391
NA 92-391
NA 142-391
NA 1-200NA121-160
NA 192-391
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were long, slender and had a herringbone-like appearance, which suggested polarity of 
a supposedly helical structure. Nucleocapsid-like structures of similar appearance were 
observed after expression of RSV N by baculovirus, a phenomenon previously 
observed by Meric et al. (1994). In addition, ring structures of a similar width to the 
nucleocapsids were visible. Nucleocapsid-like structures were visible with His-N 
expressed in E. coli. However, the nucleocapsid-like structures formed were generally 
shorter than those obtained from RSV-infected cells or from recombinant baculovirus 
expression. They had the appearance of stacks of discs and lacked the polarity 
observed in non-bacterial systems. Ring structures were also present with the 
bacterially expressed protein.
A lysate of bacteria expressing His-tag p-galactosidase was used as negative control. 
The lysate was separated by buoyant density gradient and equivalent fractions at 
which His-N would be most concentrated in similar gradients were analysed by EM. 
Neither ring nor nucleocapsid-like structures were observed. This confirms that these 
structures were a feature of N protein expression and were neither native to bacteria 
nor a feature of histidine-tag proteins.
The N mutants were also investigated by EM. Ring and nucleocapsid-like structures 
were observed with each of the carboxy terminus deletion mutants (Figure 8.7 and 
Table 8.1). Ring abundance varied between mutant preparations. However, 
nucleocapsid-like structures created with each mutant protein had the shared 
appearance of stacks of discs lacking polarity, similar to those created with full-length 
His-N protein. The mutant NA242-391 was difficult to purify and frequently contained a 
high amount of contaminating bacterial debris. A picture of NA242-391 nucleocapsid- 
like structures was therefore unavailable. As previously observed (Figure 8.3), the 
carboxy deletion mutants migrate to a buoyant density of approximately 1.29 g / cm3 
upon equilibrium gradient centrifugation, indicating that they may be associated with 
RNA.
With NA121-160 only rings were apparent, no nucleocapsid-like structures were 
observed. EM investigation of NA1-200 preparations revealed an absence of ring and 
nucleocapsid-like structures. Only large protein aggregates were observed (Figure 8.7 
and Table 8.1).
106
Chapter 8
Protein Rinqs NucleocaDsid-like Structures
His-N + +
NA342-391 + +
NA292-391 + +
(NA242-391 + +)
NA192-391 + +
NA142-391 + +
NA92-391 + +
NA1-200 - -
NA121-160 + -
Table 8.1: Structures present in His-N mutant gradient samples, observed by EM.
'+' indicates the presence and indicates the absence of structure.
8.4 RNA Extraction from N Protein Buoyant Density Gradients
The protein densities and EM data, suggest the possible association of RNA with N 
proteins. N-derived proteins were isolated by immuno-precipitation from the appropriate 
fractions, using an antibody to the histidine-tag. Protein recovery was confirmed by 
western blot. RNA was extracted by phenol/chloroform, ethanol precipitation and 
subsequently end-labelled with 32P; the products were analysed by denaturing 
polyacrylamide gel electrophoresis and visualised by phosphorimagery.
RNA was detected in association with His-N but not with NA1-200 (Figure 8.8 b). Each 
protein had been successfully immuno-precipitated as demonstrated by western blot 
(Figure 8.8 a). Discreet RNA bands of different sizes were present in the His-N protein 
lane. The different lengths may represent the ring and nucleocapsid-like structures of 
i varying sizes observed by EM.
I
Immuno-precipitation and RNA extraction from the remaining N protein mutants was 
performed (Figure 8.9). By western blot, bands representing His-N, NA121-160, 
NA242-391, NA192-391, NA142-391 and NA92-391 were present (Figure 8.9 a). NA1-
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Figure 8.8: Immuno-precipitation and RNA extraction assay performed on CsCI 
gradient fractions (i).
The clarified lysates of bacteria expressing His-N protein and NA1-200 were separated 
by CsCI density gradient. The gradients were fractionated and investigated by western 
blot with antibody directed against the Histidine-tag. Immunoprecipitation of His-N and 
NA1-200 was performed in gradient fractions containing highest protein concentrations. 
Precipitation was confirmed by western blot with antibody directed against the 
Histidine-tag (a). RNA was phenol: chloroform extracted from the precipitated protein, 
ehd-labelled with 32P and investigated by 6% polyacrylamide gel electrophoresis (b). 
Radiolabelled bands were visualised by phosphorimagery. Negative controls include 
the immuno-precipitate from gradient fractions of untransformed bacterial lysate, (a) 
and (b), and protein A alone (b). Both His-N and NA1-200 proteins have been 
successfully immuno-precipitated. In (a), a band larger than 46 kDa is visible in the 
control and NA1-200 lanes, possibly created by capture of the detection antibody by 
Protein A, remaining from immuno-precipitation.
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Figure 8.9: Immuno-precipitation and RNA extraction assay performed on CsCI 
gradient fractions (ii).
The clarified lysates of bacteria expressing His-N protein and its mutant derivatives 
were separated by CsCI density gradient. The gradients were fractionated and 
investigated by western blot with antibody directed against the Histidine-tag. 
Immunoprecipitation of His-N protein and its mutant derivatives was performed in 
gradient fractions containing highest protein concentrations. Precipitation was 
confirmed by western blot with antibody directed against the Histidine-tag (a). RNA was 
phenol: chloroform extracted from the precipitated protein, end-labelled with 32P and 
investigated by 12% polyacrylamide gel electrophoresis (b). Radiolabelled bands were 
visualised by phosphorimagery. The lysate of bacteria expressing histidine-tag p -  
galactosidase separated by CsCI gradient provided a control in both (a) and (b). Lanes 
1 to 8 present mutant protein samples as follows: 1 (NA1-200), 2 (NA121-160), 3 
(NA342-391), 4 (NA292-391), 5 (NA242-391), 6 (NA192-391), 7 (NA142-391) and 8 
(NA92-391).
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Chapter 8
200, NA342-391 and NA292-391 were absent suggesting a failure of immuno- 
precipitation. A second smaller band of unknown origin is present in some lanes. 
However, the resulting RNA profiles of the different proteins were sufficiently dissimilar 
to exclude the possible influence of this unknown protein. His-tag (3-galactosidase was 
used as negative control in this experiment. Upon examination of the phosphorimage 
(Figure 8.9 b), RNA was found to have been associated with NA242-391, NA192-391, 
NA142-391 and NA92-391. As observed in Figure 8.8 (b), there was variety in RNA 
length and band intensity. NA121-160 in Figure 8.8 (b) possessed a single RNA band 
present within the lane. This may represent the predominance of a single structure 
within NA121-160. Unfortunately, RNA was absent from the N protein lane suggesting 
failure of either RNA extraction or radiolabelling.
To clarify this data, the experiment was repeated (Figure 8.10). Upon this occasion, 
two samples each of His-N, NA1-200, NA121-160, NA342-391 and NA292-391 were 
investigated. Each protein was recovered by immunoprecipitation, with the exception of 
NA342-391 samples and one sample of NA292-391 had a low concentration of 
recovered protein (Figure 8.10 a). Radiolabelled RNA was found with His-N, NA121- 
160 and NA292-391, though band intensity was much reduced in the sample extracted 
from low protein concentration (Figure 8.10 b). The pattern of RNA bands was similar 
in each case suggesting that each protein associated with RNA in such a way as to 
provide greater stability to specific lengths. Therefore, the resulting protein-RNA 
structure may contain areas of weakness leading to the creation of varied lengths of 
RNA upon disruption. The intensity of RNA bands appears to reflect the concentration 
of protein recovered by immuno-precipitation. Several bands were observed with 
NA121-160 in contrast with the single band noted in Figure 8.9 (b). RNA was not 
isolated from lanes of NA1-200 and NA342-391. The latter protein was not recovered 
by immuno-precipitation therefore the absence of RNA was not unexpected. However, 
NA1-200 protein was precipitated therefore the lack of RNA confirmed the inability of 
NA1-200 to bind RNA.
8.5 Discussion
The analysis of full-length N proteins from different origins by equilibrium density 
gradient indicated that recombinant N behaved in a similar manner to that derived from 
RSV (Figure 8.1 and 8.2). Each protein migrated to a density similar to that of viral
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Figure 8.10: Immuno-precipitation and RNA extraction assay performed on CsCI 
gradient fractions (iii).
The clarified lysates of bacteria expressing His-N protein, NA1-200, NA121-160, 
NA342-391 and NA292-391 were separated by CsCI density gradient. The gradients 
were fractionated and investigated by western blot with antibody directed against the 
Histidine-tag. Immunoprecipitation of His-N protein and its mutant derivatives was 
performed in gradient fractions containing highest protein concentrations. Precipitation 
was confirmed by western blot with antibody directed against the Histidine-tag (a). RNA 
was phenol: chloroform extracted from the precipitated protein, end-labelled with 32P 
and investigated by 12% polyacrylamide gel electrophoresis (b). Radiolabelled bands 
were visualised by phosphorimagery.
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ribonucleoproteins (RNPs) (1.29 to 1.31 g / cm3). The recombinant proteins, 
baculovirus-N and His-N, shared a common peak density of ca. 1.30 g / cm3. RSV- 
derived N was present at a density of 1.29 g / cm3. The slight differences in protein 
densities may arise from over-expression of recombinant protein and subsequent over­
loading of the gradient in comparison with that derived from RSV. Sampling error may 
account for the differences observed. However, it is clear that N protein, expressed 
from heterologous sources, behaved in a similar manner to viral protein.
Mutant N proteins were investigated by equilibrium density gradient (Figure 8.3). Peak 
densities occurred in the range of 1.2629 g / cm3 (NA342-391) to 1.3023 g / cm3 (His- 
N). The range of densities may reflect subtle differences in protein-RNA association or 
structure, causing mutant proteins to peak at slightly different densities. Alternatively, 
experimental variation may offer an explanation. The lowest peak densities were 
obtained with proteins NA1-200 and NA342-391, which led to their further investigation 
(Figure 8.4). It was subsequently shown that NA342-391 density was identical to that of 
NA292-391, indicating a similarity in protein behaviour. The amino-terminal mutant 
proteins NA1-200 and NA121-160 were studied in parallel. Analysis confirmed that 
NA1-200 density was lower than that of NA121-160, and hence other mutants. This 
would suggest that NA1-200 does not form RNPs, that is, if we take density to reflect 
the association of protein with RNA.
Full-length and mutant N proteins were also investigated on preformed CsCI gradients. 
The mutant protein peak densities lay in a range from 1.2561 g / cm3 (NA121-160) to 
1.2919 g / cm3 (NA192-391) (Figure 8.6). In general, values were lower than those 
obtained by equilibrium gradient. This may result from failure of preformed gradients to 
reach buoyant density equilibrium as mentioned previously.
Potential nucleocapsid-like structures were observed under the EM (Figure 8.7). 
Isolates with RSV-N and with baculovirus-N contained long, slender RNPs with a 
herringbone-like appearance. In addition, ring structures were obtained following 
baculovirus-N expression. It is postulated that the majority of the rings are created 
upon shearing of the larger nucleocapsid-like structures (P. Yeo, personal 
communication). Therefore, their presence in recombinant protein and absence from 
the RSV samples may suggest that structures created with the former are less stable. 
EM investigation of recombinant His-tag N protein samples identified the presence of
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both nucleocapsid-like and ring structures. The nucleocapsid-like structures were 
shorter and lacked the polarity observed with N protein expressed in eukaryotic cells, 
having the appearance of a stack of discs. Structural appearance may reflect 
differences in conformation of the recombinant proteins expressed in bacteria 
compared with that expressed in eukaryotic cells.
Ring and nucleocapsid-like structures were observed for each of the carboxy-deletion 
N mutants. Structure abundance and nucleocapsid length varied between samples. 
However, their appearance was comparable to that of structures formed with full length 
His-N.
The lines of evidence above, that is, the similar densities to viral nucleocapsids and the 
formation of nucleocapsid-like structures, suggest that RNA was encapsidated by the 
recombinant proteins. RNA was recovered from His-N, NA121-160 and the carboxy 
terminal deletion mutants following protein isolation on CsCI gradients. RNA was not 
detected with NA1-200 and NA342-391, although for the latter, lack of protein 
expression or isolation means that no conclusive arguments can be made. Subsequent 
attempts have been made to analysis this construct, but expression has been 
problematical (C. Loney, personal communication). Thus, like other Mononegavirales, 
the RNA binding domain may be found in the amino-terminus of N. A significant 
proportion of the RNA binding domain exists within the first 100 amino acids of the N 
protein.
Differences were observed with the amino-terminal N mutants. Rings, but no 
nucleocapsid-like structures, were obtained with NA121-160. This perhaps suggests 
that the internal deletion affects either the ability of His-N to form more than one turn of 
the helix or that helices, if able to form, were unstable, resulting in the production of 
rings. RNA extracted from NA121-160 formed a single discreet band (Figure 8.9). It is 
possible that the single RNA species was obtained from the circular rings. However, 
RNAs of different lengths were isolated from a second gradient performed with NA121- 
160 (Figure 8.10). In the associated western blot, products of protein breakdown are 
visible. Therefore, it is possible that the additional RNA bands may result from RNA- 
binding by these protein fragments. NA1-200 samples lacked ordered structures, but 
contained numerous large, pleomorphic aggregates of an undefined nature. The 
unstructured appearance of NA1-200 and the absence of recovered RNA suggest that
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the carboxyl-terminus of N has little, if any, involvement in the binding of RNA and the 
assembly of nucleocapsid-like structures.
The work presented in this chapter represents only preliminary data and requires 
repetition to confirm and further elucidate these observations. However, the use of a 
different protein expression system may be advisable. Samples prepared for EM were 
considered to be "dirty" due to contaminating bacterial proteins and probably not 
suitable for high resolution structural determination. This was also apparent when 
noted that the nucleocapsids obtained from bacterial cells have a different appearance 
to those generated in eukaryotic cells. N protein sequences are identical; the 
differences probably arise from a change in protein conformation that may occur during 
nucleocapsid assembly. Therefore, though bacteria provided a good host for 
preliminary studies, it may be advisable to graduate to a more advanced expression 
system for further analysis, such as the baculovirus system.
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9 General Discussion
At the beginning of this study, RSV research had only recently been re-established 
within the Institute of Virology. Therefore, a considerable portion of the project was 
dedicated to generating reagents of use within the laboratory and developing suitable 
protocols for their investigation. Work presented in this thesis was performed 
concurrently with investigations into other aspects of RSV N protein biology such as a 
study on the association between N and cellular proteins. In addition, the interaction 
between viral N and P proteins and the domains responsible therein were investigated 
by P. Yeo, C. Loney and J. Murray. Investigation of the N protein-RNA interaction, and 
of the resulting macromolecular structures presented herein, complemented the 
ongoing work on the RSV nucleocapsid within the laboratory.
The main objectives achieved during the project may be summarised as follows:
• A system for the expression and purification of recombinant N protein (His-N) was 
developed, providing the core reagent for this study. The protein was subsequently 
used, within the laboratory, in experiments to map potential P-binding sites, 
generating data that has been published (Murray et al., 2001).
•  The RNA sequence specificity of N was investigated, employing a variety of in vitro 
techniques. The N demonstrated a lack of sequence specificity in its interaction with 
RNA.
• The location of the RNA-binding domain within N was investigated. Considering 
data from Chapters 6, 7 and 8, it was deduced that regions that contribute 
significantly to the binding and encapsidation of RNA are situated within the amino- 
terminal portion of the N protein.
• EM studies demonstrated the formation of ordered structures upon His-N protein 
expression in bacteria. Data presented herein, in conjunction with laboratory- 
acquired knowledge of the P binding sites and the panel of N-specific Mabs, may 
present a powerful tool in the further study of the nucleocapsid.
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• The protocol for His-N purification has been refined to the extent that it may, with 
further development, enable full-length N protein to be investigated by high 
resolution structural studies such as X-ray crystallography.
9.1 Preliminary Studies and Expression of Recombinant N protein.
Before the aims of the project were addressed, virus growth and protein behaviour 
were studied by western blot, RIPA and IFA (Chapter 3). The expression of viral 
proteins of expected size was confirmed by western blot, employing a panel of 
antibodies directed against specific viral components. RIPA investigation of protein 
interactions occurring during RSV infection confirmed the interaction between N and P, 
an established association previously observed in human RSV (Garcia-Barreno et al., 
1996; Slack & Easton, 1998) and in bovine RSV (Krishnamurthy & Samal, 1998). 
Possible interactions between N, M and M2-1 were observed, though the precise 
nature of the association requires further elucidation. The interesting nature of the 
association between N protein and MAb a-N15 was observed in the RIPA. In contrast 
with other a-N MAbs, a-N15 precipitated only a small amount of N and no P protein. 
Peptide mapping studies identified the antagonistic nature of the binding of MAb a-N15 
and P to the N protein (Murray et al., 2001). It is possible that MAb a-N15 detects an 
epitope that is found only on nucleocapsids, further studies are in progress. Similar 
MAbs have been described for RV (Kawai et al., 1999).
The N protein ORF was successfully cloned into pET16b (Novagen) and expressed in 
E. coli strain BL21 (DE3) pLysS. Sufficient quantities of soluble protein were obtained 
to allow purification by nickel-affinity chromatography. Western blot analysis detected 
considerable amounts (> 70% of the total expressed) of recombinant protein within the 
insoluble fraction. Subsequent experiments suggest that a proportion of this may 
represent His-N assembled with bacterial RNA into nucleocapsid-like structures, a 
feature common to N proteins (Iseni etal., 1998; Spehner etal., 1991). Structures were 
pelleted with cell debris upon ultra-centrifugation (> 50,000 xg) of the lysate prior to 
isolation of the protein. Therefore, only soluble His-N, mostly in the form of a monomer, 
is purified. This initial level of His-N purity was sufficient to enable analysis of the 
sequence specificity of His-N:RNA binding. Further purification steps were necessary 
to prepare protein suitable for UV crosslinking and analysis by mass spectrometry. The 
level of His-N purity eventually obtained may conceivably enable higher resolution
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structural analysis such as X-ray crystallography. However, problems presented by the 
inherent stickiness of the protein would need to be addressed to enable sample 
concentration to a level appropriate for such studies. One approach would be 
proteolytic digestion of His-N to obtain more soluble fragments. Thus, the data in 
Figure 7.8 may be helpful in elucidating which proteases to employ.
9.2 N-RNA Interactions
In vitro analysis demonstrated the ability of His-N to bind RNA in a non-sequence 
specific manner, a feature common to the nucleocapsid proteins of other 
Mononegaviruses, for example MV, VSV and SeV (Curran et al., 1995; Masters & 
Banerjee, 1988; Spehner etal., 1991). However, within the infected cell, only assembly 
upon viral genomic/antigenomic RNA is observed. Masters & Banerjee (1988) 
demonstrated that the specificity of interaction observed between VSV N and viral RNA 
was conferred by the P protein. P apparently maintains N in soluble form, preventing 
illegitimate assembly on non-viral RNA. It is believed that nucleocapsid assembly is 
permitted upon the recognition by the N:P complex of an encapsidation signal within 
the viral leader sequence. Similar P-directed prevention of non-specific association 
between N and cellular RNAs has been demonstrated for SeV and MV (Curran, 1996; 
Curran et al., 1993; Spehner et al., 1997). In SV5, this role may be provided by the V  
protein (Precious et al., 1995). Yang et al. (1998) reported that the rabies virus N had a 
greater affinity for viral leader RNA than for that of non-viral origin. However, non­
specific encapsidation was still observed.
The location of the RSV N protein domain responsible for binding RNA formed the core 
objective of this study. Though sequence homology among the paramyxovirus N 
proteins is relatively low, comparison of the amino-terminal 80% of each suggests 
reasonably conserved sequences; greater variation occurred in the carboxy-terminal 
region (Curran et al., 1993). The amino-terminus of paramyxovirus N proteins are 
relatively basic and reasonably hydrophobic in nature. Combined, these characteristics 
suggest that the RNA-binding site may be present within the amino-terminal domain. 
The protein may be visualised as a globular amino-terminal core with an exposed 
carboxy-terminal tail, supported by the bilobed appearance of VSV N protein under the 
EM (Masters & Banerjee, 1988).
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The N protein RNA-binding domain may be conformational in nature, that is, non- 
adjacent amino acids, rather than a single primary sequence, may contribute to the 
interaction. This may make identification of the region(s) responsible more complicated. 
From data presented in Chapters 5 through to 8, a potential RNA-binding region may 
be deduced. By north-western analysis, a band of approximately 30 kDa was detected 
in samples of purified His-N able to bind RNA (Figure 5.9). An amino-terminus His-N 
breakdown product of the same mass was frequently detected upon western blot 
analysis with antibody directed against the histidine-tag (for example, in Figure 4.6). 
Therefore, it is proposed that this places the RNA-binding domain in the amino-terminal 
two-thirds of N. Lack of involvement of the carboxy-tail has been observed for SeV. 
Mountcastle et al. (1974) demonstrated that trypsin treatment of SeV nucleocapsids 
removed the carboxy- tail of the N protein; nucleocapsid structure was left largely intact 
though the structure increased in rigidity. Despite their normal appearance and 
provision of resistance to RNase digestion, loss of the SeV N carboxy tail prevented 
the nucleocapsid from acting as a template for RNA synthesis. Subsequently, using the 
mini-genome system, Khattar et al. (2000) confirmed that the ability of bovine RSV N to 
encapsidate RNA and for the nucleocapsid to function as a template, are separate; the 
division of the amino- and carboxy-termini of the RSV N apparently mimic the SeV 
scenario.
It is proposed that the RNA-binding domain of RSV N is not present at the extreme 
amino terminus. This assumption is based on the NaOH protein fragment investigated 
by UV crosslinking and observed to bind RNA (Figure 7.5). Analysis of the fragment by 
western blot was performed with antibodies specific to the N protein and the histidine- 
tag. However, the fragment was unreactive with any of the MAbs tested. MAb a-N009 
binds to an epitope within the region 16 to 35 aa, i.e. near the extreme end of the 
amino terminus of N, which is also the position of the histidine-tag. Therefore, the lack 
of detection with either antibody suggests that this region of the amino-terminus is 
absent from the NaOH fragment. Thus, the RNA-binding site may be located in the 
region from ca. 35 to 260 aa, as deduced from the above and from the estimated size 
of the amino-terminal 30 kDa fragment.
The locale of the N RNA-binding domain may be further refined by data obtained from 
the structural studies of His-N and its mutant derivatives. The largest RSV N deletion 
mutant, NA92-391, was still found in association with RNA. Therefore, the location of
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the RNA-binding site may be found between amino acids 35 and 92. Deletions of 
amino acids 1 and 399 of the SeV N protein (524 aa) either abolished nucleocapsid 
assembly and presumably RNA-binding or caused reduction in protein function 
(Buchholz et al., 1993). Deletions in the carboxy-terminal of the SeV N had no effect on 
nucleocapsid formation, a situation similar to that reported in this thesis. The ability of 
NA92-391 to bind RNA has now been confirmed on a number of occasions (C. Loney 
and K. MacLellan, personal communication).
The ability of His-N to bind RNA is unaffected by the histidine-tag, as demonstrated by 
UV crosslinking, north-western analysis and structural studies. If the hypothesised 
RNA-binding domain is correct, the site at the extreme amino-terminal of the protein, 
occupied by the His-tag, is not involved in the association with RNA and nucleocapsid 
assembly, a result supported by conclusions from Khattar et al., (2000).
The presence of the RNA-binding site in the amino terminus of N protein was further 
supported by the failure to extract RNA from NA1-200 protein. This mutant migrated to 
a slightly lower peak density in CsCI equilibrium gradient compared with that of full- 
length and remaining His-N mutants. The difference in protein behaviour was mirrored 
by the results of RNA extraction. Examination by EM revealed the absence of ordered 
structures in NA1-200 samples and the presence of large protein aggregates. CsCI 
gradient analysis of SeV N and mutant derivatives indicated that proteins with a density 
lower than 1.27 g / cm3 were devoid of RNA (Myers et al., 1999). A similar low density 
was observed with the RSV mutant NA1-200. In addition, Myers et al. (1999) suggest 
that RNA-binding by the SeV N is achieved via hydrophobic interactions, rather than by 
acid -  base association. In this present study, the isoelectric point of N was reduced in 
His-N but was still able to bind RNA.
Preliminary investigation, by mass spectrometry, identified a peptide within the carboxy 
terminal of His-N that was potentially modified by association with RNA. This peptide 
may represent another region of N involved in, or near to, the RNA-binding domain. If 
involved, it is only minimally responsible for binding RNA as absence from the carboxy 
deletion mutants apparently does not hinder association with RNA. Kouznetzoff et al. 
(1998) predicted an involvement of amino acids 298 to 352 in the RNA-binding region 
of rabies virus N (450 aa), i.e. three-quarters along the length of the protein. 
Conceivably, the folding of the N protein may bring regions of the amino- and carboxy-
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termini into proximity which could explain the data. Recent work within the laboratory 
has produced data suggesting that a potential P binding site in the amino-terminus of 
the RSV N protein interacts with the carboxy-terminus region (C. Loney, unpublished 
results). Krishnamurthy & Samal (1998) confirmed the conformational nature of bovine 
RSV N by an investigation of the N-N interaction using the yeast two-hybrid system. 
Internal deletions were not tolerated from the protein resulting in the failure of self­
association. As the deletions were generally non-overlapping, the major conclusion 
could be that N has a high degree of conformation which may be easily disrupted. 
Fortunately, this was not observed within this study. A change in the conformation of N 
may also occur upon the binding of RNA. Analysis by mass spectrometry detected 
novel peptides present after the binding of RNA to His-N (Table 7.1). Their occurrence 
may result from a change in protein conformation upon association with RNA and 
subsequent exposure of trypsin cleavage sites, hitherto protected. Conformational 
change has been demonstrated in the maturation of the nucleocapsids of MV and RV 
(Gombart et al., 1993; Kawai et al., 1999). It has been noted that the RSV N acquires a 
resistance to proteolytic digestion during the infection process, suggesting the 
occurrence of a maturation step (Cash et al., 1979). Whether this can be related to the 
conformational change observed upon His-N:RNA interaction is intriguing.
9.3 Nucleocapsid Structure
The presence of RNA complexed to His-N within the CsCI gradients suggested the 
possibility that nucleocapsid-like structures may form within the bacteria. Meric et al. 
(1994) previously reported that, when expressed from recombinant baculovirus, RSV N 
spontaneously formed nucleocapsid-like structures, although whether they contained 
RNA was not investigated. Similarly, in the absence of other viral components, the N 
protein of MV has the ability to self-assemble into nucleocapsid-like particles, possibly 
by associating with cellular RNAs (Spehner et al., 1997; Warnes et al., 1995). Similar 
behaviour had been observed with SeV N, producing nucleocapsids identical in density 
and morphology to the authentic particles only smaller, possibly due to the assembly 
with shorter RNAs (Myers et al., 1997). Recently N:RNA complexes have been 
reported for VSV and rabies virus after heterologous expression.
It was determined that all of the carboxy-terminal mutants and His-N formed 
nucleocapsid-like structures. The data within this thesis indicates that they are
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associated with RNA. A second species of His-N:RNA complex was also observed, 
that is the occurrence of 'rings' which appear to represent one turn of the nucleocapsid. 
The nucleocapsid-like structures formed with His-N have a different appearance to 
those generated in eukaryotic cells, as observed by EM (Figure 8.7). His-N forms 
structures lacking polarity with the appearance of a stack of discs compared with the 
longer nucleocapsid of herringbone appearance observed with viral-N and Bac-N. This 
difference suggests that the bacterial cell environment in some way affects 
recombinant N protein. It perhaps causes altered conformation and thereby affects the 
protein-protein interaction potentially responsible for the change in conformation from a 
series of discs to structures with polarity. Thus, it looks like the final stage of 
nucleocapsid formation cannot occur in bacterial cells, whether this can be related to 
the discussion above about changes in N conformation, and nucleocapsid maturation, 
remains an enigma.
The amino terminus deletion mutant NA121-160, which bound RNA (Figure 8.9), 
produced only ring structures. Therefore, the absence of longer nucleocapsid-like 
structures is probably not a feature of disrupted RNA association but is more likely a 
feature of altered protein-protein binding. Interaction between N proteins on adjacent 
turns of the nucleocapsid helix may be disrupted in this mutant, increasing the fragility 
of the nucleocapsid and its propensity to shear into component rings (P. Yeo, personal 
communication).
Ring structures generated with His-N were isolated from CsCI gradients and 
investigated by computer image analysis (work performed by D. Bhella) (Figure 9.1). 
Rings were observed to contain 10 potential subunits, the same number as that 
observed in the rings isolated from nucleocapsid preparations of the rhabdoviruses 
VSV and rabies virus (Green et al., 2000; Iseni et al., 1998). In contrast, 13 subunits 
have been observed in the ring structures of SeV (Egelman et al., 1989). Comparison 
of ring structure and N protein mass suggests that RSV is more similar to rabies and 
the rhabdoviruses than to the paramyxoviruses. Comparison with other members of the 
Paramyxoviridae has shown that RSV, and probably the subfamily Pneumovirinae, are 
structurally distinct from the Paramyxovirinae (P.Yeo, D. Bhella, personal 
communication). This represents an active area of research for the group. The NA121- 
160 construct may provide a source of ring structures, free of contaminating
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Figure 9.1: A ring structure isolated from fractions of a His-N CsCI gradient and 
visualised by computer image analysis of EM pictographs.
The ring is composed of 10 His-N monomers encapsulating RNA in an RNase A- 
resistant structure. The internal pore is 6 nm in diameter and the external ring structure 
is 17 nm in diameter.
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nucleocapsid-like structures, for high level structural resolution which would enhance 
our knowledge of the nucleocapsid.
9.4 A Potential Map of the RSV N Protein
Data presented in this thesis, and generated in the laboratory by colleagues, have 
contributed to a proposed model of domain structure for N protein (Figure 9.2). As 
previously described, the deduced RNA-binding site has been located to the region 35 
to 92 aa. The region 121 to 160 aa appears important in helical stability of the resulting 
nucleocapsid. Therefore, it is involved in an aspect of N-N interaction. P protein binding 
sites have been located to positions 46 to 65 and 301 to 335. (Murray et al., 2001). An 
additional putative binding site for P is located from 211 to 230 (C. Loney, personal 
communication). Also found within the carboxy-terminus (amino acids 192-391) is a 
site for binding M (data not included, P. Yeo personal communication). There are 
obvious gaps in the map, for example amino acids 161 to 210, whose function has not 
been determined. These may simply represent hinge regions linking domains together 
or acting as regions of flexibility. Future work will try to identify other interacting regions, 
i.e. for M2-1, both in this linear model and in a three-dimensional spatial model based 
on reconstruction of the RSV nucleocapsid.
9.5 Conclusion
Work presented in this thesis has generated reagents, in the form of histidine-tagged N 
protein and deletion mutant derivatives, for use in the laboratory. Protocols for the 
purification of full-length recombinant protein have been established. In addition, 
protocols for UV crosslinking and mass spectrometry have been developed and 
optimised in anticipation of their further use. Future work will involve the transference of 
the mutants into the baculovirus system as one problematical aspect of this study has 
been the contamination of protein preparations with bacterial proteins. The baculovirus 
produces cleaner preparations (and shows that hindsight is a great advantage). Thus, 
the transfer of mutants to recombinant baculovirus and their subsequent expression 
may generate proteins, and hence nucleocapsids, of more realistic conformation. 
Mutants may then be used to further map the N protein domains. Purification of 
baculovirus-expressed N proteins may be performed to enable subsequent high- 
resolution analysis by NMR or by X-ray crystallography. The work presented in this 
thesis has made a number of observations that should form the basis of future work
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Figure 9.2: Potential domains of the N protein of RSV.
The deduced RNA-binding site is present between amino acids 35 and 92. The N 
protein may be divided more broadly into an amino terminus domain (1 to 92 aa) able 
to bind RNA and assemble into nucleocapsid-like structures and a carboxy terminus 
(93 to 391 aa), dispensable for nucleocapsid assembly in vitro. The region 121 to 160 
aa (purple) is possibly required for helical stability of the nucleocapsid. Therefore, it is 
potentially required for N-N interactions. Two P-binding sites (46 to 65 aa and 301 to 
335 aa) are presented in blue. A putative binding site for P (211 to 230 aa) is also 
presented in blue and marked Antigenic sites to which MAbs a-N3, a-N9 and a- 
N15 bind are presented in yellow.
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within the RSV group. It has initiated work on structural aspects of RSV that were not 
envisaged at the beginning of the study and hopefully will contribute to the 
understanding of RSV.
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11 Appendices
11.1 Buffer Reagents
11.1.1 Tissue Culture 
PBS
0.17 M Sodium Chloride
3.35 mM Potassium Chloride
1.84 mM Potassium Dihydrogen Phosphate
10 mM Sodium Dihydrogen Phosphate
Adjusted to pH 7.4
11.1.2 Bacterial Culture
2YT Growth Medium 
5 g Sodium Chloride
16 g Bactotryptone
10 g Yeast Extract
1 litre dH20 , sterilised by autoclaving
SOC Growth Medium
1 mM Sodium Chloride
0.25 mM Potassium Chloride
2 mM Magnesium Chloride
2 mM Glucose
1 litre dH20 , sterilised by autoclaving
11.1.3 Yeast Culture
Lithium Acetate/TE Buffer 
10 mM Tris Base
1 mM EDTA
0.1 M Lithium Chloride
Adjusted to pH 7.6
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Z-Buffer
60 mM Disodium Hydrophosphate
46 mM Sodium Dihydrogen Phosphate
10 mM Potassium Chloride
2 mM Magnesium Sulphate
Z-Buffer/X-Gal Solution 
100 ml Z-Buffer
0.27 ml |3-Mercaptoethanol
1.67 ml X-Gal Solution (40 mg ml"1 Dimethyl Formamide)
11.1.4 DNA Manipulation
1x TAE Buffer
40 mM Tris-Base
2 mM EDTA
0.1 % (v/v) Glacial Acetic Acid
6x DNA Loading Buffer 
0.25% (w/v) Bromophenol Blue 
0.25% (v/v) Xylene Cyanol FF 
30% (v/v) Glycerol
In 1x TAE buffer
10x Ligation Buffer
250 mM Tris-HCI pH 7.5
50 mM Magnesium Chloride
25% (w/v) PEG 8000
5 mM DTT
4 mM ATP
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11.1.5 Protein Manipulation
10 mM Imidazole Phosphate Buffer
10 mM Imidazole
10 mM Disodium Hydrophosphate
10 mM Sodium Dihydrogen Phosphate
500 mM Sodium Chloride
Adjusted to pH 7.4, sterilised by filtration
Tris-Glvcine Acrvlamide Gel
10% Acrvlamide Separatina Gel 4% Acrvlamide Stacking Gel
3.3 ml 
2.6 ml
4.1 ml 
200 pi 
15 pi
30% Acrylamide *
ProtoGel Running Buffer
(1.5 M Tris-HCI, 0.384% SDS, pH 8.8)
dH20
10% (w/v) APS 
TEMED
1.3 ml 
2.5 ml
6.2 ml 
200 pi 
15 pi
30% Acrylamide *
ProtoGel Stacking Buffer
(0.5 M Tris-HCI, 0.4% SDS, pH 6.8)
dH20
10% (w/v) APS 
TEMED
* UltraPure ProtoGel: 30% (w/v) Acrylamide: 0.8% (w/v) Bis-Acrylamide Stock Solution 
(37.5:1) (National Diagnostics)
3x Sample Loading Buffer
10 ml ProtoGel Stacking Buffer
8 ml 25% (w/v) SDS
5 ml (3-Mercaptoethanol
10 ml Glycerol
0.25% (w/v) Bromophenol Blue
Tank Buffer
50 mM Tris Base
50 mM Glycine
3.5 mM SDS
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Tris-Tricine Acrvlamide Gel
16% Acrvlamide Separating Gel 4% Acrvlamide Stacking Gel
16 ml 30% Acrylamide 1.62 ml 30% Acrylamide
10 ml Tris-HCI/SDS, pH 8.45 3.10 ml Tris-HCI/SDS, pH 8.45
(3 M Tris Base; 10 mM SDS) (3 M Tris Base; 10 mM SDS)
0.83 ml dH20 7.78 ml dH20
3.17 ml Glycerol 200 pi 10% (w/v) APS
200 pi 10% (w/v) APS 15 pi TEMED
15 pi TEMED
3x Tricine Sample Buffer
2 ml 4x Tris-HCI/SDS, pH 6.8
(12 M Tris-Base; 40 mM SDS; pH adjusted with HCI)
2.4 ml Glycerol
0.8 g SDS
0.31 g DTT
2 mg Coomassie Blue G-250
Final volume was increased to 10 ml with dH20
Anode Running Buffer 
0.2 M Tris-Base
Adjusted to pH 8.9 with HCI
Cathode Running Buffer 
0.1 M Tris-Base
0.1 M Tricine
0.1% (w/v) SDS
Coomassie Blue Stain 
7% (v/v) Acetic Acid
5% (v/v) Methanol
Coomassie Blue
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De-stain Solution 
7% (v/v)
5% (v/v)
Acetic Acid 
Methanol
Silver Stain Buffers (Pharmacia Biotech) 
Fixative Buffer
40% (v/v) 
10% (v/v)
Ethanol
Glacial Acetic Acid
Sensitising Buffer 
30% (v/v)
0.125% (w/v) 
0.2% (w/v)
6.8% (w/v)
Ethanol
Gluteraldehyde 
Sodium Thiosulphate 
Sodium Acetate
Silver Solution 
0.25% (w/v) 
0.015% (w/v)
Silver Nitrate 
Formaldehyde
Developing Buffer 
2.5% (w/v) 
0.0075% (w/v)
Sodium Carbonate 
Formaldehyde
Stop Buffer
1.46% (w/v) EDTA-Na2.2H20
Western Blot Transfer Buffer 
25 mM Tris Base
200 mM Glycine
20% (v/v) Methanol
Adjusted to pH 8.3 with HCI
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Wash Buffer (Tween 20-PBS)
0.1% (v/v) Tween 20
0.17 M Sodium Chloride
3.35 mM Potassium Chloride
1.84 mM Potassium Dihydrophosphate
10 mM Sodium Dihydrogen Phosphate
Adjusted to pH 7.4
ECL Reagents
ECL Solution 1 ECL Solution 2
2.5 mM Luminol 
0.4 mM Coumaric Acid 
0.1 M Tris-CI pH 8.5
0.02% (v/v) Hydrogen Peroxide 
0.1 M Tris-CI pH 8.5
11.1.6 Immunoprecipitation 
RIPA Buffer x1
150 mM Sodium Chloride
10 mM Tris-HCI pH 8
1 % (w/v) Sodium Deoxycholate
1%(v/v) Triton X100
1%(w/v) SDS
1x Machamer Buffer
150 mM Sodium Chloride
50 mMTris-CI, pH 8
5 mM EDTA
1% (v/v) Triton X100
Proteinase Inhibitor
Lithium Chloride Wash Buffer 
0.6 M Lithium Chloride
0.1 M Tris-HCI pH 8.0
1 % (v/v) (3-Mercaptoethanol
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11.1.7 RNA -  Protein Association 
TE Buffer
10 mM Tris Base
1 mM EDTA
Adjusted to pH 7.6
10x TBE Buffer
1 M Tris Base
0.8 M Boric Acid
10 mM EDTA
Adjusted to pH 8.2-8.4
5x RNA Bindina Buffer
50 mM Tris-HCI, pH 7.2
0.5 M Potassium Chloride
15 mM Magnesium Acetate
5 mM EDTA
10x HBB
250 mM Hepes, pH 7.5
250 mM Sodium Chloride
50 mM Magnesium Chloride
10 mM DTT
10x HYB100
0.2 M Hepes, pH 7.5
1 M Potassium Chloride
25 mM Magnesium Chloride
1 mM EDTA
10 mM DTT
0.5% (v/v) Nonidet P-40
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11.1.8 Nucleocapsid Preparations 
1x TNE Buffer
150mM Sodium Chloride
10 mM Tris Base
1 mM EDTA
Solutions Weiqht (a) placed in 
100 ml TNE Buffer
Refractive Index Densitv 
(g / cm3)
5% (w/v) Sucrose 5 - -
25% (w/v) Caesium Chloride 30.69 1.3550 1.2275
30% (w/v) Caesium Chloride 38.57 1.3607 1.2858
40% (w/v) Caesium Chloride 56.78 1.3735 1.4196
5x Polynucleotide Exchange Reaction Buffer
350 pM ADP
250 mM Imidazole (pH 6.8)
60 mM Magnesium Chloride
5 mM p-Mercaptoethanol
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11.2 Primer Sequences
11.2.1 Primers used in the Cloning of RSV N ORF 
N (Forward)
5’ TGGGGCAAAGGATCCGATGGCTCTTAGCAAAGTCAAGTTGA 3’ 
N (Reverse)
5’ TTCAGGAGCGGATCCTTCCATGATGATTTATTTGCCCCATT 3’
GGATCC represents the Bam HI restriction site introduced into the N ORF by cloning 
primers; ATG is the start codon.
11.2.2 Site-Directed Mutagenesis Primers 
NA1-200
5’ GCAGCGGCCATATCGAAGGTCGTCATATGCTCGAGGATCCGATGCCC 
AAGGACATAGCCAACAGCTTCTATGAAGTGTTTGAAAAAC 3’
NA121-160
5’ CATTGGCAAGCTTAACAACTTGTATAGCAGCATTAGTAATAA 3’
11.2.3 PCR Deletion Primers 
N Forward
5’ CATATGCTCGAGGATCCGATGGCTCTTAGCAAAGTC 3’
NA342-391
5’ CTTTGCTGCATCATATGGATCCTGATTTCACGGTGTACCTCTGTACTCTC 3’ 
NA292-391
5’ GGTAGAATCCTGCTTCAGGATCCAATTTTCAGGCATATTCATAAACC 3’
NA242-391
5’ CATAGGCATTCATAAAGGATCCTGCAAATCACCCTTCAACTCTACTG 3’
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NA192-391
5’ GTAGTAAG CCTTT GTAAG GAT CC ATTT CT C ATTTTAG G AC ATTATTAG 3’ 
NA142-391
5’ CATGCCTGTATTCTGGAGGATCCTCTCCTCATTCTTTTAGCATTTTTTTG 3’
NA92-391
5’ GATGTGTTGTTACATCGGATCCATTTCATTTTACATGATATCCC 3’ 
NA42-391
5’ ATAACATGCCACATAACGGATCCATGTGTCACTGCACATCATAATTAG 3’
GGATCC represents the Bam HI restriction site and TCA, the stop codon, introduced 
into the N ORF by deletion primers.
11.2.4 Sequencing Primers 
T7 Promoter
5’ ATTAATACGACTCACTATAG 3’
T7 Terminator
5’ GCTAGTTATTGCTCAGCGGT 3’
N S E Q 2  (internal)
5’ GGGCAAGTGATGTTACGG 3’
N SEQ 3 (internal)
5’ ACTGATTTTGCTAAGACT 3’
N REV (internal)
5’ ATACCTATTAACCCAGTG 3’
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11.3 DNA Templates for RNA Probes
11.3.1 Specific Probe (Synthesised Oligo)
5’ AAT TTA ATA CGA CTC ACT ATA GGG ACG CGA AAA AAT GCG TAC 
3’ TTA AAT TAT GCT GAG TGA TAT CCC TGC GCT TTT TTA CGC ATG
AAC AAA CTT GCA TAA ACC AAA AAA AT 3’
TTG TTT GAA CGT ATT TGG TTT TTT TA 5’
The T7 promoter is presented in red. Transcription begins immediately after the TATA 
sequence, generating a transcript of 47 nucleotides. RSV leader sequence is 
presented in blue.
11.3.2 Non-Specific Probe (Sal l-cut Bluescript plasmid)
5’ TAA TAC GAC TCA CTA TAG GGC GAA TTG GGT ACC GGG CCC 
3’ ATT ATG CTG AGT GAT ATC CCG CTT AAC CCA TGG CCC GGG
CCC CTC GAG G 3’
GGG GAG CTC C 5’
The T7 promoter is presented in red. The transcribed sequence is presented in blue 
(32 nucleotides).
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11.4 Histidine-Tagged Nucleocapsid Protein sequence
1 HHHHHHHHHHSSGHIEGRHMLEDPMALSKVKLNDTLNKDQLLSSSKYTIQ
51 RSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRLGR
101 EDTIKILRDAGYHVK ANGVDVTTHRQDINGKEMKFEVLTLASLTP EIQIN
N a 92-391 N m 21-160
151 IEIESRKSYKKMLKE MGEVAPEYRHDSPDCGMIIl/CIAALVITKLAAGDR
N  \142-391 N a 121-160
201 SGLTAVIRRANNVLK NEMKRYKGLL PKDIANSFYEVFEKHPHFIDVFVHF
N a 1 92-391 N  1-200
251 GIAQSSTRGGSRVEG IFAGLFMNAYGAGQVMLRWGVLAKSVKNIMLGHAS
N \242-391
301 VQAEMEQVVEVYEYA QKLGGEAGFYHILNNPKASLLSLTQFPHFSSVVLG
N \292-391
351 NAAGLGIMGEYRGTP RNQDLYDAAKAYAEQLKENGVINYSVLDLTAEELE
N  A342-391
401 AIKHQLNPKDNDVEL *
Reverse
Mutants
The histidine-tag and inter-linking amino acids are presented in blue.
G l a s g o w
UN .'VERS 
libr ar y
5vn
1TY
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